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ABSTRACT  
   
The highly predictable structural and thermodynamic behavior of deoxynucleic 
acid (DNA) and ribonucleic acid (RNA) have made them versatile tools for creating 
artificial nanostructures over broad range. Moreover, DNA and RNA are able to interact 
with biological ligand as either synthetic aptamers or natural components, conferring direct 
biological functions to the nucleic acid devices. The applications of nucleic acids greatly 
relies on the bio-reactivity and specificity when applied to highly complexed biological 
systems. 
This dissertation aims to 1) develop new strategy to identify high affinity nucleic 
acid aptamers against biological ligand; and 2) explore highly orthogonal RNA 
riboregulators in vivo for constructing multi-input gene circuits with NOT logic. With the 
aid of a DNA nanoscaffold, pairs of hetero-bivalent aptamers for human alpha thrombin 
were identified with ultra-high binding affinity in femtomolar range with displaying potent 
biological modulations for the enzyme activity. The newly identified bivalent aptamers 
enriched the aptamer tool box for future therapeutic applications in hemostasis, and also 
the strategy can be potentially developed for other target molecules. Secondly, by 
employing a three-way junction structure in the riboregulator structure through de-novo 
design, we identified a family of high-performance RNA-sensing translational repressors 
that down-regulates gene translation in response to cognate RNAs with remarkable 
dynamic range and orthogonality. Harnessing the 3WJ repressors as modular parts, we 
integrate them into biological circuits that execute universal NAND and NOR logic with 
up to four independent RNA inputs in Escherichia coli. 
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CHAPTER 1 
NUCLEIC ACIDS BEYOND GENETIC CODING: NANOFABRICATION, SENSING 
AND REGULATION 
Deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) have emerged as 
versatile tools for functions far beyond genetic information storage or transmission. The 
highly predictable intra- or inter-molecular Watson-Crick base-pairing and well 
characterized thermodynamic behavior confer them high programmability as building 
materials for constructing desired structures in varying scales. When combined with 
interactions with other biological components, these DNA/RNA fabricated structures can 
exhibit biological functions such as in sensing or regulation in a modular and 
programmable way. Lots of efforts have been made in this rapidly expanding field to 
explore the utilization of rationally designed nucleic acid devices in biological applications, 
bridging their structural and functional aspects to realize nanoscale machinery that actuate 
in biological systems.  
1.1 DNA/RNA in nanofabrication 
Over the past decades, DNA and RNA have been intensively studies for 
constructing various nanoscale constructs. The use of nucleic acids as building material for 
nanoscale constructions was based on their periodic three-dimensional structure, 
predictable base-pairing, and immobile crossover motifs. DNA and RNA are able to form 
antiparallel double crossovers (DX) or paranemic crossovers (PX) that are rigid enough as 
build blocks for nanofabrication, and RNA has additional structural motifs like kissing 
loops interactions or multi-way junction structures that can either be designed or taken 
from nature. Various strategies have been applied in constructing different types of 
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nanostructures, such as: 1) 1-D1, 2-D2 arrays, and 3-D3 lattices using repetitive building 
blocks; 2) polyhedral structures4 based on multi-way junctions; 3) origami structures5,6,7 
using one or multiple viral genome DNA as scaffolds and hundreds of staple strands to 
assist the folding into desired 2-D or 3-D structure; 4) single stranded DNA tiles8 that build 
up the structure modularly with small tile bricks; 5) single stranded DNA/RNA origami9 
that self-fold into nanostructures; 6) RNA nanostructures that can be produced and formed 
in vivo10. 
The programmability of the DNA/RNA nanostructures and the ease of 
incorporation with other external motifs make them ideal platform for executing desired 
biological functions. Functional entities can be attached to the deliberately designed 
nucleic acid structures with high addressability to confer bio-reactivity to the nanomaterial. 
For functional motifs like DNA/RNA aptamers, direct linkage via sequence extension or 
base-pairing can be readily realized; for components other than nucleic acids, chemical 
linkage can also be achieved but with extra effort for the modification. These 
functionalized DNA/RNA nanostructures are now acting as novel tools to facilitate 
biological applications in fundamental biological studies as a regulatory platform for 
precise control over distance, shapes and anchor points11,12,13,14, or in diagnostic 
applications to strengthen or amplify the signal15, or in therapeutic applications as delivery 
carrier to address payloads and actuate the release of cargo16,17.  
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Figure 1.1 Different types of DNA/RNA nanostructures. a, left: 1-D DNA assay based on 
double crossovers1. middle: 2-D RNA array based on RNA double crossovers long-
distance kissing loop interactions2; right: 3-D DNA crystal formed with 4x6 motif3; b, 
representative complex DNA polyhedral structure4; c, DNA origami structures with long 
scaffold DNA.  From left to right: single scaffold origami5; multi-scaffold wireframe 
origami6; multi-scaffold 3-D origami7 formed by shape-complementarity. d: 3-D structures 
constructed from single stranded DNA tile8; e: single stranded DNA origami (left) and 
RNA origami (right) 9. f: RNA nanostructures that are formed in vivo10. 
 
1.2 Aptamer: bridging nucleic acids and other molecules 
Another significant aspect of the noncanonical functions of DNA and RNA is that 
with specific three-dimensional structures they can behave like antibody to bind with 
cognate target molecules with high affinity and specificity. Unlike antibodies, aptamers are 
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easier to synthesize and modify owing to their nucleic acid properties, and they are more 
thermal stable that they can refold into functional structure after getting denatured. 
Moreover, it’s relatively easy to modulate the structure of aptamer to disrupt or restore its 
binding capacity by interaction with other nucleic acid portion through base-pairing. The 
identification of aptamer sequences can be achieved through an in vitro screening process 
termed Systematic evolution of ligands by exponential enrichment (SELEX)18,19. Ever 
since the introduction of this technology in early nineties, a lot of aptamers have been 
identified and widely applied as the sensing, targeting or regulatory elements in various 
applications like bio-sensing20 and regulation21, disease diagnostics22, biomarker 
discovery23, and drug delivery16,17. Despite the impressive achievements with the 
established aptamers, the application expansion is still restricted by the limited aptamer 
tool kit. High performance aptamers are still in great demand in aspects of high affinity 
and enzymatic stability to prompt their applications in biological systems.   
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Figure 1.2 Aptamers in biological applications. Biomarker discovery: adapted from ref 23; 
Cancer cell imaging: adapted from ref 22; biosensing: adapted from ref 20; in vivo 
regulation: adapted from ref 21; drug delivery: adapted from ref 17. 
 
1.3 In vivo regulation with RNA 
For in vivo applications, RNA intrinsically outperforms DNA primarily due to their 
natural single stranded form in biological systems and their more sophisticated structural 
folding. In nature, RNA molecules play essential roles in living organisms, carrying 
functions far beyond their role as the intermediary between genes and proteins. 
Furthermore, RNAs can adopt a wide variety of different structures for binding different 
ligands and catalyzing chemical reactions.  The versatility of RNAs in both function and 
structure makes them important regulatory components in nature for sensing and 
transducing signals via structural switching upon ligand binding. In recent years with 
increasing understanding of these natural regulatory pathways, researchers have succeeded 
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in manipulating biological processes with artificial devices such as riboregulators or 
riboswitches that act in response to different molecular stimuli. 
1.3.1 Riboregulator 
Gene regulation can be achieved at post-transcriptional level by tuning ribosomal 
binding site (RBS) accessibility to ribosomes. One of the first modular artificial 
riboregulator designs was reported by Isaacs et al.24 in 2004. This engineered riboregulator 
introduced a short RBS-complementary sequence in cis to block the recognition of the RBS 
by ribosome. The cis-repressive RNA (crRNA) was composed of an RBS complementary 
sequence and a pYrimidine-Uracil-Nucleotide-puRine motif (YUNR) which forms a loop 
to mediate loop-linear intermolecular interaction with trans-activating RNA (taRNA) 
molecule. The taRNA-crRNA cognate interaction releases the sequestered RBS and 
activates downstream gene expression. However, this design was limited in orthogonality 
because of sequence constraints in crRNA design that requires the integration of 
endogenous YUNR motif as well as invariable base-pairing to RBS sequence. Later 
works25,26 extended the orthogonal library size by mutating the YUNR motif in the loop 
domain and by expanding the loop size, demonstrating that YUNR motif is dispensable 
and the RNA-RNA interaction in cells are largely determined by RNA complex thermo-
stability and seed region for activation, which makes computational based de novo design 
possible for artificial riboregulators. Taken together the RBS secondary structure 
importance in gene regulation, the toehold activation in promoting RNA interaction and 
thermodynamic-based de novo computational design, Green et al. developed large 
orthogonal toehold switches with greatly improved performance in dynamic range27. These 
riboregulators sequestered the secondary structure around start codon, instead of base-
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pairing with RBS sequence or start codon, enabling protein regulation in response to an 
arbitrary trigger RNA with few sequence constraints. The trans-cis RNA interaction was 
initiated by 5’ toehold via thermodynamically favorable linear-linear interactions, enabling 
modulation of protein expression over two orders of magnitude. Taking advantage of the 
high dynamic range and orthogonality of the toehold switches, Green et al. extended this 
work to construct multiple-input RNA based computing circuits to enable complex 
translational regulations in cells28. 
The riboregulators that operate at the transcriptional level have also been widely 
studied. Using transcriptional regulation, the RNA input signals can be propagated by the 
synthesis of the output RNA, which is a desirable property for constructing genetic circuits. 
Starting from natural transcriptional attenuators which promotes the formation of a 
downstream intrinsic terminator upon binding with a complementary antisense RNA, 
Lucks et al.29 engineered orthogonal attenuator variants through rational mutagenesis of 
the attenuator hairpin loop and collar sequences. However, the dynamic range and 
orthogonal library size were still limited by designs preserving the endogenous loop-loop 
mediated RNA interaction which limits the structural folding and thermodynamic free 
energy. To achieve higher performance, the Lucks group30 optimized their transcriptional 
regulators using computational design and constructed high performance and orthogonal 
Small Transcription Activating RNAs (STARs). STARs employed thermodynamically 
favored linear-linear RNA interactions to reconstruct the sequestered terminator and use 
the 5’ linear region as the seed for specific RNA recognition, achieving up to 9171±3881 
fold activation, which is the highest dynamic ranges by an RNA riboregulator to date. 
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Figure 1.3 Mechanisms of two classes of synthetic riboregulators. a, toehold switches that 
regulate gene expression from translational level31; b, STARs that regulate gene expression 
from transcriptional level30. 
 
1.3.2 Riboswitch 
RNA-based regulation can be achieved by RNA base-pairing interactions like the 
RNA-sensing riboregulators discussed above or by interactions between RNA and small 
molecule ligands that occur in riboswitches. In the latter case, the binding of small 
molecules to RNA triggers allosteric structural switching that leads to changes in gene 
expression. Yen et al.32 incorporated a ribozyme into an mRNA sequence to promote self-
cleavage of the RNA transcripts and suppression of translation. They then selected 
molecular ligands that bound to the ribozyme and inhibit the self-cleavage to encourage 
protein translation. This ribozyme-based regulation strategy requires small molecule 
screening, which cannot be rationally designed and is limited by the relatively invariable 
ribozyme sequence. In order to make the ribozyme-based regulation design more modular 
and extensible, Win and Smolke33 fused an RNA aptamer to a ribozyme to make an 
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allosteric ribozyme responsive to small molecules. The binding of small molecules in the 
aptamer region or sensor region is able to either disrupt or reconstruct the ribozyme 
structure, achieving up- or down-regulation of the protein of interest. Another work34 
achieved trans-regulation through modular, tunable allosteric riboswitches to regulate 
expression of transcripts in a ligand-binding manner. The conformation change upon 
binding with a target small molecule releases a sequestered antisense RNA sequence for 
binding with the mRNA for translational regulation. When combining with in vitro aptamer 
screening platform, these allosteric aptamer based regulation schemes can be extended to 
a vast array of potential target molecules. Riboswitch based gene regulation was also 
achieved through RNA interference. Kumar21 and Beisel35 independently worked with 
aptamers having affinity for small molecules to allosterically reconstruct or disrupt the 
RNA substrate structure for Drosha to regulate the RNA interference pathway, 
demonstrating another aspect of gene regulation by artificial non-coding RNA. Protein-
sensing regulatory components have also been successfully created in an impressive work 
led by the Smolke group36. They integrated a protein binding aptamer into intronic 
locations of an alternatively spliced transcript placed before the gene of interest. The 
presence of a target protein was sensed by the intron-embedded aptamer, causing exclusion 
of a middle exon which contains a premature stop codon and promoting the synthesis of 
downstream genes. By linking disease makers to apoptosis-related protein output, they 
demonstrated their success to rewire the cellular signaling pathways to regulate the cell 
behaviors. 
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Figure 1.4 Mechanisms of riboswitches that give gene regulation in cis33 or in trans34.  
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CHAPTER 2 
DNA SCAFFOLD-ASSISTED SELECTION OF HIGH AFFINITY BIVALENT 
APTAMERS FOR HUMAN ALPHA-THROMBIN 
2.1 Abstract 
Multivalent aptamers that interact with target protein through multiple sites exhibit 
much stronger binding strength against their target ligands compared to their monovalent 
counterparts, which gives them great potential in diagnostic or therapeutic applications. In 
this work, we designed a single stranded DNA library (1015 molecules, each 145 nt) that 
contains fixed sequences regions that is expected to self-fold into a predefined DNA 
nanostructure, presenting two random-looped sites for bivalent aptamer evolution. From 
this library, a group of ultra-strong bivalent aptamers against human -thrombin (with 
apparent KD ~340 fM) were easily identified through a simple 7-round conventional 
SELEX, saving the effort for a post-SELEX multimer construction and optimization step. 
Further characterization of the aptamer-target binding sites demonstrated that the dominant 
bivalent aptamers consist of two aptamers binding to exosite I and exosite II, respectively, 
indicating a cooperative binding between the two aptamers and thrombin. It is observed 
that the monovalent aptamers that bind to exosite II mildly inhibit the thrombin peptide 
cleavage activity but stimulates the blood coagulation, while the aptamers binding to 
exosite I show little effect on the thrombin cleavage activity but strongly inhibit 
coagulation. The bivalent aptamer we selected herein shows a much stronger inhibition of 
the thrombin cleavage activity and also displays an extremely potent anticoagulation effect 
in human plasma, far better than the direct thrombin inhibitor argatroban or the established 
monovalent thrombin aptamer TBA, demonstrating their great potentials in therapeutic 
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applications. The method developed here can be easily adapted to conventional SELEX, 
opening new route for fast selection of multivalent aptamers for other targets with superior 
binding affinity.   
2.2 Introduction 
Nucleic acid aptamers are oligonucleotides that bind to specific target molecules. 
Systematic evolution of ligands by exponential enrichment (SELEX)1, 2 has been a very 
powerful strategy for developing DNA or RNA aptamers for interested targets, ranging 
from small molecules3, 4, proteins, organelles5, 6, cells7 to even tissues8. When bound to 
functional epitopes on target molecules, some of the aptamers exhibit biological effects 
such as stimulating cell internalization7 or inhibiting enzyme activity as antagonist9. Due 
to their easy synthesis and modification, small sizes and less of immunogenicity compared 
with antibody, aptamers have been intensively studied in sensing, diagnostic and 
therapeutic applications. The high affinity of the aptamers is a critical requirement for these 
intended applications. Aptamers bind to target protein molecules mostly through 
electrostatic interaction, hydrogen bonding and shape complementarity, therefore 
increasing the interaction interface between aptamer and the target protein is an attractive 
strategy to achieve higher affinity. However aptamers are usually smaller than 30nt, 
although it’s selected from a library with 30-60nt randomized nucleotides. Therefore it’s 
not an effective way to use longer library size to increase contact area10. The joining of two 
aptamers that bind to different epitopes on the same protein target could generate hetero-
bivalent interaction and greatly increase the aptamer affinity, however this bivalent 
aptamer construction strategy requires the identification of two aptamers that target 
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different sites, and also the optimization of the linker sequence between the two aptamers 
to achieve better coorperativity11.  
Theoretically, from a single selection process, for the aptamers binding with a target 
species larger than their own size, the sequences of the aptamers that show binding to 
different epitopes on the same target can be simultaneously evolved. However nearly all 
aptamers identified so far for a given target protein molecule are specific for the same 
binding epitope. This is possibly because of the existence of a specific epitope on the target 
molecules surface that contains a clusters of contact points that had a stronger DNA-
interacting capacity than anywhere else. This will result in a set of dominant aptamers that 
all bind to this same site during selection12. Therefore it is hard to select two different 
aptamers that bind to the same target but to different epitopes, because aptamers targeting 
the weaker epitopes will be gradually discarded in the selection process and lose the 
competition to the stronger binder, i.e. the winner takes all. Current efforts for isolating 
aptamers targeting discrete epitopes normally require introducing chemical diversity to 
oligonucleotides to increase potential interactions with proteins13, or a second SELEX with 
masking the stronger epitope to eliminate its competition in aptamer evolution14. It remains 
a big challenge to concurrently isolate aptamers recognizing nonoverlapping epitopes on 
the same protein from conventional SELEX platform with unmodified DNA library.   
 Giving the fact that bivalent aptamers demonstrate stronger binding affinity than 
monovalent aptamer, we therefore postulate that it is possible to screen pairs of aptamers 
that bind to two different epitopes on the same target molecule simultaneously through a 
single-step SELEX, as long as enough evolutional space for both of the two aptamers is 
provided and the pairing information is retained during selection. DNA nanostructures15, 
  17 
16, 17 meet the requirements since it can be easily incorporated into the selection library, and 
the DNA nanostructure as scaffold provides addressable platform for individual aptamer 
evolution. Besides, the structure scaffold and the library can be enzymatically amplified 
among selection cycles and refold to retrieve the confirmation of the two aptamer sites. To 
achieve the simultaneous evolution of two unique aptamers to the same target, we designed 
a single-stranded DNA (ssDNA) nanostructure, within which two 20-nt random loops for 
aptamer evolution are included. The conserved segments in the library allow each strand 
to self-fold into a two-helix tile through two paranemic cohesion interactions. This two-
helix tile acts as a scaffold, supporting the two random loops that each extends from the 
end of one of the helixes for aptamer evolution.  
As a proof of concept, human α thrombin was chosen as the target protein for our 
bivalent aptamer selection. Thrombin is a multifunctional protein in coagulation pathway 
that has two existing aptamers binding to two different sites with potentials in therapeutic 
applications18, 19,. TBA is a 15-nt aptamer that targets exosite I on thrombin with a KD of 
34 nM20, and HD22 is a 29-nt aptamer binding to thrombin exosite II with a KD of 0.5 
nM19. Exosite I and II are two anion binding sites flanking the thrombin activity center, 
providing the specificity of thrombin binding to its substrate, receptor or cofactors to 
modulate thrombin activity. Exosite I binds to fibrinogen and to some coagulation 
cofactors, and exosite II binds with heparin and predominantly mediates the binding with 
platelet receptor GPIbα together with exosite I. The binding of TBA inhibits the exosite I 
dependent fibrinogen clotting, while HD22 shows inhibited platelet activation21 but 
negligible prolongation for fibrinogen clotting time22. The bivalent aptamer constructed by 
joining these two aptamers via various association methods showed greatly improved 
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binding affinity and anticoagulant efficacy11, 22, 23, 24, 25. The existence of the two anion-
binding exosites made up of positively charged amino acids increases the chance of success 
in the selection of a hetero-bivalent aptamer for the target, and the existing two aptamers 
can serve as the reference in binding sites characterization for newly identified aptamers. 
Moreover, the development of bivalent aptamer for thrombin has great potential as new 
anticoagulant candidate.  
From the SELEX results, bivalent aptamers rapidly enriched the pool during 
selection as expected. The representative bivalent aptamer ThAD has a super-strong 
binding affinity with dissociation constant of approximately 343 fM, making it the 
strongest aptamer known to date. ThAD binds to thrombin in a 1:1 ratio, and the two 
aptamers ThA and ThD in the bivalent aptamer have demonstrated to cooperatively bind 
to exosite I and exosite II on thrombin. In addition, aptamer ThA, when bound to thrombin 
exosite II, gives inhibition for thrombin cleavage activity possibly through allosteric effect 
on the active center, which is a new feature compared with established aptamers. Owing to 
the tight binding on the exosites and the allosteric effect on the cleavage activity center, 
the bivalent aptamer ThAD gives strong inhibition for thrombin cleavage activity. In the 
anticoagulation test, ThA and ThB stimulated the coagulation cascade while ThC and ThD 
strongly suppressed the coagulation cascade. ThAD gave potent anticoagulant effect even 
with 5 nM concentration against 5 nM of thrombin. Overall our work gave the first 
successful demonstration for hetero-bivalent aptamer screening from a library with 
predefined structural features in a single SELEX, and the newly identified aptamers are 
very promising candidates for modulating the coagulation cascade.  
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2.3 Results and Discussion 
2.3.1 SELEX and Binding Characterization 
A two-helix DNA nanostructure with three paranemic crossovers was designed as 
the scaffold to support two 20-nt random loops (Fig. 2.1a) for aptamer selection against 
human α-thrombin. The library has a total length of 145-nt long, including the 40-nt 
random sequences in the two loop regions, and a total of 105-nt constant sequences that 
self-fold to form the stem regions of the scaffold structure. The random sequences are 
segregated by the scaffold into two 20-nt loops, each extending from the same ends of the 
two parallel DNA helixes. The loop size of 20-nt was chosen to minimize its impact on the 
scaffold structure folding while preserving enough nucleotides for adequate interactions 
with the target molecule. Generally, in aptamer sequences part of the nucleotides form 
structural support and are thus variable, and the highly conserved nucleotides contacting 
the target molecule are usually less than 20-nt. We expect the scaffold in the library 
structure would provide structural support for the contacting nucleotides in the loop 
resembling the frequently found stem-loop structure in established aptamers. Also, the 
enclosed state of the random region is more likely to encourage the formation of 
complicated confirmations like G-quadruplex in the loop region. Moreover, the two 
random regions in total consist of 40 nucleotides, comparable to the random size of 
conventional SELEX (30 nt-60 nt), so a reasonable sequence diversity can be reached with 
an input of 1015 molecules without further expanding the library size. The loops attached 
on the DNA nanostructure are expected to have ~2-3 nm in their average diameter with a 
~2-4 nm center-to-center distance. The dimensions agree with the dimension of human α 
thrombin (4.5 × 4.5 × 5.0 nm), suggesting a reasonable spacing between the two loops.  
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Figure 2.1 The structural selection library design and selection progress. a, Scaffolded 
SELEX library design: the conserved regions of the single-stranded DNA (colored) intra-
molecularly fold into a parallel 2-helix structure by paranemic cohesion; two random 
sequenced loops (gray) extending from the ends of the 2-helix are used for the bi-valent 
aptamer selection. The scaffolded library is shown in scale with human α thrombin. b, 
SELEX progression monitored by flow cytometry for the 5th, 6th and 7th round selected 
library. Thrombin coated magnetic beads or unmodified beads were incubated with 100 
nM of ssDNA library and rinsed before flow cytometry measurement.  
 
The DNA library was continuously screened with thrombin as the target protein for 
7 cycles using a magnetic bead based method for binding and separation. The thrombin 
molecules were modified covalently on the magnetic beads. The beads without thrombin 
modification were used in the counter-selection to remove sequences non-specifically 
binding to the surface of the beads. DNA isolated after screening was amplified with FITC-
labeled primer so that the recovered single stranded DNA pool can be used for 
fluorescence-based binding assay. The selection progress was monitored by flow 
cytometry for 5th, 6th or 7th selected library. To our surprise, after only 5 cycles of 
selection, the library already showed a strong binding to the target protein. As the selection 
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cycle increases, the remaining DNA library showed increased binding strength toward the 
thrombin modified beads and decreased binding toward the unmodified beads (Fig. 2.1b), 
which indicated the enrichment of specific thrombin-binding aptamers in the selection 
pool.  
The 7th round selection product was sequenced by Miseq and the sequence results 
were analyzed. The most abundant 100 sequences from the pool gave 1000 reads in total 
(appendix A, supplemental table S2.1), which were then further analyzed by sequence 
alignment (Fig. 2.2a). The loop sequences that serve as the potential binding motifs were 
mostly (84.2%) aligned into 4 major families A, B, C and D (Fig. 2.2a and 2.2b), strongly 
indicating their dominant binding behavior in the selection pool. Although these families 
are G-rich, they don’t show sequence resemblance with either TBA or HD22, indicating 
the identification of new aptamers. These four families are highly conserved with slight 
tolerance of nucleotides change in a few positions. It is noted that the family A (96%) and 
B (100%) almost exclusively showed in the left loop, however and family C (100%) and 
D (72%) mostly showed in the right loops (appendix A, supplemental table S2.1). 
Remarkably, in the top 100 full length sequences, most of them have two functional loops 
with frequent pairs between families A-D, B-D, and D-D (Fig. 2.2c), supporting our 
hypothesis that bivalent aptamers could win the selection owing to their higher affinity 
compared with monovalent aptamers. It’s worth mentioning that the multivalency can 
either be heterodivalency or homodivalency, meaning the two aptamers on the selected 
bivalent aptamers can bind to either the same or discrete epitopes, although we believe 
heterodivalency should provide larger interacting surface and be stronger compared with 
homo-bivalent interactions. The survival of homo-bivalent aptamer with two D family 
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sequences suggests family D might bind to a strong epitope so the avidity provided by two 
D binders could rival that from hetero-bivalent pairs.  
 
Figure 2.2 Sequencing analysis and binding characterization. a, Family alignment for the 
loop region for the most frequent sequences (top 100 sequences) from the sequencing 
results; alignment was done by clustal omega online tool. The percentage to the right is the 
percentage of each sequence variant in the family, ranking from highest to lowest; b, 
Distribution of the sequence families in the sequencing pool (top 100 sequences, 1000 
reads); c, Distribution of the bivalent aptamer pairs in the sequencing pool; d, Binding of 
the individual aptamers A, B, C, D with thrombin-modified magnetic beads by flow 
cytometry; aptamer concentration: 100 nM. e, Native gel shift assay for the binding of both 
monovalent and bivalent aptamers (1 µM) with thrombin (1 µM). The gel was stained with 
ethidium bromide for showing bands containing DNA. For each sample, left lane: no 
thrombin; right lane: with thrombin. 
 
To characterize the individual binding behavior of the selected sequences, we firstly 
chose the most frequent sequences (A1, B1, C1 and D5) in each of the four families as 
representative aptamers (Fig. 2.2a; D5 was chosen since A1D5 was the top 1 pair selected 
in the pool), termed aptamers ThA, ThB, ThC, and ThD, respectively. Since the stem-loop 
structure in the original scaffold could be important for the proper aptamer folding, the four 
individual loop sequences were each designed with a constant 15-bp stem to restore their 
proper conformation (appendix A, supplemental table S2.2, Fig. S2.1). The results showed 
that all of these four loop motifs show significant binding to thrombin, demonstrating the 
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successful screening of four thrombin aptamers (Fig. 2.2d and 2.2e). Further results showed 
that a stable stem is required for ThA but not as important for ThD (Fig. S2.2). 
To test the binding behaviors of the bivalent aptamers, we then constructed bivalent 
aptamers from these 4 families of monovalent aptamers by using all 16 combinations of a 
pair between these four aptamers (although not all of the combinations had occurred in 
significant amount in the final pool of selection) and attach them on the 2-helix scaffold 
structure as the same as in the library design, and their bivalent binding capability with 
thrombin was checked by native gel electrophoresis (Fig. S2.3).  Among these, the bivalent 
aptamer ThAD showed a high occurrence frequency (13.9%, Fig. 2.2b) in the selected 
library, and from the gel shift assay this aptamer mostly gave a 1:1 aptamer: thrombin 
binding behavior. The binding behaviors of ThDA, ThAC, and ThCA to thrombin are 
similar to that of ThAD, although these three combinations did not show significant 
occurrence rate in the final selected pool. The aptamer ThBD also showed a significant 
occurrence frequency in the selection pool (22.5%, Fig. 2.2c), but its binding with thrombin 
was different from that of the aptamer ThAD. The major band migrates significantly slower 
than the 1:1 binding species, which can be possibly explained as forming a stable 2:2 
aptamer: thrombin complex. This hypothesis can be supported by the fact that thrombin 
naturally forms a dimer upon binding to platelet receptor GPIbα with interaction from 
exosite I of one thrombin and exosite II from the other thrombin to the receptor molecule26. 
The binding of ThDB, ThCB and ThBC with thrombin is similar as that of ThBD, with the 
major band in the gel showing the slower migrating 2:2 complex. The aptamer ThDD is 
another combination showing significant occurrence frequency in the final pool. The 
binding of ThDD with thrombin showed a smearing band suggesting less uniform or stable 
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complexes in gel assay. Similarly, ThAA, BB, BA, AB, CC and CD also gave less uniform 
bands.  
We chose the best behaved bivalent aptamer ThAD for further characterization. 
Aptamers and thrombin were incubated with 1:1 ratio. All of the aptamer ThAD were 
bound to thrombin molecules and showed slower migration. However when either one of 
the loop was removed, with only one of the aptamer remaining on the two-helix stem, the 
binding strength decreased as indicated by the unbound aptamers (Fig. 2.2e), indicating the 
cooperativity between these two aptamers upon binding to thrombin. Bivalent aptamer AD 
also demonstrated excellent specificity toward thrombin, with no binding to other tested 
proteins (Fig. S2.4). 
2.3.2 Binding Sites Characterization 
We then conducted a competitive assay to identify the binding sites of these four 
monovalent aptamers ThA, ThB, ThC and ThD, together with the bivalent aptamer ThAD, 
in comparison with  the two established thrombin aptamers (TBA and HD22), which are 
known to bind to thrombin exosite I (TBA) and thrombin exosite II (HD22), respectively. 
200 nM of nonlabeled selected aptamer was preincubated with thrombin-modified beads 
before another 10 nM of FITC-labeled aptamer (much lower concentration than those 
preincubated aptamers) was added to compete for the binding sites. Fluorescence from the 
FITC-labeled aptamers (10 nM) binding with unblocked thrombin beads was used as the 
positive control. If the aptamers added later share the same binding epitope with the 
preincubated aptamer, they will have to displace the blocking aptamer to give a 
fluorescence signal.  In the competition for the same binding site, a stronger binder is able 
to displace a weaker binder at a lower concentration, while a weaker (or comparable) binder 
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is difficult to displace a stronger binder unless it is present in a much larger excess.  On the 
other hand, if the aptamers added later have a different (non-overlapping) binding site with 
the preincubated aptamer, they will mostly likely not be affected by the preincubated 
aptamers and will give a fluorescence signal as strong as the control (Fig. 2.3a).  
 
Figure 2.3 Competitive assay for identifying binding sites. a, Schematic diagram of 
competitive assay; top: two aptamers bind to non-overlapping epitopes on the protein 
surface without competition; bottom: two aptamers bind to overlapping sites on the protein 
surface thus show competition. b, Fluorescence heat map for reciprocal competitive assay 
by FACS (with thrombin modified on magnetic beads). Fluorescence from 10 nM of 
aptamers on thrombin coated beads without blocking aptamers was used to normalize the 
fluorescence in presence of blocking aptamers. Background fluorescence from magnetic 
beads was not subtracted for calculation. 
 
The results (Fig. 2.3b, appendix A, supplemental Fig. S2.5) showed that aptamer 
ThA and aptamer ThB competed with aptamer HD22 without affecting the binding from 
aptamer ThC, ThD or TBA, and aptamer ThC and ThD competed with aptamer TBA 
without affecting binding from aptamer ThA, ThB or HD22. This demonstrated that 
aptamer ThA and ThB binds to an epitope overlapping with that of HD22 on thrombin 
(exosite II), and aptamer ThC and ThD bind to another epitope overlapping with that of 
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TBA on thrombin (exosite I). Remarkably, the aptamers ThC and ThD were able to almost 
completely displace off aptamer TBA at a considerably much lower concentration, this 
indicated that the binding of aptamer ThC and ThD should be much stronger than that of 
the aptamer TBA. Given the fact that the aptamers ThA and ThD bind to two distinct 
epitopes on thrombin that each competes aptamer HD22 or TBA, it is not surprising that 
the bivalent aptamer ThAD, comprising of both aptamers on their most adapted scaffold, 
competed with all of the tested aptamers with both a strong blocking efficiency and a strong 
displacement capability. This explains why the bivalent aptamer ThAD rapidly won the 
selection among all the other competitors. An allosteric linkage27,28 was also observed 
between exosite I and exosite II in the results as indicated by percent fluorescence >100% 
when the blocking aptamer binds to a different epitope than the FITC-labeled aptamer, for 
example, the binding signal from ThC and ThD which bind to exosite II increased when 
exosite I was bound to ThA, ThB or HD22.  
2.3.3 Dissociation Constant (KD) Measurement 
Filter binding assay29 was conducted to measure the apparent dissociation constant 
for the individual aptamers ThA and ThD. The results gave a KD of 232±23 pM for aptamer 
ThA and a KD of 8.6±0.7 pM for aptamer ThD (Fig. 2.4a and 2.4b), demonstrating much 
improved binding affinity compared with the established thrombin aptamers (KD(HD22) 
0.5 nM, KD(TBA) 34 nM). Notably, the binding affinity from aptamer ThD is almost 30 
folds higher than that of aptamer ThA. This proves our hypothesis that it is possible to 
identify a weaker binding aptamer targeting a weaker epitope from a bivalent aptamer 
library even in the presence of a stronger aptamer targeting a stronger epitope. However 
without the spatial linkage of the two in the DNA scaffold, the weaker one would have 
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been lost in the library during the traditional monovalent aptamer screening process. The 
high affinity of the new aptamers should at least partly come from the stem-loop features 
in the library design, which gave rise to the high-quality conformational folding in the loop 
region. 
 
Figure 2.4. KD measurement for aptamer ThA, ThD and bivalent aptamer ThAD, ThBD 
and ThDA. a and b, KD measurement for the two monovalent aptamers  individually using 
a radioactive filter binding assay; c, KD measurement for the bivalent aptamer ThAD, 
ThBD and ThDA by a competitive assay with 100 nM FITC labeled aptamer ThD as the 
competitor aptamer. Bivalent aptamer concentration was: 0.25 nM, 0.5 nM, 1 nM, 2 nM, 4 
nM, 6 nM, 8 nM, 10 nM, 20 nM and 40 nM. The fluorescence intensity obtained for FITC-
ThD bound with thrombin modified beads without competing aptamers was set as top 
asymptote, and fluorescence intensity obtained from FITC-ThD bound to non-coated beads 
without competing aptamers was set as bottom asymptote. 
 
With the known KD of aptamer ThD, the KD of the bivalent aptamer ThAD and 
ThBD was indirectly measured with a competitive assay using aptamer ThD as the 
competing ligand (Fig. 2.4c, histogram shown in appendix A, supplemental Fig. S2.6; see 
competitive gel assay in appendix A, supplemental Fig. S2.7).  In the competitive assay, a 
fixed concentration of FITC-labeled aptamer ThD (100 nM) was mixed with a series of 
concentrations of non-labeled bivalent aptamer and added to thrombin modified beads. 
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After 14 hours of equilibration, the fluorescence intensity was monitored by flow 
cytometry. The IC50 value was obtained from the dose responsive fitting curve of the 
bivalent aptamers, and the Cheng-Prusoff equation KD(ThAD) = IC50/(1+[L]/KD(ThD)) 
was used to calculate the KD value for the bivalent aptamers. The KD(ThAD) such obtained 
is 343 fM, showing an ultra-strong binding affinity. In comparison with the monovalent 
aptamers, the bivalent aptamer ThAD displayed a ~ 676 fold increase in binding strength 
from that of aptamer ThA, and a ~ 25 fold increase from that of aptamer ThD, which greatly 
supports the superiority of multivalent binding when multiple monovalent aptamers are 
adapted on a structural scaffold. Bivalent aptamer ThBD that also occurs with high 
frequency in the selection library displayed a KD of 504 fM with affinity slightly lower 
than that of ThAD.  
2.3.4 DNA Scaffold characterization and thrombin immobilization 
We then tested how the linkage structure would affect the bivalent aptamer binding 
with target protein. We firstly titrated the distance between the aptamer ThA and ThD on 
a four-helix DNA tile (Fig. 2.5a, see detailed design in appendix A, supplementary Fig. 
S2.8). Results showed that the bivalent aptamer kept strong binding to thrombin when the 
two aptamers are adjacent to each other or one helix apart (about 2-4 nm); this is also the 
expected movement range of the loops that allow both of the two loops to bind on the 
opposite sides of the protein target based on the diameter of the protein, the lengths of the 
loops, and the distance between their attachment sites, assuming both the attachment sites 
of the loops to the rigid stem are flexible. The binding behavior starts to change when the 
inter-loop space increased to 2 helixes (> 4 nm) (Fig. 2.5a), showing a slower migration 
for the aptamer-thrombin complex. This is probably because only one aptamer was bound 
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to thrombin resulting in a less constrained structure. Aggregation was also observed for 
this 2-helix interspaced bivalent aptamer possibly due to crosslink between tiles bridged 
by thrombin molecules. The results indicate the optimal distance between the two aptamer 
loops is required to allow them to bind to the same target cooperatively.   
In addition to the strict distance requirement, the relative orientation of the aptamer 
on the scaffold also affects the binding strength. We swapped the loops on the stem from 
ThAD to ThDA in the single stranded PX tile structure and compared their binding affinity 
(Fig. 2.4c). Unless both loops can rotate freely in the steric angles from their attachment 
site (which is not likely due to the double linkage of each loop to the stem), they would be 
expected to display different exposed surfaces under the minimal structural strain. From 
the binding assay by native gel (appendix A, supplemental Fig. S2.3), the binding behavior 
of ThAD and ThDA with the target was similar, however, from a competitive binding 
assay, the binding strengths of the two bivalent aptamers ThAD and ThDA were different 
that ThAD is stronger than ThDA by 2 folds (Fig. 2.4c). This also helps to explain why the 
bivalent aptamer ThDA failed to survive in a significant amount in the final screening 
process (Fig. 2.2c).  
The scaffolded bivalent aptamer can be constructed by annealing two strands (Fig. 
2.5b, left) into a PX tile. In the design, the stem regions for supporting the aptamer loops 
are 8- base pairs, and the two paranemic crossovers are one turn apart with external arms 
with 7- base pairs to eliminate topological trap. The tile obtained this way well restores the 
originally selected bivalent aptamer, displaying the same binding behavior with single 
stranded ThAD (Fig. 2.5b, middle). In order to further demonstrate that the PX tile structure 
contributes in regulating the distance and orientation for the aptamer pair, we removed the 
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base pairing in the paranemic cohesion region in the scaffold in ThAD which results in an 
opened and flexible structure with only one Holliday junction (Fig. 2.5b, right). With the 
mutated scaffold, the bivalent aptamer binds to thrombin with only one arm showing a 
slower migration, losing the cooperative binding from both aptamers.  
The PX scaffold was further replaced with a free polyT linker termed 
ThAD_linkerT18. Although the flexible bivalent aptamer ThAD_linkerT18 showed 
cooperative binding with thrombin (Fig. 2.5c), the binding strength was lower than the PX 
tile scaffolded ThAD. In competition with equal molar concentration of ThAD, most of the 
ThAD_linkerT18 was displaced off indicated by the major unbound bottom band. The 
linkage structure characterization further support that the winner bivalent aptamers were 
optimized through screening on the predefined scaffold.  
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Figure 2.5. Bivalent aptamer on different scaffold. a, Distance titration for bivalent aptamer 
ThAD on a 4-helix tile; tile concentration: 100 nM; thrombin concentration: 100 nM. b, 
Lane1 and 2, two strands formed PX structured bivalent aptamer; lane3 and 4, bivalent 
ThAD with PX scaffold; lane 5 and 6, bivalent aptamer with mutated scaffold removing 
the paranemic cohesion base pairing. Bivalent aptamer concentration: 500 nM; thrombin 
concentration: 500 nM. c, Lane1, ThAD-linkerT18; lane2, 500 nM of ThAD-linkerT18 
incubated with 500 nM of thrombin; lane3, 500 nM of ThAD-linkerT18 mixed with 500 
nM of ThAD and incubated with 500 nM of thrombin. Gels for a and b were stained with 
ethidium bromide for imaging, and gel for c was directly imaged for FITC-labeled 
ThAD_linkerT18. d, Patterned immobilization of thrombin on DNA origami by bivalent 
aptamers. Origami concentration: 2 nM. Left: no thrombin; the index at one corner is 
visible, while the pairs of aptamers also show as small bumps. Right: 20 nM thrombin. 
Scale bar: 200 nm 
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Moreover, bivalent aptamers, due to their intrinsic DNA structural base and strong 
binding capacity, can be easily incorporated into DNA nanostructures to capture their target 
proteins and organize them into desired patterns. To demonstrate this, four pairs of bivalent 
aptamer, i.e. ThA and ThD, were organized on a rectangular DNA origami (Fig. 2.5c, 
appendix A, supplemental Fig. S2.9), with intra-pair distance 10 nm and inter-pair 
distances of 16 nm. The aptamers addressed on the surface of the origami were extended 
with a 7-bp stem and a 2-T flexible linker at both sides, giving flexibility in the aptamer 
swinging and rotation. The expected protein pattern was successfully visualized under 
AFM (Fig. 2.5c) that the binding occurs only between the close-distance pairs. Considering 
that thrombin in the bound state to the bivalent aptamer could possibly be inhibited for its 
biological function, this makes it possible to use DNA nano-cargos to deliver activity 
silenced thrombin to reduce background activity from thrombin before it reaches the target 
site. 
2.3.5 Biological functions of newly identified aptamers 
We further analyzed if these high affinity aptamers would affect the biological 
functions of thrombin. Firstly we directly measured the kinetics of thrombin cleavage 
activity by monitoring the cleavage of a FITC/Quencher peptide substrate by 10 nM of 
thrombin in complex with aptamers. From the result (Fig. 2.6a, left), 10 nM of aptamer 
ThA showed moderate inhibition for thrombin activity (orange curve) while the same 
concentration of aptamer ThD didn’t obviously affect thrombin activity (blue curve). A 
simple mixture of 10 nM aptamer ThA and 10 nM aptamer ThD showed almost the same 
level of inhibition with that from aptamer ThA (green curve). However, the bivalent 
aptamer ThAD that has aptamer ThA and ThD joined by a scaffold structure, displayed 
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much stronger inhibition for thrombin cleavage activity (pink curve), even stronger than 
argatroban of the same concentration (brown curve), a direct thrombin inhibitor for clinical 
treatment of thrombosis30. However, although ThAD gave sensitive attenuation for 
thrombin cleavage activity with a molar ratio of 1:1, high dose of ThAD didn’t show 
increased inhibition (Fig. 2.6b, right), meaning the binding of ThAD could only partially 
inhibit thrombin cleavage activity. This suggests an indirect inhibition behavior different 
from the direct inhibitor argatroban that binds to the enzymatic activity center. Since ThA 
binds to exosite II, we speculate that the binding of ThA allosterically affects the activity 
center over long distance, which is also observed in other published work31. This increased 
inhibition by the bivalent aptamer ThAD comes from the functional inhibition from the 
aptamer ThA, as well as from the tight bivalent binding assisted from the aptamer ThD. It 
is worth mentioning that although the aptamer HD22 binds to an overlapping site as 
aptamer ThA with a comparable affinity, it shows a much less inhibition for thrombin 
activity (Fig. S2.10), indicating a different binding behavior from ThA. This suggests that 
our bivalent aptamer offers a novel allosteric modulation over thrombin activity. 
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Figure 2.6. The biological functions of aptamers in thrombin activity inhibition and 
anticoagulation. a, thrombin cleavage activity assay. Thrombin concentration: 10 nM; 
argatroban or aptamer concentration: 10 nM. b, Dose dependent thrombin activity with 
titration of ThAD or argatroban. ThAD concentration was: 40 pM, 200 pM, 1 nM, 2 nM, 
4 nM, 10 nM, 20 nM, 40 nM, 80 nM.  Argatroban concentration was: 100 pM, 1 nM, 4 
nM, 10 nM, 20 nM, 40 nM, 80 nM, 200 nM, 400 nM, 10 µM. Thrombin concentration: 10 
nM; c, fibrin generation test with 5 nM of thrombin and 20 nM of argatroban or each 
aptamer (concentration before mix with plasma). Left: fibrin generation curves for 
argatroban, TBA and HD22; middle: fibrin generation curves for monovalent aptamer 
ThA, ThB, ThC, ThD; right: fibrin generation curves for bivalent aptamer ThAD, ThBD 
and ThDD. 
 
Now that the bivalent aptamers targets the exosite I and exosite II on the thrombin 
molecule with allosterically affecting the activity center, we speculated that the aptamers 
should have potent anticoagulant effect in the coagulation cascade. Then we tested the 
anticoagulant effect of the aptamers by fibrin clotting assay using pooled human plasma. 5 
nM of thrombin was mixed with 20 nM of different test ligands, including argatroban, 
TBA, HD22, and our monovalent or bivalent aptamers, and then added to human plasma 
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to initiate the coagulation cascade. From our results, with this low concentration (20 nM), 
argatroban and TBA gave only slight anticoagulant effect with 160s and 39s time delay in 
fibrin generation respectively, and HD22 gave 97s of time delay but then slightly 
accelerated the coagulation cascade (Fig. 6, left). Our aptamer ThC and ThD that bind to 
exosite I gave astonishingly strong anticoagulant effect that even after 40 minutes the 
cascade was still tightly suppressed (Fig. 6, middle).. The blocking of exosite I by our high 
affinity aptamers blocked the fibrinogen acquisition on the thrombin, thus effectively 
inhibited the fibrin generation. Aptamer ThA and ThB, on the other hand, delayed the 
cascade inhibition by 115s and 110s and then showed strong acceleration effect for the 
cascade (Fig. 6, middle). This time delay can be explained by the allosterically hampered 
enzymatic activity upon binding with ThA or ThB on exosite II as we observed in the 
previous cleavage activity assay. Although the activity is partially reduced, the binding at 
exosite II might have another allosteric change in exosite I that prompt the acquisition of 
other coagulation factors, for example FV32, which results in the activation of these factors 
in the coagulation cascade and therefore gives thrombin burst to accelerate the fibrin 
generation. Bivalent aptamer ThAD, ThBD and ThDD, which contain the potent 
anticoagulant ThD, also tightly suppressed the coagulation for more than 40 minutes (Fig. 
6, right). To demonstrate the superiority of bivalent aptamer, ThAD was further titrated 
with ratio to thrombin varying from 8:1 to 1:1 with thrombin at 5 nM concentration. Results 
showed that within 40 minutes the coagulant cascade was suppressed to the same level as 
negative control even with 1:1 aptamer: thrombin ratio at 5 nM input concentration (Fig 
S2.11). 
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2.4 Conclusion 
In conclusion, we have directly selected bivalent aptamer that shows femtomolar 
range (343 fM) binding affinity to human α thrombin from a single-stranded DNA library 
featured with a self-folded structural scaffold. The DNA scaffold not only acts as a platform 
to support two independent aptamers in close distance and controlled orientation, it can 
also be amplified together with the selected aptamers, which helps to retain the pairing and 
structural information during the selection cycles. The most adapted aptamer pair was very 
effectively and efficiently selected in a few rounds of selection owing to the cooperative 
binding that confers high affinity as well as high displacement capability. Interestingly, 
majority of the winner bivalent aptamers from the library have two aptamers that bind to 
two distinct epitopes on the target protein, supporting the idea that it is possible to generate 
multivalent aptamers that have a larger contact interface with the protein thus stronger 
binding using a nanostructured DNA scaffold. A monovalent aptamer that binds to a 
relatively weaker epitope would be overwhelmed by other strong binders and discarded in 
the regular SELEX process, but now it may still survive the screening process when it is 
part of a bivalent aptamer, that owing to the cooperative binding the bivalent aptamer may 
display a much stronger binding than any of the individual aptamers on their own. The 
monovalent aptamer ThD that bind to exosite I displays low picomolar binding affinity 
(8.6 pM), much stronger than that of the established aptamer TBA, and it has highly strong 
anticoagulant effect. The monovalent aptamer ThA that binds to exosite II has slightly 
stronger binding affinity (232 pM) compared with HD22 but exhibits much stronger 
acceleration effect on the coagulation cascade. Bivalent aptamer ThAD can tightly bind to 
thrombin and partially reduce thrombin cleavage activity by allosterically affecting the 
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reaction center, and it’s such a potent anticoagulant ligand that it can completely suppress 
the coagulation cascade for 40 minutes in human plasma with a concentration of 5 nM 
against 5 nM of thrombin. The acceleration effect from ThA and the suppression effect 
from ThD makes them ideal tools for studying thrombin functions, and the extremely high 
affinity and anticoagulant function from bivalent aptamer ThAD makes it a very promising 
anticoagulant candidate in clinical applications. Moreover, the ssDNA scaffold assisted 
SELEX can be tuned to suit for different potential targets for future screening applications.  
2.5 Experimental Methods 
2.5.1 DNA Purification and Quantification 
DNA oligonucleotides were purchased from IDT DNA and were purified with 6-
12% denaturing polyacrylamide gel electrophoresis (PAGE). DNA bands were cut from 
the gel, eluted in elution buffer (500  mM ammonium acetate, 10  mM magnesium acetate, 
2  mM sodium ethylenediaminetetraacetic acid [EDTA], pH 8.0), separated from the gel 
blocks using Costar Spin X filtration columns (Corning, cellulose acetate membrane with 
0.22  μm pore size), and precipitated in 60% ethanol at -20°C. The DNA precipitates were 
collected by centrifugation and vacuum dried before rehydration in water and 
quantification by UV absorbance at 260 nm with Nanodrop spectrometer. 
2.5.2 DNA Ligation for Construction of the Single-Stranded Library 
Due to oligonucleotide synthesis limitation, strands longer than 90-nt were ligated 
with two short sequences by T4 DNA ligase (NEB). The 5’-end of the downstream 
sequence was phosphorylated and joined to the 3’-end of the other sequence by annealing 
with a 30-nt overlapping complementary sequence in 1×TAE/Mg2+ buffer (40 mM Tris, 
20 mM acetic acid, 2 mM EDTA and 12.5 mM magnesium acetate, pH 8.0). The nick 
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point was then sealed by T4 ligase through overnight incubation at room temperature in 
1×T4 reaction buffer (NEB, provided in the kit). The product was then purified using 
denaturing PAGE to recover the full length ligated products.  
2.5.3 SELEX 
The oligo-DNA library was designed to contain two 20-nt random sequences 
(TCAGGCTCTCGAGAGTTGCAGAAGTNNNNNNNNNNNNNNNNNNNNACTTCT
GCCTGCATCGAGACACCAGTTTTTCTGGTGAGCTAGTGCAGACATGATCNNN
NNNNNNNNNNNNNNNNNGATCATGTAACTCCTAGCTGCCTGA) nested in three 
segments of fixed sequences. After annealing, the three fix-sequence regions of the strands 
in the library are expected to intra-molecularly self-fold into a two-helix stem through 
paranemic cohesions that have the two random-sequenced loops extending from the same 
ends of the two helices. Human alpha thrombin (Haematologic Technologies Inc.) was 
immobilized on magnetic beads (Pierce™ NHS-Activated Magnetic Beads) according to 
merchandise manual. In the first round of selection, DNA library with 1.5 x 1015 molecules 
was incubated with 10 μL of thrombin coated magnetic beads in binding buffer ( PBS 
supplemented with 10 mM KCl, 5 mM MgCl2, 1 mg/mL BSA, 1 mg/ mL yeast tRNA and 
0.05% Tween-20, pH 7.4) for 1h, and the beads were then collected by magnetic stand 
(DynaMag™-2 Magnet, Thermo Fisher Scientific) and rinsed with washing buffer (PBS 
supplemented with 10 mM KCl, 5 mM MgCl2 and 0.05%Tween-20, pH 7.4) for three 
times. The bound DNA was eluted in water after heat denaturation at 95°C for 10 min, and 
then amplified by specific primers by PCR. The forward primer (/56-
FITC/TCAGGCTCTCGAGAGTTGCA) is labeled with FITC at the 5’-end, and the 
reverse primer has an extended poly A20 sequence in the 5’-end joined by 18-atom hexa-
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ethyleneglycol spacer what is the purpose of these modifications? (available in IDT DNA 
modification; 
AAAAAAAAAAAAAAAAAAAA/iSp18/TCAGGCAGCTAGGAGTTACA). The 
organic spacer stops the DNA polymerase during PCR extension, thus generating partial 
duplex PCR products with two strands having different lengths that allow easy separation 
in denaturing page gel.  The FITC labeled ssDNA was then recovered from gel for the next 
round of selection. After three rounds of selection, counter selection with unmodified beads 
was introduced before the positive selection to remove any nonspecific aptamers that bind 
to the beads. The selection stringency was gradually increased by reducing the inputs of 
the DNA library and the beads, shortening the library incubation time, extending the 
counter selection time, and increasing the washing volume and repeats. 
2.5.4 DNA structure thermal annealing program 
DNA structures were annealed in 1X TAE/Mg2+ buffer (40 mM Tris, 20 mM acetic 
acid, 2 mM EDTA and 12.5 mM magnesium acetate, pH 8.0) with following program: 
incubate under 90 oC for 5 minutes, and then decrease by 2 oC to 76 oC with incubation 
time of 5 minutes for each step; the decrease by 4 oC to 24 oC with incubation of 5 minutes 
for each step. 
2.5.5 Flow Cytometry Characterization of the Binding  
Flow cytometry measurements were performed using a Stratedigm S1300EXi cell 
analyzer equipped with a A600 high-throughput autosampler. The concentration of 
thrombin coated beads was calculated with Pierce™ BCA Protein Assay Kit to be 27 nM. 
Thrombin coated beads (0.1 nM) were incubated with FITC-labeled oligonucleotides at 
room temperature in binding buffer (PBS supplemented with 10 mM KCl, 5 mM MgCl2, 
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1 mg/mL BSA, 1 mg/ mL yeast tRNA and 0.05% Tween-20, pH 7.4) for 30 min and rinsed 
with washing buffer for three times before resuspension in the washing buffer (PBS 
supplemented with 5 mM MgCl2 and 10 mM KCl) for flow cytometry analysis. 
Unmodified magnetic beads were used as negative control.  
2.5.6 Test the Binding of the Selected Aptamers Using Gel Shift Analysis 
DNA oligonucleotides were incubated with thrombin in binding buffer without 
tRNA at room temperature for 30 min and loaded into 5% native PAGE gel. Gel 
electrophoresis was run at 18 °C for 30 min to 1.5 h, and then the gel was stained with 
ethidium bromide or 10x SYBR Gold for imaging with Biorad Gel Doc XR+ imaging 
system.  
2.5.7 Filter Binding Assay to Determine the Very Low Apparent KD 
ssDNA aptamers were 5′-end labeled with γ32P-ATP by using T4 PNK (NEB) for 
30 min at 37 °C in PNK buffer. The reaction mixture was applied to G25 microspin 
columns to remove unreacted γ32P-ATP, and the resulting radioactive-labeled ssDNA was 
incubated at a final concentration of 2 pM (aptamer A) or 1 pM (aptamer D) with increasing 
amounts of thrombin in binding buffer. After incubation at room temperature for 30 min, 
the reaction mixture was filtered through nitrocellulose membranes and washed with 1 mL 
of washing buffer (PBS supplemented with 5 mM MgCl2 and 10 mM KCl) for three times. 
After being dried, the membrane was exposed on a storage phosphor screen and analyzed 
on a FUJIFILM FLA-3000 with the AIDA Imagequant software. All experiments were 
performed in triplicates. 
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2.5.8 Competitive Assay for Identifying the Binding Sites  
200 nM of nonlabeled aptamer with known binding site on thrombin was 
preincubated with thrombin-modified magnetic beads (0.1 nM) in binding buffer for 30 
min, and then the FITC-labeled competing aptamer with a final concentration of 10 nM 
was added for a 30min incubation. Fluorescence from the FITC-labeled aptamers binding 
with the unblocked thrombin beads was used as the positive control. Fluorescence intensity 
was then measured using flow cytometry. 
2.5.9 Competitive FACS Assay for Ultra-Low KD Measurement 
A fixed final concentration (100 nM) of FITC-labeled aptamer ThD was mixed with 
increasing concentrations of un-labeled competing aptamer and then incubate with 
thrombin coated beads (0.04 nM) for 10 hours to reach equilibrium. Fluorescence from 
FITC-ThD binding with the unblocked thrombin beads was used as the positive control, 
and fluorescence from FITC-ThD binding with uncoated magnetic beads was used as 
negative control. Fluorescence was then measured with flow cytometry. IC50 value was 
obtained by fitting with dose-dependent curve with positive and negative fluorescence 
signal as top and bottom asymptote respectively, and KD for aptamer AD was calculated 
from the Cheng-Prusoff equation: Ki = IC50/(1+[L]/KDL, where Ki stands for the 
dissociation constant for the unlabeled ligand, KDL is the dissociation constant for the 
labeled ligand, and [L] is the fixed concentration of the labeled ligand.  
2.5.10 Thrombin Cleavage Activity Assay 
The cleavage assay was performed with SensoLyte ® 520 Thrombin Activity Assay 
Kit according to the merchandise manual. Argatroban or aptamers were incubated with 
thrombin in binding buffer (PBS supplemented with 5 mM MgCl2 and 10 mM KCl) for 10 
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min at 37 oC with a total volume of 10 µL and then added to 10 µL of assay buffer with 
FAM-peptide substrate, and fluorescence readout from the cleavage product was 
monitored in a 96 well plate immediately with BioTek Synergy H1 microplate reader. 
2.5.11 Fibrin clotting assay 
5 nM of Thrombin was incubated with 20 nM of argatroban or aptamers at room 
temperature in binding buffer (PBS supplemented with 5 mM MgCl2 and 10 mM KCl) for 
10min. Pooled human plasma (innovative research inc, 100Ml, Na citrate) was thawed in 
room temperature water bath, and then centrifuged at 8000 xg for 10 min in 4 oC room to 
separate fat in the plasma. Clear plasma was collected and mixed with 25 mM of CaCl2 
with 3: 1 plasma: CaCl2 volume ratio. Plasma was quickly added to 96 well clear bottom 
plate with 100 µl per well and mixed with 75 µl of thrombin-argatroban (or aptamer) 
mixture. Free thrombin without any ligand was added to plasma as positive control, and 
buffer without thrombin or ligand was used as negative control. Absorbance at 407 nm was 
monitored in a 96 well plate immediately with BioTek Synergy H1 microplate reader. 
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CHAPTER 3 
HIGHLY ORTHOGONAL RNA RIBOREGULATORS FOR TRANSLATIONAL 
REPRESSION 
Adapted with permission from Kim, J., &Zhou, Y., Carlson P. D., Teichmann, M., Simmel, 
F. C., Silver, P. A., Collins, J. J., Lucks, J. B., Yin, P., Green, A. A. (2019). De-Novo-
Designed Translational Repressors for Multi-Input Cellular Logic. Nature Chemical 
Biology, manuscript under review. Copyright 2019 Nature publishing group. 
3.1 Abstract 
In synthetic biology, recent advances have demonstrated the advantages of de novo 
design for riboregulators that increase gene expression in response to a trigger RNA, 
however systems that demonstrate the inverse behavior, a decrease in gene expression upon 
triggering, have yet to be reported. Here we present a molecular programming strategy that 
uses de-novo-designed RNAs to realize a family of high-performance RNA-sensing 
translational repressors that down-regulates gene translation in response to cognate RNAs 
with remarkable dynamic range and orthogonality. In our design, the switch RNA contains 
a weak RBS (ribosomal binding site)-bearing hairpin with sequence recognition sites on 
both sides to respond to nearly arbitrary triggers or target RNAs. The very unstable RBS-
hairpin enables the downstream gene expression, however this near-threshold translational 
active state is easily switched to translationally repressed state by the robust three way 
junction (3WJ) formed between the sensor and the input trigger RNA, giving an average 
of 43-fold GFP reduction for the top 20 devices. The small number of base pairing between 
the switch and the trigger RNA also improves the device orthogonality, yielding orthogonal 
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sets of up to 15 devices. Taken together, these capabilities make the 3WJ repressors 
valuable new tools for biotechnological applications. 
3.2 Introduction 
Synthetic biology aims to provide an engineering-driven approach towards building 
biological entities with complex and novel functionality using well-characterized modular 
parts. Precise and programmable control of gene expression is becoming a basic 
requirement for many synthetic biology applications as well as biotechnology in general. 
For example, the ability to control the expression of multiple genes will aid in optimization 
of biosynthetic pathways for industrial chemical production while maximizing productivity 
and minimizing toxicity to host organisms1. Moreover, continued advances in gene 
regulation provide crucial new capabilities for emerging synthetic biology applications in 
areas such as cell-based therapies2 and advanced biomaterials3. A basic requirement for 
engineering complex systems is a large repertoire of regulators that are modular, 
programmable, homogeneous, predictable, and easy to compose. Though there have been 
numerous reports describing the mining of regulatory elements from natural organisms4,5 , 
such mined parts require further scrutiny to assess their dynamic range, compatibility, and 
crosstalk.  
Due to their simple base-pairing rules and well-characterized thermodynamic 
parameters, RNA molecules provide an alternative means to construct genetic circuits with 
advantages in terms of programmability, predictability, and composability compared to 
most proteins. In a seminal study6, RNA base-pairing design rules were used to create 
multiple orthogonal sense-antisense RNA partners that regulate translation. Building on 
the natural pT181 transcriptional attenuator system, a set of orthogonal mutants of a natural 
  48 
antisense RNA–mediated transcriptional attenuation system were successfully 
demonstrated7,8. Further, a number of synthetic RNA-based translational repressors were 
described by exploring orthogonal mutants starting from the well-known IS10 antisense 
RNA–mediated translation control system9. These previous reports described RNA-based 
repressor designs where the specificity and efficiency of the control systems can be largely 
explained by the thermodynamics of RNA interactions. However, in a number of instances, 
the strategy for creating a family of orthogonal devices was based on the design features 
observed in natural systems or derived from previous work, thereby failing to fully 
capitalize on the sequence space and design features accessible to de-novo-designed 
riboregulators. 
To achieve truly synthetic de novo RNA regulatory elements, we have previously 
reported toehold switches10 that relied on two crucial design principles for regulation of 
prokaryotic translation: first, the accessibility of ribosomal binding site (RBS) and start 
codon was limited without resorting to direct base-pairing to either of those conserved 
translational elements; second, linear-linear nucleic acid interactions based on toehold-
mediated strand-displacement reactions11 were used as the trigger mechanism instead of 
using loop regions to initiate interactions7,9. These strategic changes resulted in a large 
library of synthetic riboregulator parts that showed wide dynamic range, and little 
crosstalk, enabling sophisticated translational control in vivo12. Here we describe a new 
type of de-novo-designed RNA-based repressors termed three-way junction (3WJ) 
repressors that build on the design strategies of toehold switches to achieve effective 
translational inhibition. The 3WJ repressors employ toehold-mediated interactions to 
strongly repress translation in response to trigger RNAs with nearly arbitrary sequences, 
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including full-length mRNAs, and can decrease gene expression in excess of 100-fold, a 
substantial improvement over previous RNA-based translational repressors9 and 
comparable to protein repressors obtained from genomic mining5. The repressors 
demonstrates significantly low crosstalk owing to the short exposed linear region in the 
RNA trigger. Furthermore, in-cell SHAPE-Seq measurements are used to directly confirm 
the formation of three-way junction structures in the 3WJ repressors following binding of 
the trigger RNAs.  
3.3 Results 
3.3.1 Design of Synthetic Translational Repressors 
Previously, we developed toehold switches that repress translation using a hairpin 
secondary structure that sequesters the RBS and start codon within a hairpin loop and stem, 
respectively (Fig. 3.1a). A single-stranded toehold domain a* at the 5′ end of the switch 
RNA hairpin provides the initial binding site for a single-stranded trigger RNA strand, 
which has a complementary domain a. Upon binding of the cognate trigger molecule to the 
hairpin and completion of a toehold-mediated branch migration, the RBS and start codon 
are freely available for ribosome binding and translation of the downstream gene. The lack 
of sequence constraints in designing trigger RNA molecules greatly expanded the set of 
orthogonal toehold switches and the use of thermodynamically and kinetically favorable 
toehold-mediated interactions provided wide dynamic range12. 
We sought to obtain a library of programmable, wide dynamic range translational 
repressors analogous to the toehold switches and devised repressors inspired by the design 
principles of these earlier riboregulators. The repressor adopts a three-way junction 
structure to suppress translation and is thus referred to as a three-way junction (3WJ) 
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repressor (Fig. 3.1b, see appendix B, Supplementary Information and Supplementary Fig. 
S3.1 for details). The switch RNA in these systems makes use of an unstable hairpin 
secondary structure that contains an RBS in the loop region and a start codon in the stem 
region. Despite its high secondary structure, this unstable hairpin was previously 
demonstrated to be translationally active in toehold switch mRNA sensors13. On either side 
of the unstable hairpin are two single-stranded domains a* and b*. We hypothesized that 
transient formation of the bottom stem domain of the hairpin would co-localize these two 
domains to provide an effective binding site for a complementary trigger RNA. To take 
advantage of this design feature and improve repressor orthogonality, we designed cognate 
triggers where domain b is mostly contained in a hairpin secondary structure and a toehold 
domain a and part of domain b is located at the 3’ end. When the trigger RNA is expressed, 
the toehold initially binds to the a* domain and part of the b* domain of the switch RNA. 
The switch RNA b* domain then completes a branch migration to unwind the trigger RNA 
stem. The resulting trigger-switch complex has a stable three-way junction structure that 
effectively sequesters the RBS and start codon within the loop and stem of the switch RNA, 
respectively, and strongly represses translation. Despite the use of a trigger with a hairpin 
structure to improve device orthogonality, the 3WJ repressors can also detect nearly 
arbitrary trigger RNAs provided that the trigger RNA sequence does not lead to an in-frame 
stop codon in domain b*. 
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Figure 3.1 Operating mechanisms of de-novo-designed repressors and in vivo library 
characterization. a, Toehold switches repress translation through programmed base pairs 
before and after the start codon (AUG), leaving the ribosomal binding site (RBS) and start 
codon regions completely unpaired. RNA-RNA interactions are initiated via a single-
stranded interaction domain called a toehold. The toehold domain a* of switch RNA binds 
to a complementary a domain on the trigger RNA, initiating branch migration through 
domain b to open up the RBS and start codon of the switch RNA. b, The switch RNA of 
the three-way junction (3WJ) repressors contains an unstable hairpin structure that allows 
ribosomal access to the RBS and start codon and provides two single-stranded domains a* 
and b* for trigger binding. The trigger RNA has a hairpin structure and employs the toehold 
domain a to bind to the switch RNA whereupon branch migration through domain b forms 
a three-way junction structure that prevents ribosomal access to the RBS and start codon. 
c, Fold reduction of GFP fluorescence levels obtained 3 hr after induction for a library of 
48 3WJ repressors. Relative errors for the ON and OFF translation states are from three 
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biological replicates. Relative errors for GFP fold reduction were obtained by adding the 
relative errors of the repressor ON and OFF state fluorescence measurements in quadrature. 
 
3.3.2 In Silico Design of Repressor Libraries and In Vivo Validation  
We generated libraries of both translational repressors de novo using the NUPACK 
nucleic acid sequence design package14. A total of 48 3WJ repressors were designed and 
validated in vivo (see appendix B Supplementary Table S3.1, S3.2 and S3.3 for sequence 
information). Members of the 3WJ repressor library were selected to minimize the potential 
for the non-cognate trigger RNAs to interact with the switch RNA. The E. coli BL21 Star 
DE3 strain with an IPTG-inducible genomic T7 RNA polymerase and decreased RNase 
activity was used for repressor characterization. A medium-copy plasmid containing the 
switch RNA regulating GFP and a high-copy plasmid encoding trigger RNA were 
transformed into E. coli. For measurements in the absence of a cognate trigger RNA, a non-
cognate RNA strand with high secondary structure was transcribed from the high-copy 
plasmid.  
Figure 3.1c shows the fold reduction of GFP fluorescence observed for the 3WJ 
repressor library after three hours of IPTG induction. The GFP fold reduction was 
measured from the geometric mean fluorescence of GFP obtained from flow cytometry for 
cells in the ON state expressing the non-cognate trigger RNA and in the repressed OFF 
state expressing a cognate trigger RNA (see appendix B Supplementary Fig. S3.2 for ON 
and OFF state GFP expression levels). Cell autofluorescence was not subtracted from either 
the ON or OFF state fluorescence for determination of the GFP fold reduction. Among all 
the 3WJ repressors tested, a high fraction of these devices at 71% or 34 out of 48 provided 
at least 10-fold reduction of GFP expression, while a smaller fraction (8% or 4 out of 48) 
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yielded exceptionally high 50-fold or more reduction in GFP. Although BL21 Star DE3 is 
an RNase-deficient strain, we found that the 3WJ repressors provided greater than 20-fold 
reduction of GFP in E. coli BL21 DE3 cells with wild-type RNase levels (see appendix B, 
Supplementary Fig. S3.3a and S3.3b). In general, longer time of incubation and higher 
IPTG concentration provides improved GFP fold reduction for 3WJ repressors, primarily 
due to the expression and accumulation (appendix B, Supplemental Fig. S3.3c and S3.3d). 
3.3.3. SHAPE-Seq Measurements of 3WJ Repressor Structure 
To better understand the operating mechanism of the synthetic repressors, our 
collaborator Paul Carlson performed in-cell SHAPE-Seq15 on several devices with varying 
repression efficiencies. The weaker secondary structures of the 3WJ repressors enabled 
SHAPE-Seq studies for multiple trigger-switch interaction lengths. In the SHAPE-Seq 
experiment, 1-methyl-7-nitroisatoic anhydride (1M7) is introduced into the cell culture. 
1M7 covalently modifies cellular RNAs in a structure-dependent manner, preferentially at 
positions that are unstructured and unconstrained by interactions. These modifications can 
be detected by reverse transcription stops coupled to high-throughput sequencing, and the 
mapped modification positions can then be used to calculate a reactivity value (β) at each 
nucleotide. Higher reactivities correspond to flexible or unstructured nucleotides, and 
lower reactivities indicate constrained interactions such as base-pairing or stacking effects. 
Simultaneous measurements of GFP expression using the same cell cultures used for 
structural probing allow direct links to be drawn between the performance of repressor 
variants and their structures. 
We first studied a single 3WJ repressor switch RNA and three trigger variants, with 
interaction lengths ranging from 18 to 25 nts (Fig. 3.2, see appendix B, Supplementary 
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Table S3.4 for sequence information). Functional characterization demonstrated active 
translation from the switch RNA and strong translational repression upon trigger 
expression (Fig. 3.2b). SHAPE-Seq reactivity measurements of these variants showed 
remarkable agreement with the proposed in silico design strategy. When the trigger RNA 
was not expressed, we observed a trend of high reactivities across the switch RNA 
sequence (Fig. 3.2c). This reactivity signature supports the design hypothesis that the 
switch hairpin is sufficiently weak to facilitate structural disruption by ribosomes, leading 
to active translation. A striking difference is seen when a trigger RNA is expressed (Fig. 
3.2d). Sharp drops in reactivity are observed precisely at the predicted binding sites of each 
trigger (a-a* in blue and b-b* in red), providing structural evidence of trigger binding 
across the junction. Moreover, drops in reactivity also occur within the stem of the switch 
RNA hairpin at regions predicted to form the hairpin structure, providing direct evidence 
that trigger binding leads to the formation of a stable, translationally inaccessible 3WJ 
structure. Interestingly, higher reactivities are observed at several positions around the base 
of the hairpin when the triggers are present (specifically U16-U19), suggesting slight 
fraying or flexibility at the base of the trigger-switch three-way junction. We also studied 
a second 3WJ repressor with different triggers. These experiments also showed formation 
of the intended three-way junction structure in the repressed state (see appendix B, 
Supplementary Information for details and Supplementary Fig. S3.4). To the best of our 
knowledge, these results represent the first structural confirmation of the regulatory 
mechanism of a completely de-novo-designed riboregulator. 
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Figure 3.2 In-cell SHAPE-Seq confirmation of the 3WJ repressor mechanism. a, Design 
schematic for testing 3WJ repressor variants. A 3WJ repressor switch was characterized 
using in-cell SHAPE-Seq, either expressed alone or co-expressed with a trigger RNA. 
Several triggers were tested, varying in their designed binding length (ab) to either side of 
the switch hairpin. b, Functional characterization of switch plasmid expressed without 
trigger (green) and with triggers of increasing interaction length (blue). Strong repression 
is observed upon trigger binding, with longer triggers showing increased repression 
efficiency. c, In-cell SHAPE-Seq reactivity profile of the switch RNA expressed alone. A 
trend of high reactivities is observed across the molecule, consistent with the design 
hypothesis that the switch hairpin can be disrupted by ribosome binding, leading to active 
translation. d, In-cell SHAPE-Seq reactivity profiles of the switch co-expressed with 
trigger RNAs. Sharp drops in reactivity are observed at the predicted trigger binding sites 
(a-a* and b-b*) and within the switch hairpin, suggesting formation of a stable 3WJ 
structure when the trigger is bound. The RBS and start codon (AUG) positions are 
indicated. 
 
3.3.4 Evaluation of Repressor Orthogonality 
One of the prerequisites for higher-order logic processing is the orthogonality of 
regulatory components with respect to one another. We thus measured in vivo the 
interactions between pairwise combinations of different repressor trigger and switch 
RNAs. Crosstalk in terms of GFP fold reduction was calculated by dividing the GFP 
fluorescence obtained from a non-cognate trigger and a given switch RNA by the 
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fluorescence of the switch in its triggered state. Typically, non-cognate trigger-switch pairs 
showed significantly higher GFP output as compared to cognate trigger-switch pairs as 
shown in Figure 3.3. Based on the short exposed single-stranded regions of the 3WJ 
repressor trigger RNAs, which reduced the potential for interaction with switch RNAs, and 
the partially concealed RBS and start codon within a weak stem to discourage interactions 
in trans with non-cognate trigger RNAs, we anticipated that the 3WJ repressor devices 
would show high orthogonality. We measured the pairwise trigger-switch interactions for 
16 of the top devices (Fig. 3.3a). The 3WJ repressor library showed substantially low 
crosstalk while maintaining strong repression of cognate trigger-switch pairs (see appendix 
B, Supplementary Fig. S3.5 for GFP expression levels). In fact, we found that a set of 15 
out of the 16 3WJ repressors tested provided at least 17-fold reductions in GFP expression 
in the presence of the cognate trigger compared to any of the other 14 non-cognate triggers 
in the orthogonal set. Moreover, we only observed significant crosstalk in a single pairwise 
interaction, which occurred between switch 40 and trigger 19 (red box in Fig. 3.3a). 
To quantify the orthogonality of the devices, we determined the maximum number 
of repressors that could be used to provide a given minimum level of overall dynamic range 
(Fig 3.3b, see appendix B, Supplementary Table S3.5 for the sets of orthogonal repressors). 
This analysis showed high performance in orthogonal library size and dynamic range for 
the 3WJ repressor. For example, eight-device 3WJ repressor set yielded an overall dynamic 
range of 29-fold. We also applied this analysis to measurements of the 3WJ repressors 
induced over longer four- and five-hour induction times. As the induction time increased, 
the overall fold reduction of GFP in the cells generally increased, leading to parallel 
improvements in device orthogonality. For instance, an eight-device orthogonal 3WJ 
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repressor library provided a dynamic range that rose to 73-fold after five hours of induction. 
Moreover, a set of six 3WJ repressors provided a remarkable library dynamic range of 118 
at the five-hour time point. 
 
Figure 3.3 Assessment of 3WJ repressor orthogonality. a, Three-way junction repressor 
crosstalk measured by flow cytometry for 256 trigger-switch combinations 3 hours after 
induction. All but one of the 240 non-cognate combinations provide at least 14-fold 
higher GFP expression than cognate pairs. b, Comparison of overall library dynamic 
range and orthogonal library size for the 3WJ repressors. Three-way junction repressor 
orthogonal library size and dynamic range increase over the 3- to 5-hour IPTG induction 
time. 
 
3.3.5 mRNA-Sensing Repressors 
The ability to detect nearly arbitrary trigger RNA molecules enables synthetic 
repressors to respond to intracellular mRNAs and has potential diagnostic 
applications12,13,16. We left the riboregulator design unchanged and selected target mRNA 
binding sites by determining 27-nt regions having low secondary structure (Fig. 3.4, table 
S3.6). 
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Figure 3.4 mRNA sensing using repressor-based devices. a, Design schematic of the 
mRNA-sensing 3WJ repressors. The region within the mRNA sequence used to trigger 
repression is emphasized in red. b, Fluorescent protein (FP) fluorescence observed for 3WJ 
repressors targeting two different pairs of antibiotic resistance mRNAs. c, Fold reduction 
of GFP for the 3WJ repressor mRNA sensors.  
 
The mRNA-sensing repressors were validated against several mRNAs encoding 
antibiotic resistance genes: the kanamycin resistance protein (kanR), and aadA conferring 
resistance to spectinomycin. We constructed kanR and aadA sensors that both regulated 
GFP output. The mRNA-sensing repressors were then tested using procedures employed 
for library validation and expression induced for 5 hours using IPTG. Figure 3.4b displays 
the fluorescence intensity of the fluorescent proteins GFP produced by the repressors with 
and without expression of the target mRNAs. For both mRNA sensors, protein expression 
is significantly reduced in the presence of the cognate mRNA. Mean fluorescence 
intensities were then used to determine the fold reduction of GFP for the mRNA sensors 
(Fig. 3.4c). 3WJ repressors provided 20-fold reductions in GFP fluorescence upon 
inhibition by the kanR mRNA, and yielded 5-fold reductions in GFP expression in response 
to aadA mRNAs. These results show that the programmable repressors can be used to 
strongly inhibit output protein expression in response to functional mRNAs. 
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3.4 Discussion 
We have developed a new type of high-performance translational repressors using 
de novo RNA sequence design. The synthetic three-way junction repressors provide 
performance that is comparable to protein-based transcriptional repressors and a substantial 
improvement over earlier RNA-based translational repressors. A previous 20-component 
protein repressor library selected from genomically mined parts yielded an average 51.3-
fold reduction in reporter expression5, while translational repressors based on the IS10 
antisense RNA system reduced GFP expression by up to ~10-fold9. In comparison, the top 
20 3WJ repressors provided protein-like performance with average GFP reductions of 43-
fold. Previously, the IS10 system was extended to form an orthogonal library of six devices 
with under 20% crosstalk9. However, the 3WJ repressors, which feature designs better 
optimized to reduce crosstalk, provided enhanced orthogonality with 15 repressors yielding 
17-fold dynamic range. In general, the synthetic repressors exhibited narrower dynamic 
range compared to toehold switch translational activators, primarily due to translation that 
occurs prior to trigger-switch binding. Overall, the 3WJ repressors represent a versatile 
new set of components to add to the rapidly expanding RNA synthetic biology toolkit. 
We also successfully applied in-cell SHAPE-Seq15, which combines in-cell probing 
of RNA structure with gene expression measurements, to simultaneously characterize 
RNA structure and function in high-throughput for the 3WJ repressors. Analysis of 3WJ 
repressors yielded the first direct structural evidence to support the mechanistic model of a 
de-novo-designed riboregulator and also revealed potential pit-falls in our design 
strategies. These results highlight how SHAPE-Seq can be used to confirm design 
principles and understand potential failure modes of synthetic riboregulators. Moreover, 
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the ability of RNA structure probing methods to detect interactions such as long-range 
tertiary structures and RNA-protein binding17 will make them even more important as the 
complexity of de-novo-designed riboregulators continues to increase. Indeed, we expect 
that future application of SHAPE-Seq to ribocomputing gate RNA designs will help 
uncover relationships between sequence, structure, and function. Such efforts, in concert 
with forward engineering strategies driven by thermodynamic models, RNA sequence 
design, and automated design methodologies18, have the potential to provide sizeable 
improvements in de-novo-designed riboregulator performance and RNA-based computing 
architectures.  
We further anticipate that the ability of 3WJ repressors to detect nearly arbitrary 
RNAs will prove useful in cell-free diagnostic systems12,13,16,19 for identification of 
specific pathogen nucleic acids and their use of universal RNA-RNA interactions could 
enable their application in other prokaryotic hosts. 
3.5 Experimental Methods 
3.5.1 Strains and growth conditions  
These E. coli strains were used in this study: BL21 Star DE3 (F- ompT hsdSB (rB-
mB-) gal dcm rne131 (DE3); Invitrogen), BL21 DE3 (F- ompT hsdSB (rB-mB-) gal dcm 
(DE3); Invitrogen), and DH5α (endA1 recA1 gyrA96 thi-1 glnV44 relA1 hsdR17 (rK-mK+) 
λ-). All strains were grown in LB medium at 37°C with appropriate antibiotics: ampicillin 
(50μg mL-1), spectinomycin (25 μg mL-1), and kanamycin (30 μg mL-1).  
3.5.2 3WJ repressor library construction  
Plasmids were constructed using PCR and Gibson assembly. DNA templates for 
repressor switch and trigger RNA expression were assembled from single-stranded DNAs 
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purchased from Integrated DNA Technologies. The synthetic DNA strands were amplified 
via PCR and then inserted into plasmid backbones using 30-bp homology domains via 
Gibson assembly20. All plasmids were cloned in the E. coli DH5α strain and validated 
through DNA sequencing. Backbones for the plasmids were taken from the commercial 
vectors pET15b (ampicillin resistance, ColE1 origin), pCOLADuet (kanamycin resistance, 
ColA origin), and pCDFDuet (spectinomycin resistance, CDF origin) from EMD 
Millipore, and the repressor DNA was inserted upstream of the T7 terminator sequence to 
replace their respective multiple cloning sites. GFPmut3b-ASV, GFPmut3b with an ASV 
degradation tag21, was used as the reporter for the repressor switch plasmids except for the 
kanR mRNA sensor that used mCherry as the reporter. Sequences of elements commonly 
used in the plasmids are provided in appendix B, Supplementary Tables.  
3.5.3 3WJ repressor expression 
3WJ repressor switch and trigger RNAs were expressed using T7 RNA polymerase 
in BL21 Star DE3, an RNase-deficient strain, with the T7 RNA polymerase induced with 
the addition of isopropyl β–D-1-thiogalactopyranoside (IPTG). Selected sets of toehold 
and 3WJ repressor switch and trigger RNAs were also tested in BL21 DE3 strain with the 
T7 RNA polymerase induced with the addition of IPTG. For both strains, cells were grown 
overnight in 96-well plates with shaking at 900 rpm and 37°C. Overnight cultures were 
then diluted by 100-fold into fresh LB media with antibiotics and returned to shaker (900 
rpm, 37C). After 80 minutes, both strains were induced with 0.1 mM IPTG and cells were 
returned to shaker (900 rpm, 37°C) until the flow cytometry measurements at specified 
times post-induction.  
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3.5.4 Flow cytometry measurements and analysis 
Flow cytometry measurements of 3WJ repressor libraries and their ribocomputing 
devices were performed using a Stratedigm S1300EXi cell analyzer equipped with a A600 
high-throughput autosampler. Cells with the 3WJ repressor systems were diluted by a 
factor of ~17 into phosphate-buffered saline and detected as described above with 40,000 
cells recorded for each measurement. Cell populations were gated according to their FSC 
and side scatter (SSC) distributions as described previously12, and the GFP or mCherry 
fluorescence levels of these gated cells were used to measure circuit output via the 
geometric mean from at least three biological replicates. Fold reductions of GFP or 
mCherry fluorescence levels were then evaluated by taking the geometric mean 
fluorescence output of toehold or 3WJ repressor switch with a non-cognate trigger and 
dividing it by the fluorescence output with a cognate trigger. Cellular autofluorescence was 
not subtracted prior to determining the fold reduction. 
3.5.6 SHAPE-Seq measurements and analysis 
In-cell SHAPE-Seq measurements were carried out as described by Watters et al.15. 
Briefly, 3WJ repressor variants were transformed into BL21 Star DE3 as in the functional 
characterization experiments. Overnight cultures were diluted by a factor of 100 into 1.2 
mL of fresh LB with antibiotics. Following IPTG induction and 5 h additional subculture, 
100 µL cells were removed and diluted by a factor of ~100 for functional characterization, 
which was performed using a BD Accuri cell analyzer with a high-throughput sampler. 500 
µL of the remaining culture was then added to 13.3 µL of 250 mM 1M7 or 13.3 µL of 
DMSO (control solvent). Cells were returned to shaking for 3 minutes to allow 1M7 to 
react, then cellular RNAs were Trizol extracted and reverse transcribed using a custom 
  63 
reverse transcription primer specific for GFPmut3b (5’-
CAACAAGAATTGGGACAACTCCAGTG-3’). Additional 5’ and 3’ sequencing 
adapters were then added. Following 2 x 35 bp paired-end Illumina sequencing, ß 
reactivities were calculated as described by Aviran et al.22. Error bars represent the standard 
deviation of three samples, each probed from a separate transformation on a separate day. 
Replicate samples were only processed in parallel during final sequencing.  
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CHAPTER 4 
RNA REPRESSOR-BASED MULTI-INPUT CELLULAR LOGIC GATES 
Adapted with permission from Kim, J., &Zhou, Y., Carlson P. D., Teichmann, M., Simmel, 
F. C., Silver, P. A., Collins, J. J., Lucks, J. B., Yin, P., Green, A. A. (2019). De-Novo-
Designed Translational Repressors for Multi-Input Cellular Logic. Nature Chemical 
Biology, manuscript under review. Copyright 2019 Nature publishing group. 
4.1 Abstract 
Efforts to construct synthetic biological circuits with more complex functions have 
often been hindered by the idiosyncratic behavior, limited dynamic range, and crosstalk of 
commonly utilized parts. The three-way junction (3WJ) repressors with high dynamic 
range and high orthogonality are ideal regulatory elements for constructing sophisticated 
cellular circuits with NOT logic. Harnessing the 3WJ repressors as modular parts, we 
integrate them into biological circuits that execute universal NAND and NOR logic with 
up to four independent RNA inputs in Escherichia coli. 
4.2 Introduction 
Starting with the first demonstrations of toggle switches1 and oscillators2 in 
Escherichia coli, synthetic biology approaches have yielded novel and increasingly 
sophisticated gene circuitry over the years including synchronized oscillators3,4, logic 
gates5,6,7,8, memory devices9,10, analog signal processors11,12, and state machines13. Bacteria 
enhanced with engineered genetic circuits have found use as memory devices in the 
mammalian gut environment18 and have been deployed against tumors in mouse models14. 
Cancer cell classifiers15 have further expanded the utility of synthetic circuitry for 
biomedical applications. Despite these advances, many of the regulatory elements in 
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previous work overlap or are not compatible with each other, thereby limiting the ability 
to integrate such diverse components and elementary systems towards more complex 
circuits for biotechnological applications. The idiosyncratic nature of many protein 
regulatory elements presents challenges in their use in circuits with complex regulatory 
behavior. Recently, these challenges were addressed for protein-based regulatory parts by 
using insulation and computer-aided design strategies to scale up the complexity of 
combinatorial16 and sequential17 logic circuits in bacteria. In mammalian cells, the highly 
specific DNA-modifying activities of recombinases were used to implement over 100 
genetic circuits with minimal optimization18, while composable viral proteases were used 
to construct a variety of protein-only circuits19. De-novo designed RNA regulators 
demonstrated great advantages in programmability for their highly predictable structural 
and thermodynamic behavior. The modular and programmable nature of toehold switches 
provided a general framework for their integration into multi-input logic processing 
ribocomputing devices20 and enabled their deployment in diagnostic systems21,22,23,24. In 
previous work, however, NOT logic was only achieved by using antisense RNAs, which 
imposed sequence constraints and precluded efficient implementation of the universal 
NAND and NOR logic gates. Recent work has highlighted the importance of robust 
universal logic gates as building blocks for constructing complex genetic circuitry16,17,25. 
A crucial factor in the development of these systems has been the generation of large 
libraries of repressors that carry out NOT logic by suppressing gene expression26,27. 
Accordingly, the development of analogous libraries of high-performance RNA-based 
repressors could enable more efficient and complex forms of biomolecular logic. Based on 
our previous established three-way junction (3WJ) translational repressors, validated high-
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performance 3WJ repressors with low crosstalk are integrated into ribocomputing devices 
to achieve NOR and NAND logic with up to four sequence-independent input RNAs, 
providing universal building blocks for logical computation. Overall, this study 
demonstrates that computer-driven design and ribocomputing strategies can be 
successfully applied towards achieving robust translational repression. 
4.3 Results 
The modular and programmable nature of the 3WJ repressors makes them ideal 
candidates for integration into ribocomputing devices for implementing sophisticated 
genetic programs. We have previously demonstrated that toehold switch riboregulators can 
be incorporated into such RNA-based computing systems for multi-input intracellular 
computation using RNA input signals and protein signals20,28. These devices employ RNA-
RNA interactions for all signal processing tasks and they co-localize signal processing 
functions by using gate RNA transcripts containing one or more riboregulator modules 
upstream of the output gene. We thus applied the ribocomputing strategy to the repressors 
to enable efficient computation of NAND and NOR logic functions in living cells. 
4.3.1 Two-input NAND Logic Circuitry 
We implemented repressor-based gate RNAs integrating multiple repressor hairpin 
modules upstream of the output gene. The comparatively weak secondary structure of the 
3WJ repressors and their short trigger RNA binding sites were ideal for incorporation into 
gate RNAs. We implemented a two-input NAND gate RNA composed of two orthogonal 
3WJ repressor hairpins separated by a 17-nt single-stranded spacer domain (Fig 4.1a). In 
the presence of only one input RNA, the input can bind to repress translation from its 
corresponding hairpin module. However, translation of the output gene will continue from 
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the unrepressed hairpin module, since the ribosome can translate through weak hairpin 
secondary structures and duplexes formed by input and gate RNAs. As a result, only upon 
binding of both input RNAs at the same time to the gate RNA will output gene expression 
be fully inhibited. Figure 4.1b shows the mean GFP fluorescence intensity obtained from 
the two-input NAND circuit after 6 hours of induction by IPTG (see appendix C, 
Supplementary Fig. S4.1a for GFP population histograms of all ribocomputing circuits). 
The RNA inputs and the gate RNA were expressed from separate plasmids through the T7 
promoter in BL21 Star DE3 cells. In cases where an input RNA was not present, a non-
cognate RNA was expressed in its place. We evaluated the resulting two-input NAND gate 
and found that GFP expression remained strong except for the logical FALSE case with 
both inputs expressed after 6 hours of induction by IPTG (Fig. 4.1b). Small decreases in 
GFP expression were observed when only one of the input RNAs was present, likely as a 
result of inhibition of one of the two translation initiation sites from the gate RNA. The 
GFP fold reductions of the circuit show a large 88-fold decrease in expression in response 
to the two input RNAs compared to null input case (Fig 4.1c). This reduction was at least 
a factor of 33 higher than any of the changes in expression observed for single-input cases. 
 
Figure 4.1 two-input NAND logic operations using repressor-based devices. a, Design 
schematic of a two-input NAND gate constructed from 3WJ repressors. In the gate RNA, 
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two switch hairpin modules are inserted in-frame and upstream of the reporter gene. Both 
input RNAs are required to bind to the gate RNA to prevent gene expression. b, c, GFP 
fluorescence (b) and fold reduction (c) measurements of multiple input combinations for 
the two-input NAND gate based on 3WJ repressors. The GFP fold reductions of devices 
are calculated by dividing the GFP fluorescence from gate RNA obtained for the null input 
case by the GFP fluorescence for given input combinations. Relative errors for ON and 
OFF states are from the SD of three biological replicates. Relative errors for the 
ribocomputing device fold reductions were obtained by adding the relative errors of the 
sensor ON and OFF state fluorescence measurements in quadrature. 
 
4.3.2 Two-input NOR Logic Circuitry 
To implement NOR ribocomputing devices responsive to two sequence-
independent input RNAs, we developed a new gate RNA architecture that exploited co-
localized intramolecular interactions (Fig 4.2a and appendix C, Supplementary Fig. S4.2a). 
These NOR gate RNAs contain multiple sequestered trigger RNA sequences upstream of 
a 3WJ repressor module regulating the output gene. The trigger RNA domains x and y, 
which are complementary to the downstream repressor hairpin, are confined within the 
loops of strong hairpin secondary structures. These hairpins function as input RNA sensors 
that provide toehold domains for binding to complementary input RNA sequences. When 
an input RNA is expressed, binding to the input sensor leads to a branch migration that 
unwinds the sensor stem. This interaction releases the trigger RNA domain and enables the 
trigger to repress the downstream 3WJ repressor domain through an efficient gate RNA 
intramolecular interaction. We constructed the two-input NOR gate RNA using a validated 
3WJ repressor and two input sensor hairpins, resulting in a gate RNA regulatory region of 
312 nts. Measurements of GFP fluorescence from this gate RNA showed a substantial 
reduction in fluorescence upon expression of any of the cognate input RNAs after 6 hours 
of IPTG induction (Fig. 4.2b). We observed lower GFP output from the NOR gate RNA 
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for the null input case compared to other 3WJ repressor gate RNAs. It is likely that there 
is some repression leakage from incomplete sequestration of the trigger RNA domains. 
Despite the lower overall expression level of the gate RNA, analysis of the GFP fold 
reductions from the circuit show between 8- to 12-fold decrease in GFP output in response 
to one or two input RNAs (Fig. 4.2c) and confirm the successful operation of the new gate 
RNA design. 
 
Figure 4.2 two-input NOR logic operations using repressor-based devices. a, Design 
schematic of a two-input NOR gate based on 3WJ repressors. The gate RNA contains a 
single 3WJ repressor hairpin to regulate the output gene and a pair of trigger modules 
sequestered within the loops of strong hairpin secondary structures that sense the cognate 
input RNAs. Toehold-mediated binding of either input RNA causes the corresponding 
hairpin to unwind, which releases the trigger to bind to the 3WJ repressor module and 
inhibit gene expression. b, c, GFP fluorescence (b) and fold reduction (c) measurements of 
multiple input combinations for the two-input NOR gate based on 3WJ repressors. The 
GFP fold reductions of devices are calculated by dividing the GFP fluorescence from gate 
RNA obtained for the null input case by the GFP fluorescence for given input 
combinations. Relative errors for ON and OFF states are from the SD of three biological 
replicates. Relative errors for the ribocomputing device fold reductions were obtained by 
adding the relative errors of the sensor ON and OFF state fluorescence measurements in 
quadrature. 
 
4.3.3 Three- and Four-Input NAND Logic Circuitry 
To further evaluate the capabilities of the repressor-based ribocomputing devices, 
we implemented several logic circuits employing more than two input RNAs. NAND gate 
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RNAs based on 3WJ repressors were extended to three- and four-input operation by adding 
additional repressor modules upstream of the output gene. A three-input gate RNA for 
NOT (A AND B AND C) computations was constructed using three orthogonal 3WJ 
repressor hairpins separated by 11-nt single-stranded spacer domains (Fig. 4.3a). This 
ribocomputing device showed high GFP expression for all logical TRUE conditions 
lacking at least one of the input RNAs (Fig. 4.3b), while providing low expression for the 
logical FALSE condition with all inputs. The GFP fold reduction for this NAND circuit 
was 163-fold over the null input case and provided at least 33-fold lower GFP expression 
than the other input RNA combinations (Fig. 4.3c). We constructed a four-input device to 
evaluate the expression NOT (A AND B AND C AND D) using a gate RNA with four 
orthogonal 3WJ repressor modules separated by 17-nt single-stranded spacers, resulting in 
a gate RNA regulatory region of 365 nts (Fig. 4.3d and appendix C, Supplementary Fig. 
S4.2b). The GFP fluorescence for this device remained high for all logical TRUE 
conditions and decreased substantially when all input RNAs were expressed (Fig. 4.3e). 
Calculation of the GFP fold changes for this circuit showed a 6-fold reduction in GFP 
expression in the sole logical FALSE state (Fig. 4.3f). The overall dynamic range of the 
four-input NAND gate was substantially lower than that of the three-input NAND gate. 
We attribute the weaker performance of this circuit to the difficulty in forming the complete 
five-RNA molecular complex required for complete repression of gene expression. 
Nevertheless, the four-input NAND ribocomputing device provided at least a 3.7-fold 
reduction in GFP compared to all logical TRUE states. 
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Figure 4.3 Multi-input ribocomputing devices employing toehold and 3WJ repressors. a, 
Design schematic for a three-input NAND gate based on 3WJ repressors. The gate RNA 
contains three orthogonal 3WJ repressor hairpins in-frame and upstream of the output gene. 
b, c, GFP fluorescence (b) and fold reduction (c) measurements of multiple input 
combinations for the three-input NAND device based on 3WJ repressors. d, Design 
schematic for a four-input NAND gate based on 3WJ repressors. The gate RNA contains 
four orthogonal 3WJ repressor hairpins in-frame and upstream of the output gene. e, f, GFP 
fluorescence (e) and fold reduction (f) measurements of multiple input combinations for 
the four-input NAND device based on 3WJ repressors.  The GFP fold reductions of devices 
are calculated by dividing the GFP fluorescence from gate RNA obtained for the null input 
case by the GFP fluorescence for given input combinations. Relative errors for ON and 
OFF states are from the SD of three biological replicates. Relative errors for the 
ribocomputing device fold reductions were obtained by adding the relative errors of the 
sensor ON and OFF state fluorescence measurements in quadrature. 
 
4.4 Discussion 
Three-way junction repressors exhibit very low device crosstalk while using 
weaker RNA secondary structures and are optimal for multiplexed sensing and multi-input 
logic systems. The high performance and modularity of the 3WJ repressors enabled them 
to be incorporated into genetically compact ribocomputing devices that effectively 
computed NOT-related logic expressions with up to four different input RNAs. Previous 
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implementations of ribocomputing NOT logic have been limited by sequence constraints 
due to a reliance on antisense RNA interactions. The 3WJ repressor designs were amenable 
to integration into long gate RNAs that simultaneously detect multiple sequence-
independent trigger RNAs. The gate RNA with multiple 3WJ repressors showed good 
performance in a NAND circuit using up to four input RNAs. Alternatively, NOR gates 
can be constructed by regulating a 3WJ switch module using trigger RNAs sequestered 
within upstream hairpin domains. Since translation of the NOR gate output protein begins 
at the single 3WJ switch module, this gate RNA architecture does not require translation 
through downstream hairpins nor does it append long N-terminal sequences to the output 
protein, which both occur for previously reported OR gate RNAs. The development of 
these NOT, NAND, and NOR logic devices coupled with advances in RNA-guided 
CRISPR/Cas systems29, RNA-based transcriptional regulators25,30,31, and systems that 
merge these capabilities32 point to increasingly sophisticated forms of RNA-enabled 
genetic circuits that exploit regulation at the transcriptional, translational, and post-
transcriptional levels to achieve more dynamic and programmable cellular functions. 
4.5 Experimentl Methods 
Refer to chapter 3 for plasmid construction, cell strains and growth condition, and 
flow cytometry measurements and analysis.  
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CHAPTER 5 
PERSPECTIVES OF BIOLOGICAL APPLICATIONS OF DNA/RNA 
DEVICES 
5.1 Future directions of DNA/RNA nanotechnology 
In the past decades, researchers have put a lot of effort in constructing nucleic acid 
nanostructures with increasing complexity over broad range of scales. However less have 
been done to address the functionalization of the nanostructures for bio-reactivity in vivo. 
The future for nucleic acid nanotechnology would be emphasized on firstly the precise 
control of dynamic structural change over broad range in physiological environment, and 
also the functionalization of bio-reactive molecules on the dynamic structure. In nature, 
majority of the scaffolding or bio-reacting work have been done by proteins impressively 
with their elegant organization of all varieties of amino acids. Deciphering the protein 
folding principles have been attractive but also formidable due to its complexity and 
uncertainty1,2,3. In aspects of structural diversity and bio-reactivity to rival proteins, RNA 
outperforms DNA for in vivo applications and have been found with functions like 
scaffolding and enzyme activity in nature, for example the ribozyme4 which has self-
cleaving nuclease activity with certain structure, ribosomal RNA5 which comprises 60% 
of the ribosome weight and direct the genetic code recognition, noncoding RNA that was 
found with all kinds of regulatory effect for cellular events6,7, and most recently discovered 
guide RNA in CRIPSR/cas systems8,9,10 that direct the targeted nuclease activity. RNA is 
an important bridge between structural nucleic acid devices and bio-reactive components 
for the realization of synthetic machinery that functions in cells. With more and more 
crystal structures getting resolved for the natural RNA components, the tool box for 
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structural elements will getting enriched and greatly facilitate the construction of arbitrary 
structures that functions in vivo. At the same time, the design software will get greatly 
improved for more accurate design of desired structures. 
5.2 Perspective of riboregulator 
So far, riboregulatos have been utilizing secondary structure switch to regulate 
biological events like transcription11 or translation12. The direction of riboregulator would 
inevitably be 1) dynamic regulation over long distance through tertiary structures and 2) 
regulating more kinds of biological events. The structural motifs like kissing-loops, kink 
turns and pseudo-knot will be more readily applied in the design. With the progress in 
fundamental biology to unveil the ever mysterious cellular events, synthetic biology comes 
in and take hold, making it possible to regulate more and more biological events with 
artificial components. For example, researchers found the structural basics for RNA 
substrate in RNA interference pathway13, making it possible to more accurately manipulate 
the pathway by regulating the RNA structure. Another outstanding scientific achievement 
in this decade is the discovery and exponentially growing applications for CRIPSR 
(clusters of regularly interspaced short palindromic repeats) systems. It’s originally 
discovered when studying the acquired bacteria immunity against phage, and then the 
molecular tool has been quickly adapted to all kinds of fundamental, agriculture or 
therapeutic applications8,9,10. The key component in CRISPR is also RNA which can be 
integrated with RNA regulatory systems to achieve conditional nuclease cutting.  
In summary, the next phase of DNA/RNA technology would be structural 
regulation and interaction with biological systems with high accuracy and versatility. More 
structural parameters and high-performance bio-reactive components like aptamers will 
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constantly be in high demand, giving opportunities and challenges in fundamental studies 
and applications. 
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APPENDIX A 
SUPPLEMENTARY INFORMATION FOR CHAPTER 2 
DNA SCAFFOLD-ASSISTED SELECTION OF HIGH AFFINITY 
BIVALENT APTAMERS FOR HUMAN ALPHA-THROMBIN 
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Table S2.1 Two loop sequences in selected library for top 100 sequences 
 
ranking Left loop sequence family Right loop sequence family Repeats 
1 AGGGATGATGTGTGGTAGGC A GTAGGATGGGTAGGGTGGTC D 22 
2 AGGGTAGGTGTGGATGATGC B CTAGGTTGGGTAGGGTGGTG D 22 
3 AGGGATGATGTGTGGTAGGC A CTAGGATGGGTAGGGTGGTG D 19 
4 AGGGTAGGTGTGGATGATGC B CTAGGATGGGTAGGGTGGTG D 18 
5 AGGGTAGGTGTGGATGATGC B ATAGGTTGGGTAGGGTGGTT D 17 
6 GTAGGATGGGTAGGGTGGTC D GTAGGATGGGTAGGGTGGTC D 16 
7 AGGGTAGGTGTGGATGATGC B TAGGTTTTGGGTAGGGTGGT C 15 
8 GTAGGTTGGGTAGGGTGGTC D CTAGGTTGGGTAGGGTGGTG D 15 
9 AGGGATGATGTGTGGTAGGC A ATCGTCCAAGGGGTCAGCGT Other 15 
10 AGGGATGATGTGTGGTAGGC A TAGGTTTTGGGTAGGGTGGT C 15 
11 AGGGTAGGCGTGGATGATGC B GTAGGTTGGGTAGGGTGGTC D 14 
12 AGGGTAGGAGTGGATGATGC B GTAGGTTGGGTAGGGTGGTC D 14 
13 AGGGATGATGTGTGGTAGGC A GTAGGTTGGGTAGGGTGGTC D 13 
14 GTAGGATGGGTAGGGTGGTC D CTAGGATGGGTAGGGTGGTG D 13 
15 AGGGATGATGCGTGGTAGGC A CTAGGTTGGGTAGGGTGGTG D 13 
16 AGGGTAGGAGTGGATGATGC B CTAGGATGGGTAGGGTGGTG D 13 
17 GTAGGATGGGTAGGGTGGTC D TAGGTTTTGGGTAGGGTGGT C 13 
18 AGGGATGATGTGTGGTAGGC A ATAGGTTGGGTAGGGTGGTT D 12 
19 AGGGATGATGTGTGGTAGGC A AACATCAACAGACGTCTGTC Other 12 
20 AGGGATGATGTGTGGTAGGC A TAGGTTATGGGTAGGGTGGT C 12 
21 AGGGTAGGCGTGGATGATGC B CTAGGATGGGTAGGGTGGTG D 12 
22 GTAGGATGGGTAGGGTGGTC D GTAGGTTGGGTAGGGTGGTC D 12 
23 AGGGATGATGCGTGGTAGGC A AACTCATGTGGTGGTTCGGT Other 12 
24 AGGGATGATGTGTGGTAGGC A TGTTGCGGATGACGTCGCTT Other 12 
25 GTAGGATGGGTAGGGTGGTC D CTAGGTTGGGTAGGGTGGTG D 12 
26 AGGGATGATGTGTGGTAGGC A GCGGGCGGTACGTGGGTGTG Other 12 
27 GTAGGGTGGGTAGGGTGGTC D CTAGGTTGGGTAGGGTGGTG D 11 
28 AGGGTAGGTGTGGATGATGC B ATAGGATGGGTAGGGTGGTG D 11 
29 AGGGTAGGCGTGGATGATGC B GTAGGATGGGTAGGGTGGTC D 11 
30 AGGGATGATGTGTGGTAGGC A CGAATGTGTCGTGGCGTCGT Other 11 
31 GGGGCCATACAGAGAGGAGT Other ATAGGATGGGTAGGGTGGTT D 11 
32 GTAGGGTGGGTAGGGTGGTC D GTAGGTTGGGTAGGGTGGTC D 11 
33 CTAGGATGGGTAGGGTGGTG D TAGGTTTTGGGTAGGGTGGT C 11 
34 AGGGTTGATGTGTGGTAGGC A CTAGGATGGGTAGGGTGGTG D 10 
35 CTAGGTTGGGTAGGGTGGTG D GTAGGATGGGTAGGGTGGTC D 10 
36 CATCCAGAGGCGAACGTCGT Other CTAGGTTGGGTAGGGTGGTG D 10 
37 AGGGTAGGTGTGGATGATGC B GTAGGATGGGTAGGGTGGTC D 10 
38 CTAGGTTGGGTAGGGTGGTG D CTAGGTTGGGTAGGGTGGTG D 10 
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39 AGGGTAGGAGTGGATGATGC B GTAGGATGGGTAGGGTGGTC D 10 
40 AGGGATGATGTGTGGTAGGC A CTAGGTTGGGTAGGGTGGTG D 10 
41 AGGGATGATGTGTGGTAGGC A GTTCGCCTACCCGGGTCGTG Other 9 
42 AGGGTAGGCGTGGATGATGC B CTAGGGTGGGTAGGGTGGTG D 9 
43 TTGCCAACAATCCAGCTATT Other AGGGTTGATGTGTGGTAGGC A 9 
44 GTAGGTTGGGTAGGGTGGTC D GTAGGTTGGGTAGGGTGGTC D 9 
45 GGTCAGGTTACAAGCCGTGA Other CTAGGATGGGTAGGGTGGTG D 9 
46 AGGGATGATGTGTGGTAGGC A CTGGGCTCAGCTGGCGTGTC Other 9 
47 GTAGGTTGGGTAGGGTGGTC D CTAGGATGGGTAGGGTGGTG D 9 
48 CGTAGACTGTGCGGACCACC Other ATAGGTTGGGTAGGGTGGTT D 9 
49 CTAGGTTGGGTAGGGTGGTG D GTAGGTTGGGTAGGGTGGTC D 9 
50 AGGGTTGATGTGTGGTAGGC A GTGTTGCCGGATGGCCATCG Other 9 
51 AGGGATGATGCGTGGTAGGC A GTAGGATGGGTAGGGTGGTC D 9 
52 AGGGTAGGCGTGGATGATGC B TAGGTGTTGGGTAGGGTGGT C 9 
53 AGGGTAGGTGTGGATGATGC B ATAGGTTGGGTAGGGTGGTG D 9 
54 CTAGGATGGGTAGGGTGGTG D GTAGGATGGGTAGGGTGGTC D 9 
55 AGGGTAGGGGTGGATGATGC B ATAGGATGGGTAGGGTGGTT D 9 
56 AGGGTAGGCGTGGATGATGC B CTAGGTTGGGTAGGGTGGTG D 9 
57 AGGGATGATGCGTGGTAGGC A TGGGATGGGTCTGGTAGGCG Other 9 
58 GTAGGATGGGTAGGGTGGTC D TCTTGAACGTGGAGCGTAGT Other 9 
59 AGGGTTGATGTGTGGTAGGC A TCAATGCTGCTGGGAAGCGT Other 9 
60 GTAGGATGGGTAGGGTGGTC D TAGGTTGTGGGTAGGGTGGT C 8 
61 GTAGGGTGGGTAGGGTGGTC D CTAGGATGGGTAGGGTGGTG D 8 
62 AGGGTAGGCGTGGATGATGC B TAGGTTTTGGGTAGGGTGGT C 8 
63 AGGGTAGGGGTGGATGATGC B ATAGGATGGGTAGGGTGGTG D 8 
64 GAGCGGAGAGCGTTCTGATT Other CTAGGATGGGTAGGGTGGTG D 8 
65 AGGGATGATGTGTGGTAGGC A CAAGAGTCGTATGCGGACCG Other 8 
66 AGGGTAGGGGTGGATGATGC B CTAGGTTGGGTAGGGTGGTG D 8 
67 AGGGTAGGTGTGGATGATGC B AGGTACTGGCTGGTCGATGG Other 8 
68 CTAGGGTGGGTAGGGTGGTG D CTAGGTTGGGTAGGGTGGTG D 8 
69 AGGGTAGGTGTGGATGATGC B TAGGTTATGGGTAGGGTGGT C 8 
70 AGGGATGATGTGTGGTAGGC A CTAGGGTGGGTAGGGTGGTG D 8 
71 AGGGTAGGTGTGGATGATGC B GCCCTTCGTGCGCCGTTCAC Other 8 
72 AGGGTAGGAGTGGATGATGC B GCGCCGTGCTTTGCTACACC Other 8 
73 AGGGATGATGTGTGGTAGGC A CACCATTAGAGCAAGCGATC Other 8 
74 AGGGTTGATGTGTGGTAGGC A CTAGGTTGGGTAGGGTGGTG D 8 
75 AGGGATGATGTGTGGTAGGC A TGTTGCGCGGGACGTTCGGC Other 8 
76 AGGGATGATGTGTGGTAGGC A ATAGGTTGGGTAGGGTGGTG D 8 
77 AGGGTAGGCGTGGATGATGC B AGACGATACTATCGCACCTA Other 8 
78 GGAGGATGGTCGGGTGGGCA Other GTAGGTTGGGTAGGGTGGTC D 8 
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79 CTAGGATGGGTAGGGTGGTG D CTAGGATGGGTAGGGTGGTG D 8 
80 AGGGATGATGTGTGGTAGGC A ATAGGATGGGTAGGGTGGTT D 7 
81 AGGGATGATGTGTGGTAGGC A TGGCCCCCCTGCTTACCACT Other 7 
82 CTAGGTTGGGTAGGGTGGTG D CTAGGATGGGTAGGGTGGTG D 7 
83 CAGGTCAATTGCTGACGATC Other TTAGGATGGGTAGGGTGGTA D 7 
84 AGGGTAGGCGTGGATGATGC B TGGGATGGGTCTGGTAGGCG Other 7 
85 AGGGTAGGCGTGGATGATGC B ATAGGTTGGGTAGGGTGGTT D 7 
86 GTAGGTTGGGTAGGGTGGTC D ATAGGTTGGGTAGGGTGGTG D 7 
87 
GGGGGGGCGCGAGTGTGAG
G Other GTAGGATGGGTAGGGTGGTC D 7 
88 CTAGGTTGGGTAGGGTGGTG D TAGATAGTGTCGAATCGTCC Other 7 
89 AGGGTAGGTGTGGATGATGC B TAGGTCTTGGGTAGGGTGGT C 7 
90 AGGGATGATGTGTGGTAGGC A AGGGATGATGTGTGGTAGGC A 7 
91 AGGGTTGATGTGTGGTAGGC A GCTCACTGTTCGTATGGCCG Other 7 
92 GTAGGATGGGTAGGGTGGTC D TGTCACATCTTGTTGGGCTT Other 7 
93 AGGGATGATGTGTGGTAGGC A TAGGTCTTGGGTAGGGTGGT C 7 
94 AGGGATGATGCGTGGTAGGC A TACAGGGCTAAGCTCACATC Other 7 
95 CTAGGATGGGTAGGGTGGTG D GTAGGTTGGGTAGGGTGGTC D 7 
96 AGGGTAGGAGTGGATGATGC B CTAGGTTGGGTAGGGTGGTG D 7 
97 AGGGTAGGCGTGGATGATGC B ATAGGATGGGTAGGGTGGTT D 7 
98 AGGGATGATGTGTGGTAGGC A CTAGGGTGGGTAGGATGGTG D 7 
99 AGGGATGATGTGTGGTAGGC A ACTTAGAAGCCGTGCCTCGC Other 7 
100 AGGGTAGGCGTGGATGATGC B CTACTAGTACTCGGTGTTTC Other 7 
 
Table S2.2 Aptamers sequences used in the work 
 
Loop A AGGGATGATGTGTGGTAGGC 
Loop B AGGGTAGGTGTGGATGATGC 
Loop C TAGGTTTTGGGTAGGGTGGT 
Loop D GTAGGATGGGTAGGGTGGTC 
ThA_3stem AGTAGGGATGATGTGTGGTAGGCACT 
ThD_3stem ATCGTAGGATGGGTAGGGTGGTCGAT 
ThA_15stem CGTGTCCGCACACGTAGGGATGATGTGTGGTAGGCACGTGTGCGGACACG 
ThB_15stem CGTGTCCGCACACGTAGGGTAGGTGTGGATGATGCACGTGTGCGGACACG 
ThC_15stem CGTGTCCGCACACGTTAGGTTTTGGGTAGGGTGGTACGTGTGCGGACACG 
ThD_15stem CGTGTCCGCACACGTGTAGGATGGGTAGGGTGGTCACGTGTGCGGACACG 
TBA TTGGTTGGTGTGGTTGG 
HD22 AGTCCGTGGTAGGGCAGGTTGGGGTGACT 
ThAA 
TCAGGCTCTCGAGAGTTGCAGAAGTAGGGATGATGTGTGGTAGGCACTTCTGCCTGCATCG
AGACACCAGTTTTTCTGGTGAGCTAGTGCAGACATGATCAGGGATGATGTGTGGTAGGCGA
TCATGTAACTCCTAGCTGCCTGA 
ThBA 
TCAGGCTCTCGAGAGTTGCAGAAGTAGGGTAGGTGTGGATGATGCACTTCTGCCTGCATCG
AGACACCAGTTTTTCTGGTGAGCTAGTGCAGACATGATCAGGGATGATGTGTGGTAGGCGA
TCATGTAACTCCTAGCTGCCTGA 
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ThCA 
TCAGGCTCTCGAGAGTTGCAGAAGTTAGGTTTTGGGTAGGGTGGTACTTCTGCCTGCATCGA
GACACCAGTTTTTCTGGTGAGCTAGTGCAGACATGATCAGGGATGATGTGTGGTAGGCGAT
CATGTAACTCCTAGCTGCCTGA 
ThDA 
TCAGGCTCTCGAGAGTTGCAGAAGTGTAGGATGGGTAGGGTGGTCACTTCTGCCTGCATCG
AGACACCAGTTTTTCTGGTGAGCTAGTGCAGACATGATCAGGGATGATGTGTGGTAGGCGA
TCATGTAACTCCTAGCTGCCTGA 
ThAB 
TCAGGCTCTCGAGAGTTGCAGAAGTAGGGATGATGTGTGGTAGGCACTTCTGCCTGCATCG
AGACACCAGTTTTTCTGGTGAGCTAGTGCAGACATGATCAGGGTAGGTGTGGATGATGCGA
TCATGTAACTCCTAGCTGCCTGA 
ThBB 
TCAGGCTCTCGAGAGTTGCAGAAGTAGGGTAGGTGTGGATGATGCACTTCTGCCTGCATCG
AGACACCAGTTTTTCTGGTGAGCTAGTGCAGACATGATCAGGGTAGGTGTGGATGATGCGA
TCATGTAACTCCTAGCTGCCTGA 
ThCB 
TCAGGCTCTCGAGAGTTGCAGAAGTTAGGTTTTGGGTAGGGTGGTACTTCTGCCTGCATCGA
GACACCAGTTTTTCTGGTGAGCTAGTGCAGACATGATCAGGGTAGGTGTGGATGATGCGAT
CATGTAACTCCTAGCTGCCTGA 
ThDB 
TCAGGCTCTCGAGAGTTGCAGAAGTGTAGGATGGGTAGGGTGGTCACTTCTGCCTGCATCG
AGACACCAGTTTTTCTGGTGAGCTAGTGCAGACATGATCAGGGTAGGTGTGGATGATGCGA
TCATGTAACTCCTAGCTGCCTGA 
ThAC 
TCAGGCTCTCGAGAGTTGCAGAAGTAGGGATGATGTGTGGTAGGCACTTCTGCCTGCATCG
AGACACCAGTTTTTCTGGTGAGCTAGTGCAGACATGATCTAGGTTTTGGGTAGGGTGGTGAT
CATGTAACTCCTAGCTGCCTGA 
ThBC 
TCAGGCTCTCGAGAGTTGCAGAAGTAGGGTAGGTGTGGATGATGCACTTCTGCCTGCATCG
AGACACCAGTTTTTCTGGTGAGCTAGTGCAGACATGATCTAGGTTTTGGGTAGGGTGGTGAT
CATGTAACTCCTAGCTGCCTGA 
ThCC 
TCAGGCTCTCGAGAGTTGCAGAAGTTAGGTTTTGGGTAGGGTGGTACTTCTGCCTGCATCGA
GACACCAGTTTTTCTGGTGAGCTAGTGCAGACATGATCTAGGTTTTGGGTAGGGTGGTGATC
ATGTAACTCCTAGCTGCCTGA 
ThDC 
TCAGGCTCTCGAGAGTTGCAGAAGTGTAGGATGGGTAGGGTGGTCACTTCTGCCTGCATCG
AGACACCAGTTTTTCTGGTGAGCTAGTGCAGACATGATCTAGGTTTTGGGTAGGGTGGTGAT
CATGTAACTCCTAGCTGCCTGA 
ThAD 
TCAGGCTCTCGAGAGTTGCAGAAGTAGGGATGATGTGTGGTAGGCACTTCTGCCTGCATCG
AGACACCAGTTTTTCTGGTGAGCTAGTGCAGACATGATCGTAGGATGGGTAGGGTGGTCGA
TCATGTAACTCCTAGCTGCCTGA 
ThBD 
TCAGGCTCTCGAGAGTTGCAGAAGTAGGGTAGGTGTGGATGATGCACTTCTGCCTGCATCG
AGACACCAGTTTTTCTGGTGAGCTAGTGCAGACATGATCGTAGGATGGGTAGGGTGGTCGA
TCATGTAACTCCTAGCTGCCTGA 
ThCD 
TCAGGCTCTCGAGAGTTGCAGAAGTTAGGTTTTGGGTAGGGTGGTACTTCTGCCTGCATCGA
GACACCAGTTTTTCTGGTGAGCTAGTGCAGACATGATCGTAGGATGGGTAGGGTGGTCGAT
CATGTAACTCCTAGCTGCCTGA 
ThDD 
TCAGGCTCTCGAGAGTTGCAGAAGTGTAGGATGGGTAGGGTGGTCACTTCTGCCTGCATCG
AGACACCAGTTTTTCTGGTGAGCTAGTGCAGACATGATCGTAGGATGGGTAGGGTGGTCGA
TCATGTAACTCCTAGCTGCCTGA 
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Table S2.3 Sequences of the 4-helix tile and 2-helix PX tile 
 
4-helix tile 
4Hx_1 AGTCCAACCCCTCACCGGCTAGCTCCAATGACAGCCTGGCTAG 
4Hx_2 TAAACTGTGTTGGACT 
4Hx_3 
GGGCAAAATTGGAGCTAGCCGGTGAGGGAGACACCGAGGGTGAATCCTGCCCAGA
TTTGCAGGTTCGGGCCCTAGGGCACAAGC 
4Hx_4 TTTCTAGCCAGGCTGTCGCCCGATAATCCGTGTATGGCAGCCA 
4Hx_5 TTTGCGCCGGCTCGGGCTTTGCCCGCTTGTGCGTGTCTACAGTTTA 
4Hx_6 TTTGGTGGCGCGCCGGCGC 
4Hx_7 TGTATTTCCCCTCGCCTAGGGCCCGAACCGGATTAGCGCCACC 
4Hx_8 GGCCGTCCGAAATACA 
4Hx_9 TTTTGGCTGCCATACACTGCAAATCTGGGCAGGATTCAGGACGGCC 
4-helix tile with loopA on first helix: replace 8, 9 with sequences below 
4HX_A1D3/4_A 
TTTTGGCTGCCATACACTGCAAATCTGGGCAGGATTCAGGACGGCCAGGGATGATGT
GTGGTAGGCGGCCGTCCGAAATACA 
4-helix tile with loopD on fourth helix: replace 1, 2 with sequence below 
4HX_A1D4_D_1.2 
TAAACTGTGTTGGACTGTAGGATGGGTAGGGTGGTCAGTCCAACCCCTCACCGGCTA
GCTCCAATGACAGCCTGGCTAG 
4-helix tile with loopA on first helix and loopD on second helix: replace 7, 8, 9 with sequences below 
4HX_A1D2_A 
TTTTGGCTGCCATACACTGCAAATCTGGGCAGGATTCAGGACGGCCAGGGATGATGT
GTGGTAGGCGGCCGTCC 
4HX_A1D2_D 
GAAATACAGTAGGATGGGTAGGGTGGTCTGTATTTCCCCTCGCCTAGGGCCCGAACC
GGATTAGCGCCACC 
4-helix tile with loopA on first helix and loopD on third helix: replace 2, 5, 8, 9 with sequences below 
4HX_A1D3_D_2.5 
TTTGCGCCGGCTCGGGCTTTGCCCGCTTGTGCGTGTCTACAGTTTAGTAGGATGGGT
AGGGTGGTCTAAACTGTGTTGGACT 
4HX_A1D3/4_A 
TTTTGGCTGCCATACACTGCAAATCTGGGCAGGATTCAGGACGGCCAGGGATGATGT
GTGGTAGGCGGCCGTCCGAAATACA 
4-helix tile with loopA on first helix and loopD on fourth helix: replace 1, 2, 8, 9 with sequences below 
4HX_A1D4_D_1.2 
TAAACTGTGTTGGACTGTAGGATGGGTAGGGTGGTCAGTCCAACCCCTCACCGGCTA
GCTCCAATGACAGCCTGGCTAG 
4HX_A1D3/4_A 
TTTTGGCTGCCATACACTGCAAATCTGGGCAGGATTCAGGACGGCCAGGGATGATGT
GTGGTAGGCGGCCGTCCGAAATACA 
Sequences for 2-helix PX tile ThAD or ThDA 
2HxAD_D 
TTTCCTCTCTAAGGCATCACAAAGTCCCAGTAGGATGGGTAGGGTGGTCTGGGACTT
GTCTATTGACCAGAGAGG 
2HxAD_A 
TTCATACGGTCAATAGACGCTAGTTCAGGGATGATGTGTGGTAGGCGAACTAGCTGT
GATGCCTTGTATGAATTT 
2HxDA_A 
TTTCCTCTCTAAGGCATCACAAAGTCCCAAGGGATGATGTGTGGTAGGCTGGGACTT
GTCTATTGACCAGAGAGG 
2HxDA_D 
TTCATACGGTCAATAGACGCTAGTTCGTAGGATGGGTAGGGTGGTCGAACTAGCTGT
GATGCCTTGTATGAATTT 
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Table S2.4 Modified staple strands in rectangle origami  
 
recO_182 CGGAATTATTGAAAGGAATTGAGGTGAAAAAT 
recO_185 AGAGGCATAATTTCATCTTCTGACTATAACTA 
recO_188 TTATTACGGTCAGAGGGTAATTGAATAGCAGC 
recO_191 TGCTCAGTCAGTCTCTGAATTTACCAGGAGGT 
recO_158 ATTTTGCGTCTTTAGGAGCACTAAGCAACAGT 
recO_161 CATATTTAGAAATACCGACCGTGTTACCTTTT 
recO_164 ATACCCAAGATAACCCACAAGAATAAACGATT 
recO_167 CCTCAAGAATACATGGCTTTTGATAGAACCAC 
recO_182ThA 
CGGAATTATTGAAAGGTTCAGAAGCAGGGATGATGTGTGGTAGGCGCTTCT
GTTAATTGAGGTGAAAAAT 
recO_185ThA 
AGAGGCATAATTTCATTTCAGAAGCAGGGATGATGTGTGGTAGGCGCTTCTG
TTCTTCTGACTATAACTA 
recO_188ThA 
TTATTACGGTCAGAGGTTCAGAAGCAGGGATGATGTGTGGTAGGCGCTTCTG
TTGTAATTGAATAGCAGC 
recO_191ThA 
TGCTCAGTCAGTCTCTTTCAGAAGCAGGGATGATGTGTGGTAGGCGCTTCTG
TTGAATTTACCAGGAGGT 
recO_158ThD 
ATTTTGCGTCTTTAGGTTCAGAAGCGTAGGATGGGTAGGGTGGTCGCTTCTG
TTAGCACTAAGCAACAGT 
recO_161ThD 
CATATTTAGAAATACCTTCAGAAGCGTAGGATGGGTAGGGTGGTCGCTTCTG
TTGACCGTGTTACCTTTT 
recO_164ThD 
ATACCCAAGATAACCCTTCAGAAGCGTAGGATGGGTAGGGTGGTCGCTTCTG
TTACAAGAATAAACGATT 
recO_167ThD 
CCTCAAGAATACATGGTTCAGAAGCGTAGGATGGGTAGGGTGGTCGCTTCTG
TTCTTTTGATAGAACCAC 
Index 22:257-260 
ACGGCTACTTACTTAGTCCTCTTTTGAGGAACAAGTTTTCTTGTCCGGAACGC
TGACCAA 
Index 23:239-242 
GAGAATAGCTTTTGCGTCCTCTTTTGAGGAACAAGTTTTCTTGTGGATCGTCG
GGTAGCA 
Index 34:274-261 
CGATTTTAGAGGACAGTCCTCTTTTGAGGAACAAGTTTTCTTGTATGAACGGC
GCGACCT 
Index 35:256-243 
GCTCCATGAGAGGCTTTCCTCTTTTGAGGAACAAGTTTTCTTGTTGAGGACTA
GGGAGTT 
Index 46:255-262 
TTTCATGAAAATTGTGTCCTCTTTTGAGGAACAAGTTTTCTTGTTCGAAATCTG
TACAGA 
Index 47:237-244 
AATAATAAGGTCGCTGTCCTCTTTTGAGGAACAAGTTTTCTTGTAGGCTTGCA
AAGACTT 
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Figure S2.1 Secondary structure of 15-bp stem supported ThA, ThB, ThC, ThD 
predicted by NUPACK. Stem sequence was design by NUPACK to eliminate interaction 
with the loop region. 
 
 
 
Figure S2.2 Titrating stem length for loop A and D. Different concentrations of aptamers 
were incubated with thrombin modified beads and fluorescence was measured by FACS.  
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Figure S2.3. Gel assay for bivalent aptamer (1µM) with different loop combinations 
from the A, B, C, and D families interacting with 1µM of thrombin. The bottom band 
indicates unbound DNA aptamer, and the bands with slower migration indicates aptamer-
thrombin complex. The complex falls into three major species: AA, BA, AB, BB, DC, CD 
and DD gives 1:1 ratio binding behavior with thrombin; CA, DA, AC and AD 
combinations mostly bind to monomeric thrombin; and CB, DB, BC and BD mostly bind 
to 2:2 ratio. 
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Figure S2.4 Aptamer ThAD specificity against different proteins. 1 µM of aptamer was 
incubated with proteins (thrombin, HRP, mCherry, GFP, human cytochromeC, DhbE, 
DhbB) under room temperature for 30 minutes and tested for migration on 5% native page 
gel. 
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Figure S2.5 Histogram for aptamer competitive assay. 200 nM of blocking aptamer 
(ThA, ThB, ThC, ThD, ThAD, TBA and HD22) was preincubated with the thrombin-
beads, respectively, and 10 nM of FITC-labeled aptamer (ThA, ThB, ThC, ThD, ThAD, 
TBA and HD22) was added to compete the binding. The fluorescence intensity was read 
by flow cytometry after equilibrium. If the binding site of the competing aptamer overlaps 
with that of the preincubated aptamer, decrease in the fluorescence intensity is expected. If 
the binding site of the competing aptamer differs from that of the preincubated aptamer, 
fluorescence level should stay the same.   
 
 
Figure S2.6 Histogram for competitive assay for bivalent aptamers. 100 nM of FITC-
ThD was competed with varying concentrations of ThAD (a), ThBD (b), and ThDA (c). 
 
 
 
Figure S2.7 Aptamer KD measurement by competition assay. Left: 40 nM of FITC-
labeled aptamer ThAD was incubated with 20 nM of thrombin and competed by a series 
different concentrations of aptamer ThD ranging from 400 nM to 16 µM. Right: band 
intensity quantification by imageJ for ThAD-thrombin complex. At about concentration 3 
µM, aptamer ThD is able to displace half of the aptamer ThAD from the complex. With 
IC50  ≅ 3 µM, Kd(ThD)= 8.6 pM, and [L] = 40 nM, Kd(ThAD) = 115 fM can be obtained 
using equation Kd(ThD) = IC50/(1+[L]/Kd(ThAD)). 
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Figure S2.8 4-helix tile design for titrating aptamer ThA and ThD distance. 
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Figure S2.9 Origami probe design for thrombin immobilization. The 20-nt loops in 
aptamer ThA and ThB were added into rectangle origami staple strands with the addition 
of a 7-bp stem and four unpaired T at the bottom of the stem. The distance between two 
aptamers are 10 nm. 
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Figure S2.10 Thrombin aptamer inhibition for thrombin cleavage. 100 nM of various 
aptamer added to thrombin (27 nM) cleavage reaction. The cleavage from thrombin 
without aptamers or argatroban was used as positive control, and substrate probe without 
thrombin was used as negative control. TBA and ThD that bind to exosite I didn’t show 
much inhibition for thrombin cleavage, however ThA that binds to exosite II showed 
apparent inhibition for cleavage activity. Aptamer HD22 that also binds to exosite II 
showed less of inhibition compared with ThA. 
  108 
 
Figure S2.11 Anticoagulant assay with varying concentrations of ThAD: 0, 5 nM, 10 
nM, 20 nM, 40 nM, 80 nM. Thrombin concentration was 5 nM. 
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APPENDIX B 
SUPPLEMENTARY INFORMATION FOR CHAPTER 3  
HIGHLY ORTHOGONAL RNA RIBOREGULATORS FOR TRANSLATIONAL 
REPRESSION 
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Design of Three-Way Junction (3WJ) Repressors 
Nucleotide-level design schematics of 3WJ repressors are shown in Figure S3.1. 
The 3WJ repressor switch RNAs were designed using the core sequence of first-generation 
toehold switch number 1. This core region is indicated by the gray and black bases within 
the hairpin structure shown in Figure S3.1b and has the sequence: 
UUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACAA 
where the RBS and start codon are shown in bold. In previous studies of toehold switch 
number 1, we found that this hairpin sequence provided very high translational output 
despite its secondary structure, which suggested that the lower stem of the structure 
comprising the sequence UUGUU remained predominantly unpaired when transcribed in 
the cell. This core translational element was integrated into the 3WJ repressor by appending 
binding domains a* and b* with lengths of 15 nts and 12 nts, respectively, to either side. 
A 7-nt single-stranded domain was added downstream of b* to preserve the correct reading 
frame followed by the 21-nt linker sequence and the first 9 nts of the GFPmut3b coding 
sequence (see Supplementary Table S3.1). The 3WJ repressor trigger RNAs featured a 17-
nt toehold domain comprising the a domain and the last 2 nts of the b domain. The 
remaining 10 nts of the b domain were contained within an 8-bp stem structure and a 
portion of the 6-nt loop. The trigger RNA was designed with the 47-nt T7 terminator 
sequence (see Supplementary Table S3.1). A 3-nt single-stranded spacer region was used 
to separate the binding domains of the trigger RNA from the T7 terminator at the 3’ end of 
the transcript. 
Designs for the repressor libraries were generated using the NUPACK software 
package. The 3WJ repressors used a specified temperature of 37 °C; Mathews et al., 1999 
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energy parameters; and the prevented sequences AAAA, CCCC, GGGG, UUUU, 
KKKKKKKK, MMMMMM, RRRRRR, SSSSSS, WWWWWW, YYYYYY. 
SHAPE-Seq Measurements of a Second 3WJ Repressor 
We studied a second 3WJ repressor that demonstrated an unusual pattern of 
repression with increasing trigger length (Fig. S3.4, see Supplementary Table S3.4 for 
sequence information). In this case, expression of a trigger with an 18-nt interaction length 
showed weak (3-fold) repression (Fig. S3.4b). However, a small increase in interaction 
length to 20 nt dramatically increased the repression efficiency to 17-fold. We performed 
in-cell SHAPE-Seq on the switch and switch-trigger complexes to identify structural 
explanations for these performance differences. As expected, SHAPE-Seq of the switch 
RNA alone showed high reactivity across the molecule, corresponding to a translationally-
active state (Fig. S3.4c). Similarly, the functional 20-nt trigger variant showed a reactivity 
pattern consistent with 3WJ formation (Fig. S3.4e). However, the poorly-repressing 18-nt 
variant only showed low reactivities within the b-b* binding region, with high reactivities 
observed elsewhere. This suggests that the trigger only efficiently forms a duplex at b-b*, 
leaving the hairpin de-stabilized and accessible for ribosome binding. The modest 
repression from this trigger likely results from inhibition of translational elongation 
through b-b*, rather than inhibition of translation initiation through 3WJ formation.  
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Table S3.1 PCR primers and other sequences used for experiments 
 
Name Sequence 
T7 promoter TAATACGACTCACTATA[GGG] 
T7 terminator TAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTG 
21-nt Linker AACCTGGCGGCAGCGCAAAAG 
Switch universal forward 
primer 
GCCGGGTTTAGAAATCTGAAGCTCTAGAGAGCGCTAATACGACTCACTATAGG
G 
Switch universal reverse 
primer TTTACGCATCTTTTGCGCTGCCGCCAGGTT 
Trigger universal forward 
primer 
GCCGGGTTTAGAAATCTGAAGCTCTAGAGAGCGCTAATACGACTCACTATAGG
G 
Trigger universal reverse 
primer CCCGTTTAGAGGCCCCAAGGGGTTATGCTA 
Switch backbone forward 
primer AACCTGGCGGCAGCGCAA 
Switch backbone reverse 
primer TCTCTAGAGCTTCAGATTTCTAAACCCGGCCATAAGGGAGAGCGTCGAGATC 
Trigger backbone forward 
primer TAGCATAACCCCTTGGGGC 
Trigger backbone reverse 
primer TCTCTAGAGCTTCAGATTTCTAAACCCGGCCGAGATCTCGATCCTCTACGC 
Non-cognate RNA used 
for library 
characterization 
GGGUCUCACGCCCUCAGCUGGGCGUGAGAUGAGCCUCGUCUCCAGAUGACG
AGGCAACGUAGGAUCUGACUGAUCCUACUAU 
mCherry_adapted 
ATGCGTAAAATGGTGAGCAAGGGCGAAGAAGATAACATGGCCATCATCAAGG
AGTTCATGCGCTTCAAGGTTCACATGGAGGGCTCCGTGAACGGCCACGAGTTC
GAGATCGAGGGCGAGGGCGAGGGCCGCCCCTACGAGGGCACCCAGACCGCCA
AGCTGAAGGTGACCAAGGGTGGCCCCCTGCCCTTCGCCTGGGACATCCTGTCCC
CTCAGTTCATGTACGGCTCCAAGGCCTACGTGAAGCACCCCGCCGACATCCCCG
ACTACTTGAAGCTGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAACT
TCGAGGACGGCGGCGTGGTGACCGTGACCCAGGACTCCTCCCTGCAAGACGGC
GAGTTCATCTACAAGGTGAAGCTGCGCGGCACCAACTTCCCCTCCGACGGCCCC
GTAATGCAGAAGAAGACTATGGGCTGGGAGGCCTCCTCCGAGCGGATGTACCC
CGAGGACGGCGCGCTGAAGGGCGAGATCAAGCAGAGGCTGAAGCTGAAGGAC
GGCGGCCACTACGACGCTGAGGTCAAGACCACCTACAAGGCCAAGAAGCCCGT
GCAACTGCCCGGCGCGTACAACGTCAACATCAAGTTGGACATCACCTCCCACAA
CGAGGACTACACCATCGTGGAACAGTACGAACGCGCCGAGGGCCGCCACTCCA
CCGGCGGCATGGACGAGCTGTACAAGTAATAA 
venus_adapted 
ATGCGTAAAATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCA
TCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGC
GAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGCTGATCTGCAC
CACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGGGCTACGG
CCTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAA
GTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGA
CGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGA
ACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGG
CACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCACCGCCGACAAG
CAGAAGAACGGCATCAAGGCCAACTTCAAGATCCGCCACAACATCGAGGACGG
CGGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCC
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CCGTGCTGCTGCCCGACAACCACTACCTGAGCTACCAGTCCGCCCTGAGCAAAG
ACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCC
GGGATCACTCTCGGCATGGACGAGCTGTACAAGTAATAA 
cerulean_adapted 
ATGCGTAAAATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCA
TCCTGGTCGAGCTGGACGGCGACGTTAACGGTCATAAATTCAGCGTTAGCGGA
GAAGGCGAAGGCGATGCGACTTACGGCAAACTGACTTTGAAATTTATCTGTACC
ACGGGTAAGCTTCCTGTGCCATGGCCAACGTTGGTCACCACCCTGACGTGGGGT
GTGCAGTGCTTTGCTCGCTATCCCGACCACATGAAACAACATGACTTTTTCAAAT
CCGCGATGCCTGAGGGCTATGTCCAGGAGCGTACGATCTTTTTTAAAGATGATG
GCAACTACAAAACGCGCGCGGAAGTGAAATTCGAAGGCGATACCCTGGTAAAC
CGCATCGAACTGAAAGGGATCGACTTCAAAGAGGATGGGAACATTCTCGGCCA
TAAACTGGAATATAATGCGATTAGCGACAATGTTTATATTACTGCTGATAAGCA
GAAAAATGGTATCAAAGCTAACTTTAAAATTCGCCACAATATTGAAGATGGCTC
CGTGCAGTTAGCAGATCATTACCAACAAAACACCCCAATTGGGGACGGCCCGGT
GCTTCTGCCGGATAATCATTATCTGTCTACGCAATCCAAACTGAGTAAAGATCCA
AATGAAAAGCGCGATCATATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGAT
CACTCTCGGCATGGACGAGCTGTACAAGTAATAA 
lacZ_adapted 
ATGCGTAAAATGACCATGATTACGGATTCACTGGCCGTCGTTTTACAACGTCGT
GACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTT
TCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGT
TGCGCAGCCTGAATGGCGAATGGCGCTTTGCCTGGTTTCCGGCACCAGAAGCG
GTGCCGGAAAGCTGGCTGGAGTGCGATCTTCCTGAGGCCGATACTGTCGTCGT
CCCCTCAAACTGGCAGATGCACGGTTACGATGCGCCCATCTACACCAACGTGAC
CTATCCCATTACGGTCAATCCGCCGTTTGTTCCCACGGAGAATCCGACGGGTTGT
TACTCGCTCACATTTAATGTTGATGAAAGCTGGCTACAGGAAGGCCAGACGCGA
ATTATTTTTGATGGCGTTAACTCGGCGTTTCATCTGTGGTGCAACGGGCGCTGG
GTCGGTTACGGCCAGGACAGTCGTTTGCCGTCTGAATTTGACCTGAGCGCATTT
TTACGCGCCGGAGAAAACCGCCTCGCGGTGATGGTGCTGCGCTGGAGTGACGG
CAGTTATCTGGAAGATCAGGATATGTGGCGGATGAGCGGCATTTTCCGTGACG
TCTCGTTGCTGCATAAACCGACTACACAAATCAGCGATTTCCATGTTGCCACTCG
CTTTAATGATGATTTCAGCCGCGCTGTACTGGAGGCTGAAGTTCAGATGTGCGG
CGAGTTGCGTGACTACCTACGGGTAACAGTTTCTTTATGGCAGGGTGAAACGCA
GGTCGCCAGCGGCACCGCGCCTTTCGGCGGTGAAATTATCGATGAGCGTGGTG
GTTATGCCGATCGCGTCACACTACGTCTGAACGTCGAAAACCCGAAACTGTGGA
GCGCCGAAATCCCGAATCTCTATCGTGCGGTGGTTGAACTGCACACCGCCGACG
GCACGCTGATTGAAGCAGAAGCCTGCGATGTCGGTTTCCGCGAGGTGCGGATT
GAAAATGGTCTGCTGCTGCTGAACGGCAAGCCGTTGCTGATTCGAGGCGTTAA
CCGTCACGAGCATCATCCTCTGCATGGTCAGGTCATGGATGAGCAGACGATGGT
GCAGGATATCCTGCTGATGAAGCAGAACAACTTTAACGCCGTGCGCTGTTCGCA
TTATCCGAACCATCCGCTGTGGTACACGCTGTGCGACCGCTACGGCCTGTATGT
GGTGGATGAAGCCAATATTGAAACCCACGGCATGGTGCCAATGAATCGTCTGA
CCGATGATCCGCGCTGGCTACCGGCGATGAGCGAACGCGTAACGCGAATGGTG
CAGCGCGATCGTAATCACCCGAGTGTGATCATCTGGTCGCTGGGGAATGAATC
AGGCCACGGCGCTAATCACGACGCGCTGTATCGCTGGATCAAATCTGTCGATCC
TTCCCGCCCGGTGCAGTATGAAGGCGGCGGAGCCGACACCACGGCCACCGATA
TTATTTGCCCGATGTACGCGCGCGTGGATGAAGACCAGCCCTTCCCGGCTGTGC
CGAAATGGTCCATCAAAAAATGGCTTTCGCTACCTGGAGAGACGCGCCCGCTGA
TCCTTTGCGAATACGCCCACGCGATGGGTAACAGTCTTGGCGGTTTCGCTAAAT
ACTGGCAGGCGTTTCGTCAGTATCCCCGTTTACAGGGCGGCTTCGTCTGGGACT
GGGTGGATCAGTCGCTGATTAAATATGATGAAAACGGCAACCCGTGGTCGGCT
TACGGCGGTGATTTTGGCGATACGCCGAACGATCGCCAGTTCTGTATGAACGGT
CTGGTCTTTGCCGACCGCACGCCGCATCCAGCGCTGACGGAAGCAAAACACCA
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GCAGCAGTTTTTCCAGTTCCGTTTATCCGGGCAAACCATCGAAGTGACCAGCGA
ATACCTGTTCCGTCATAGCGATAACGAGCTCCTGCACTGGATGGTGGCGCTGGA
TGGTAAGCCGCTGGCAAGCGGTGAAGTGCCTCTGGATGTCGCTCCACAAGGTA
AACAGTTGATTGAACTGCCTGAACTACCGCAGCCGGAGAGCGCCGGGCAACTC
TGGCTCACAGTACGCGTAGTGCAACCGAACGCGACCGCATGGTCAGAAGCCGG
GCACATCAGCGCCTGGCAGCAGTGGCGTCTGGCGGAAAACCTCAGTGTGACGC
TCCCCGCCGCGTCCCACGCCATCCCGCATCTGACCACCAGCGAAATGGATTTTTG
CATCGAGCTGGGTAATAAGCGTTGGCAATTTAACCGCCAGTCAGGCTTTCTTTC
ACAGATGTGGATTGGCGATAAAAAACAACTGCTGACGCCGCTGCGCGATCAGT
TCACCCGTGCACCGCTGGATAACGACATTGGCGTAAGTGAAGCGACCCGCATTG
ACCCTAACGCCTGGGTCGAACGCTGGAAGGCGGCGGGCCATTACCAGGCCGAA
GCAGCGTTGTTGCAGTGCACGGCAGATACACTTGCTGATGCGGTGCTGATTACG
ACCGCTCACGCGTGGCAGCATCAGGGGAAAACCTTATTTATCAGCCGGAAAACC
TACCGGATTGATGGTAGTGGTCAAATGGCGATTACCGTTGATGTTGAAGTGGC
GAGCGATACACCGCATCCGGCGCGGATTGGCCTGAACTGCCAGCTGGCGCAGG
TAGCAGAGCGGGTAAACTGGCTCGGATTAGGGCCGCAAGAAAACTATCCCGAC
CGCCTTACTGCCGCCTGTTTTGACCGCTGGGATCTGCCATTGTCAGACATGTATA
CCCCGTACGTCTTCCCGAGCGAAAACGGTCTGCGCTGCGGGACGCGCGAATTG
AATTATGGCCCACACCAGTGGCGCGGCGACTTCCAGTTCAACATCAGCCGCTAC
AGTCAACAGCAACTGATGGAAACCAGCCATCGCCATCTGCTGCACGCGGAAGA
AGGCACATGGCTGAATATCGACGGTTTCCATATGGGGATTGGTGGCGACGACT
CCTGGAGCCCGTCAGTATCGGCGGAATTCCAGCTGAGCGCCGGTCGCTACCATT
ACCAGTTGGTCTGGTGTCAAAAATAA 
GFPmut3b-ASV 
ATGCGTAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAATTA
GATGGTGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGA
TGCAACATACGGAAAACTTACCCTTAAATTTATTTGCACTACTGGAAAACTACCT
GTTCCGTGGCCAACACTTGTCACTACTTTCGGTTATGGTGTTCAATGCTTTGCGA
GATACCCAGATCACATGAAACAGCATGACTTTTTCAAGAGTGCCATGCCCGAAG
GTTACGTACAGGAAAGAACTATATTTTTCAAAGATGACGGGAACTACAAGACAC
GTGCTGAAGTCAAGTTTGAAGGTGATACCCTTGTTAATAGAATCGAGTTAAAAG
GTATTGATTTTAAAGAAGATGGAAACATTCTTGGACACAAATTGGAATACAACT
ATAACTCACACAATGTATACATCATGGCAGACAAACAAAAGAATGGAATCAAAG
TTAACTTCAAAATTAGACACAACATTGAAGATGGAAGCGTTCAACTAGCAGACC
ATTATCAACAAAATACTCCGATTGGCGATGGCCCTGTCCTTTTACCAGACAACCA
TTACCTGTCCACACAATCTGCCCTTTCGAAAGATCCCAACGAAAAGAGAGACCA
CATGGTCCTTCTTGAGTTTGTAACCGCTGCTGGGATTACACATGGCATGGATGA
ACTATACAAAAGGCCTGCAGCAAACGACGAAAACTACGCTGCATCAGTTTAATA
A 
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Table S3.2 Sequence and performance information for three-way junction (3WJ) 
repressor switches 
 
Notes:  
Switch RNA sequences are listed up to the 30th base (inclusive) following the end of their 
trigger binding domain. This 30-nt sequence contains the 21-nt linker sequence and the 
first 9-nts of GFPmut3b. 
3WJ 
repressor 
ranking 
3WJ 
repressor 
index 
GFP fold 
reduction Switch sequence 
Switch 
plasmid 
Switch plasmid 
origin/Resistance 
1 20 134.2 ± 8.1 
GGGAUGAAUGAUAUACA
CUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAGCACGAAUUGAC
UACACUAAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N20_switch ColA/kanamycin 
2 19 85.2 ± 4.9 
GGGACUAAUCAGAUCUA
CUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAGCACCUAACAAG
ACUAAUCAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N19_switch ColA/kanamycin 
3 10 66.1 ± 3.2 
GGGUAGUAAGAUUAGAU
AUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAGUACAAGAACCG
AAACGAGAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N10_switch ColA/kanamycin 
4 24 56.9 ± 7.0 
GGGCUCCUAUCACUUUA
CUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAGCACACUAACUA
CAAAUUCAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N24_switch ColA/kanamycin 
5 15 44.7 ± 7.1 
GGGUCCAAAUCUUACUU
AUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUCACUACCUCGA
AUACUUAAACCUGGCGG
CAGCGCAAAAGAUGCGU
AAA 
pYZ_3WJrep_
N15_switch ColA/kanamycin 
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6 32 41.8 ± 1.1 
GGGUACUCAAGAAUUCC
AUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUCACAUACUAAC
AUUACUAAACCUGGCGG
CAGCGCAAAAGAUGCGU
AAA 
pYZ_3WJrep_
N32_switch ColA/kanamycin 
7 21 41.2 ± 1.8 
GGGACUACUAUUCACUU
AUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUCCGACACUACA
AUUUCGAAACCUGGCGG
CAGCGCAAAAGAUGCGU
AAA 
pYZ_3WJrep_
N21_switch ColA/kanamycin 
8 13 41.0 ± 5.4 
GGGACAAUCAAAUACAAA
UUGUUAUAGUUAUGAAC
AGAGGAGACAUAACAUG
AACAAUCACAUACAAAGC
AAACGAAACCUGGCGGCA
GCGCAAAAGAUGCGUAA
A 
pYZ_3WJrep_
N13_switch ColA/kanamycin 
9 2 40.3 ± 2.8 
GGGAUGAUAUUGAAUUA
CUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAGCACACUACACU
AAACAUAAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N02_switch ColA/kanamycin 
10 3 37.9 ± 2.4 
GGGAGUAUAAGAUAGAU
AUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAGUACGAAGCAAC
GAACAUAAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N03_switch ColA/kanamycin 
11 16 37.7 ± 12.7 
GGGUCCCAUUAUCUUAC
CUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAGCCUACACUACC
AUUCCCGAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N16_switch ColA/kanamycin 
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12 23 37.2 ± 6.2 
GGGCAAAUACUCCAUAUC
UUGUUAUAGUUAUGAAC
AGAGGAGACAUAACAUG
AACAAGCACAUAAACUCA
CUGAUAAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N23_switch ColA/kanamycin 
13 34 34.5 ± 2.2 
GGGCAAAGUAUCCAUCA
UUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUCACAUACUAGA
AUCUAAGAACCUGGCGG
CAGCGCAAAAGAUGCGU
AAA 
pYZ_3WJrep_
N34_switch ColA/kanamycin 
14 7 26.2 ± 1.0 
GGGCAAGAUUUAGUAGA
UUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUCCGAACGACCG
AAAUGAUAACCUGGCGG
CAGCGCAAAAGAUGCGU
AAA 
pYZ_3WJrep_
N07_switch ColA/kanamycin 
15 40 23.4 ± 1.8 
GGGAUACUUUCAAACUU
AUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUCACACUAAUCG
ACUGAAUAACCUGGCGG
CAGCGCAAAAGAUGCGU
AAA 
pYZ_3WJrep_
N40_switch ColA/kanamycin 
16 11 23.2 ± 3.9 
GGGAUCAAUCAAUUCUA
CUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUCACAUAAACCU
AAGAACUAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N11_switch ColA/kanamycin 
17 33 23.1 ± 0.8 
GGGUCCAUAUACUUCAA
UUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUCAACCUAAUUC
UGAGAUAAACCUGGCGG
CAGCGCAAAAGAUGCGU
AAA 
pYZ_3WJrep_
N33_switch ColA/kanamycin 
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18 9 22.9 ± 5.3 
GGGCGAAGAUGAUACAA
UUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAGCCACCUCACAC
UCAACAUAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N09_switch ColA/kanamycin 
19 12 22.9 ± 0.2 
GGGUGAUUGAAUAAGAA
UUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAGCCGAUAAUGAC
ACUAACUAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N12_switch ColA/kanamycin 
20 36 21.3 ± 0.8 
GGGAUGUGAUUACUAGA
UUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUCCGAACAAGCA
AUACAAGAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N36_switch ColA/kanamycin 
21 42 20.8 ± 0.5 
GGGAUUCACUUACAAGA
UUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUCACAUAGACCA
UAGAACGAACCUGGCGG
CAGCGCAAAAGAUGCGU
AAA 
pYZ_3WJrep_
N42_switch ColA/kanamycin 
22 8 20.5 ± 0.7 
GGGACAAAUCAGAUAAAC
UUGUUAUAGUUAUGAAC
AGAGGAGACAUAACAUG
AACAAGCCAAUAGAUAGA
ACACGAAACCUGGCGGCA
GCGCAAAAGAUGCGUAA
A 
pYZ_3WJrep_
N08_switch ColA/kanamycin 
23 1 19.9 ± 2.4 
GGGCAAUUAGUACUAUC
CUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAGUCACAUAACCG
CAAACUAAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N01_switch ColA/kanamycin 
  119 
24 47 17.5 ± 0.6 
GGGCAAUUCCUAAUCCU
AUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUCCAAAUAGAGC
AAAGCAGAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N47_switch ColA/kanamycin 
25 38 17.0 ± 1.1 
GGGAUGAUCGAAACGAA
UUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUACAAGAAUAGA
CAAUAGAAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N38_switch ColA/kanamycin 
26 25 16.1 ± 1.0 
GGGUAAGAAUUAGAAUC
AUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUCAGCGAACACG
AAACAUAAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N25_switch ColA/kanamycin 
27 35 15.9 ± 1.0 
GGGAAUCCAAGUUAUCA
UUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUACACAUAAAGA
CCUCAUAAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N35_switch ColA/kanamycin 
28 27 15.8 ± 2.1 
GGGAAUGAAGAUAGUGA
UUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUCCGAAUAAGCG
AACUAAGAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N27_switch ColA/kanamycin 
29 41 15.4 ± 0.5 
GGGAUCUCACCGUGUCU
AUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUCAACAUACAUC
AUACAAGAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N41_switch ColA/kanamycin 
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30 45 13.2 ± 0.6 
GGGCGACUUAAACUACU
AUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUCACUCCACGGA
AACUACUAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N45_switch ColA/kanamycin 
31 4 12.8 ± 1.1 
GGGUAAUGAAGUGAAUA
CUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAGCCAAAUGAUAC
UAAACCGAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N04_switch ColA/kanamycin 
32 48 12.4 ± 1.2 
GGGACUACUCCAUUCUA
UUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUCCAUACCUCAU
ACAACGAAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N48_switch ColA/kanamycin 
33 37 11.1 ± 0.6 
GGGAUGUGAACUUAAAG
AUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUGCGAAAUACG
GAAAUAGAAACCUGGCG
GCAGCGCAAAAGAUGCG
UAAA 
pYZ_3WJrep_
N37_switch ColA/kanamycin 
34 44 10.2 ± 0.3 
GGGUACCUUCAAAUUCC
AUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUCACCUCACUAA
CAUUAUCAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N44_switch ColA/kanamycin 
35 18 9.6 ± 0.2 
GGGCAAUCCUAUUCAUC
AUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUUCUCAACAUCA
AUCACUCAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N18_switch ColA/kanamycin 
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36 30 9.3 ± 0.7 
GGGCGAUAUGAGUAAAG
AUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUGCAAUAGAACG
AUACAAGAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N30_switch ColA/kanamycin 
37 22 7.5 ± 0.2 
GGGUCAAUCCGAUAAUC
UUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUUACUCCAAGGC
AAUGAUAAACCUGGCGG
CAGCGCAAAAGAUGCGU
AAA 
pYZ_3WJrep_
N22_switch ColA/kanamycin 
38 6 7.5 ± 0.4 
GGGAUUUAGAAGUAAGU
AUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUUCGAAGAUAU
GGGACGAUAACCUGGCG
GCAGCGCAAAAGAUGCG
UAAA 
pYZ_3WJrep_
N06_switch ColA/kanamycin 
39 29 7.5 ± 0.3 
GGGACUCCAAUUGACGA
UUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUACAUAUAGAC
UAAACAUAAACCUGGCG
GCAGCGCAAAAGAUGCG
UAAA 
pYZ_3WJrep_
N29_switch ColA/kanamycin 
40 31 7.0 ± 0.4 
GGGAAUGAAUGAUGAGA
UUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUGAGCGAACGA
GCAAUGGAAACCUGGCG
GCAGCGCAAAAGAUGCG
UAAA 
pYZ_3WJrep_
N31_switch ColA/kanamycin 
41 39 6.1 ± 0.1 
GGGCGAAUUGAAAUGAA
AUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUGACGGAAUAG
AAACUAAGAACCUGGCG
GCAGCGCAAAAGAUGCG
UAAA 
pYZ_3WJrep_
N39_switch ColA/kanamycin 
  122 
42 26 5.6 ± 0.6 
GGGUAUUACUUACCGAU
AUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUCACUCCAACGG
AACAAUCAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N26_switch ColA/kanamycin 
43 43 5.2 ± 0.4 
GGGCAUUUACCCUACUA
UUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUACACUCCAAAU
CAAAGAUAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N43_switch ColA/kanamycin 
44 28 4.6 ± 0.1 
GGGAUUUACUUAGAUAC
UUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUUACAUAUACA
UACGAACGAACCUGGCG
GCAGCGCAAAAGAUGCG
UAAA 
pYZ_3WJrep_
N28_switch ColA/kanamycin 
45 46 4.0 ± 0.0 
GGGCUCAUACUUCACUA
UUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUACACCUAACAU
AAUCACUAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N46_switch ColA/kanamycin 
46 5 2.9 ± 0.1 
GGGAUCUCCAUCUAUCCA
UUGUUAUAGUUAUGAAC
AGAGGAGACAUAACAUG
AACAAUCCAUUAAGUAAC
AAGCAGAACCUGGCGGCA
GCGCAAAAGAUGCGUAA
A 
pYZ_3WJrep_
N05_switch ColA/kanamycin 
47 14 2.2 ± 0.0 
GGGUAGAUUAAGAGUGA
UUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAUGACCUAAACGC
ACGAACUAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N14_switch ColA/kanamycin 
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48 17 2.0 ± 0.1 
GGGCAAUCUCCAAUACG
UUUGUUAUAGUUAUGAA
CAGAGGAGACAUAACAU
GAACAAGCACUUAAACCG
AAUAACUAACCUGGCGGC
AGCGCAAAAGAUGCGUA
AA 
pYZ_3WJrep_
N17_switch ColA/kanamycin 
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Table S3.3 Sequence for three-way junction (3WJ) repressor triggers 
 
Notes 
Trigger RNA sequences are listed up to the base immediately before the T7 terminator used 
to terminate transcription. 
3WJ 
repressor 
ranking 
3WJ 
repressor 
index 
Trigger sequence Trigger plasmid Trigger plasmid origin/Resistance 
1 20 
GGGACGAAUUGAUUUGUCA
AUUCGUGCGUGUAUAUCAU
UCAUCAU 
pYZ_3WJrep_N20
_trigger ColE1/ampicillin 
2 19 
GGGACCUAACAUAAACUUGU
UAGGUGCGUAGAUCUGAUU
AGUGUG 
pYZ_3WJrep_N19
_trigger ColE1/ampicillin 
3 10 
GGGACAAGAACAAUACGGUU
CUUGUACUAUCUAAUCUUAC
UAAAC 
pYZ_3WJrep_N10
_trigger ColE1/ampicillin 
4 24 
GGGACACUAACCAUAUAGUU
AGUGUGCGUAAAGUGAUAG
GAGUAA 
pYZ_3WJrep_N24
_trigger ColE1/ampicillin 
5 15 
GGGACUACCUCACACUCGAG
GUAGUGAUAAGUAAGAUUU
GGAAGU 
pYZ_3WJrep_N15
_trigger ColE1/ampicillin 
6 32 
GGGACAUACUAUAUCGUUA
GUAUGUGAUGGAAUUCUUG
AGUAAUG 
pYZ_3WJrep_N32
_trigger ColE1/ampicillin 
7 21 
GGGCGACACUAAUAGUGUA
GUGUCGGAUAAGUGAAUAG
UAGUAGA 
pYZ_3WJrep_N21
_trigger ColE1/ampicillin 
8 13 
GGGACAUACAAUGAACUUU
GUAUGUGAUUUGUAUUUGA
UUGUAGC 
pYZ_3WJrep_N13
_trigger ColE1/ampicillin 
9 2 
GGGACACUACAACUCAGUGU
AGUGUGCGUAAUUCAAUAU
CAUACU 
pYZ_3WJrep_N02
_trigger ColE1/ampicillin 
10 3 
GGGACGAAGCAUAAAGUUG
CUUCGUACUAUCUAUCUUA
UACUAAC 
pYZ_3WJrep_N03
_trigger ColE1/ampicillin 
11 16 
GGGCUACACUAAACAGGUAG
UGUAGGCGGUAAGAUAAUG
GGAGUA 
pYZ_3WJrep_N16
_trigger ColE1/ampicillin 
12 23 
GGGACAUAAACCUAUGAGU
UUAUGUGCGAUAUGGAGUA
UUUGAAA 
pYZ_3WJrep_N23
_trigger ColE1/ampicillin 
13 34 
GGGACAUACUAACAAUCUAG
UAUGUGAAUGAUGGAUACU
UUGAAA 
pYZ_3WJrep_N34
_trigger ColE1/ampicillin 
14 7 
GGGCGAACGACGAAACGGUC
GUUCGGAAUCUACUAAAUC
UUGAAA 
pYZ_3WJrep_N07
_trigger ColE1/ampicillin 
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15 40 
GGGACACUAAUACUACGAUU
AGUGUGAUAAGUUUGAAAG
UAUAAG 
pYZ_3WJrep_N40
_trigger ColE1/ampicillin 
16 11 
GGGACAUAAACAUAGAGGU
UUAUGUGAGUAGAAUUGAU
UGAUAAG 
pYZ_3WJrep_N11
_trigger ColE1/ampicillin 
17 33 
GGGAACCUAAUGUACGAAU
UAGGUUGAAUUGAAGUAUA
UGGAAUC 
pYZ_3WJrep_N33
_trigger ColE1/ampicillin 
18 9 
GGGCACCUCACCUACGUGUG
AGGUGGCAUUGUAUCAUCU
UCGUAU 
pYZ_3WJrep_N09
_trigger ColE1/ampicillin 
19 12 
GGGCGAUAAUGUUCCGUCA
UUAUCGGCAUUCUUAUUCA
AUCAUAG 
pYZ_3WJrep_N12
_trigger ColE1/ampicillin 
20 36 
GGGCGAACAAGAACAUGCUU
GUUCGGAAUCUAGUAAUCA
CAUCUA 
pYZ_3WJrep_N36
_trigger ColE1/ampicillin 
21 42 
GGGACAUAGACAAUUUGGU
CUAUGUGAAUCUUGUAAGU
GAAUAUG 
pYZ_3WJrep_N42
_trigger ColE1/ampicillin 
22 8 
GGGCAAUAGAUCAAACUAUC
UAUUGGCGUUUAUCUGAUU
UGUAUG 
pYZ_3WJrep_N08
_trigger ColE1/ampicillin 
23 1 
GGGCACAUAACAUAACGGUU
AUGUGACGGAUAGUACUAA
UUGAAA 
pYZ_3WJrep_N01
_trigger ColE1/ampicillin 
24 47 
GGGCAAAUAGAUAGAGCUC
UAUUUGGAUAGGAUUAGGA
AUUGAAA 
pYZ_3WJrep_N47
_trigger ColE1/ampicillin 
25 38 
GGGCAAGAAUAACAUUCUAU
UCUUGUAAUUCGUUUCGAU
CAUAUG 
pYZ_3WJrep_N38
_trigger ColE1/ampicillin 
26 25 
GGGAGCGAACAAUAACGUG
UUCGCUGAUGAUUCUAAUU
CUUAACA 
pYZ_3WJrep_N25
_trigger ColE1/ampicillin 
27 35 
GGGCACAUAAACUAAUCUUU
AUGUGUAAUGAUAACUUGG
AUUGAA 
pYZ_3WJrep_N35
_trigger ColE1/ampicillin 
28 27 
GGGCGAAUAAGAAUGCGCU
UAUUCGGAAUCACUAUCUUC
AUUAAC 
pYZ_3WJrep_N27
_trigger ColE1/ampicillin 
29 41 
GGGAACAUACAAAUUGAUG
UAUGUUGAUAGACACGGUG
AGAUAGA 
pYZ_3WJrep_N41
_trigger ColE1/ampicillin 
30 45 
GGGACUCCACGAAUAUCCGU
GGAGUGAUAGUAGUUUAAG
UCGUAG 
pYZ_3WJrep_N45
_trigger ColE1/ampicillin 
31 4 
GGGCAAAUGAUCAUCGUAUC
AUUUGGCGUAUUCACUUCA
UUAACA 
pYZ_3WJrep_N04
_trigger ColE1/ampicillin 
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32 48 
GGGCAUACCUCUACAAUGAG
GUAUGGAAUAGAAUGGAGU
AGUAAG 
pYZ_3WJrep_N48
_trigger ColE1/ampicillin 
33 37 
GGGCGAAAUACAAUACCGUA
UUUCGCAUCUUUAAGUUCA
CAUCGA 
pYZ_3WJrep_N37
_trigger ColE1/ampicillin 
34 44 
GGGACCUCACUUACAUUAGU
GAGGUGAUGGAAUUUGAAG
GUAAUG 
pYZ_3WJrep_N44
_trigger ColE1/ampicillin 
35 18 
GGGCUCAACAUAACAUGAUG
UUGAGAAUGAUGAAUAGGA
UUGAGA 
pYZ_3WJrep_N18
_trigger ColE1/ampicillin 
36 30 
GGGCAAUAGAAAUACCGUUC
UAUUGCAUCUUUACUCAUA
UCGAUU 
pYZ_3WJrep_N30
_trigger ColE1/ampicillin 
37 22 
GGGACUCCAAGAUAAGCCUU
GGAGUAAAGAUUAUCGGAU
UGAAUG 
pYZ_3WJrep_N22
_trigger ColE1/ampicillin 
38 6 
GGGCGAAGAUAGAUACAUA
UCUUCGAAUACUUACUUCUA
AAUCUA 
pYZ_3WJrep_N06
_trigger ColE1/ampicillin 
39 29 
GGGCAUAUAGAAUAGAGUC
UAUAUGUAAUCGUCAAUUG
GAGUAGA 
pYZ_3WJrep_N29
_trigger ColE1/ampicillin 
40 31 
GGGAGCGAACGCGAACUCGU
UCGCUCAAUCUCAUCAUUCA
UUAAG 
pYZ_3WJrep_N31
_trigger ColE1/ampicillin 
41 39 
GGGACGGAAUAACACUCUAU
UCCGUCAUUUCAUUUCAAU
UCGUAA 
pYZ_3WJrep_N39
_trigger ColE1/ampicillin 
42 26 
GGGACUCCAACUAAACCGUU
GGAGUGAUAUCGGUAAGUA
AUAGAA 
pYZ_3WJrep_N26
_trigger ColE1/ampicillin 
43 43 
GGGCACUCCAAUAGGAUUU
GGAGUGUAAUAGUAGGGUA
AAUGAGA 
pYZ_3WJrep_N43
_trigger ColE1/ampicillin 
44 28 
GGGACAUAUACUUUCAUGU
AUAUGUAAAGUAUCUAAGU
AAAUGAA 
pYZ_3WJrep_N28
_trigger ColE1/ampicillin 
45 46 
GGGCACCUAACUAACAUGUU
AGGUGUAAUAGUGAAGUAU
GAGAUG 
pYZ_3WJrep_N46
_trigger ColE1/ampicillin 
46 5 
GGGCAUUAAGUUAAGUUAC
UUAAUGGAUGGAUAGAUGG
AGAUGAU 
pYZ_3WJrep_N05
_trigger ColE1/ampicillin 
47 14 
GGGACCUAAACUAACGCGUU
UAGGUCAAUCACUCUUAAUC
UACUA 
pYZ_3WJrep_N14
_trigger ColE1/ampicillin 
48 17 
GGGACUUAAACGAAACGGU
UUAAGUGCACGUAUUGGAG
AUUGGGA 
pYZ_3WJrep_N17
_trigger ColE1/ampicillin 
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Table S3.4 Shortened triggers for SHAPE-Seq study of 3WJ repressors 21 and 13 
 
Note 
Trigger RNA sequences include the T7 terminator sequence 
Trigger name Shortened 3WJ Repressor Trigger Sequence Plasmid Name 
Trig7_len18 
GGGUGCUCGCGUUAGAGCACCCAGUGUCGGAUAAGUGAAU
UAGCAUAACCCCUUGGGGCCUCUAAACGGGUCUUGAGGGG
UUUUUUG 
pYZ_3WJrep_N21_trig
gerA18 
Trig7_len20 
GGGUGCUCGCGUUAGAGCACCCUAGUGUCGGAUAAGUGAA
UAUAGCAUAACCCCUUGGGGCCUCUAAACGGGUCUUGAGG
GGUUUUUUG 
pYZ_3WJrep_N21_trig
gerA20 
Trig7_len25 
GGGUGCUCGCGUUAGAGCACCCGUAGUGUCGGAUAAGUG
AAUAGUAGCAUAACCCCUUGGGGCCUCUAAACGGGUCUUG
AGGGGUUUUUUG 
pYZ_3WJrep_N21_trig
gerA25 
Trig8_len18 
GGGCCUGCGGCAGAGCAGGCCCUGUAUGUGAUUUGUAUU
UUAGCAUAACCCCUUGGGGCCUCUAAACGGGUCUUGAGGG
GUUUUUUG 
pYZ_3WJrep_N13_trig
gerA18 
Trig8_len20 
GGGUGCUCGCGUUAGAGCACCCUUGUAUGUGAUUUGUAU
UUGUAGCAUAACCCCUUGGGGCCUCUAAACGGGUCUUGAG
GGGUUUUUUG 
pYZ_3WJrep_N13_trig
gerA20 
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Table S3.5 Sets of orthogonal repressors with different crosstalk levels 
 
3WJ Repressor Libraries Selected After 3-hr Induction 
Library 
Size 3WJ Repressor Indices 
Library 
Dynamic 
Range (3 hr) 
Library 
Dynamic 
Range (4 hr) 
Library 
Dynamic 
Range (5 hr) 
16 2,3,7,10,11,12,13,15,19,20,21,23,24,32,34,40 3.1 6.5 11.6 
15 2,3,7,10,11,12,13,15,20,21,23,24,32,34,40 18.2 24.9 23.9 
14 2,3,7,10,11,13,15,20,21,23,24,32,34,40 18.5 24.9 23.9 
13 2,3,7,10,11,13,15,20,21,23,24,32,34 20.1 24.9 23.9 
12 2,3,10,11,13,15,20,21,23,24,32,34 23.9 28.6 23.9 
11 2,3,10,11,13,15,20,21,24,32,34 24.2 28.6 23.9 
10 2,3,10,13,20,21,23,24,32,34 25.6 28.6 23.9 
9 2,3,10,13,20,21,23,24,32 28.4 28.6 23.9 
8 2,3,10,13,20,21,23,32 29.2 57.4 42.1 
7 3,10,13,20,23,24,32 30.8 48.0 41.3 
6 10,20,21,23,24,32 40.0 47.4 42.1 
5 10,20,23,24,32 43.5 51.1 42.1 
4 19,20,21,32 47.7 62.6 50.6 
3 19,20,32 63.8 118.7 100.6 
2 20,32 87.1 145.0 122.5 
3WJ Repressor Libraries Selected After 4-hr Induction 
Library 
Size 3WJ Repressor Indices 
Library 
Dynamic 
Range (3 hr) 
Library 
Dynamic 
Range (4 hr) 
Library 
Dynamic 
Range (5 hr) 
16 2,3,7,10,11,12,13,15,19,20,21,23,24,32,34,40 3.1 6.5 11.6 
15 2,3,7,10,11,12,13,15,20,21,23,24,32,34,40 18.2 24.9 23.9 
14 2,3,10,11,12,13,15,20,21,23,24,32,34,40 18.2 28.6 23.9 
13 3,10,11,12,13,15,20,21,23,24,32,34,40 18.2 32.7 32.9 
12 3,10,11,13,15,20,21,23,24,32,34,40 18.5 39.3 32.9 
11 2,3,10,13,15,20,21,23,32,34,40 18.5 40.0 42.1 
10 2,3,10,13,15,20,21,23,32,40 18.5 41.7 42.1 
9 2,3,10,13,15,20,21,23,32 23.9 50.9 42.1 
8 2,3,10,13,20,21,23,32 29.2 57.4 42.1 
7 2,3,10,13,20,21,32 29.2 61.3 50.6 
6 2,3,10,13,20,32 33.6 70.3 66.7 
5 3,10,13,20,32 36.2 75.8 66.7 
4 10,13,20,32 40.0 90.2 66.7 
3 2,20,21 42.4 126.5 131.0 
2 2,20 67.8 197.5 237.2 
3WJ Repressor Libraries Selected After 5-hr Induction 
Library 
Size 3WJ Repressor Indices 
Library 
Dynamic 
Range (3 hr) 
Library 
Dynamic 
Range (4 hr) 
Library 
Dynamic 
Range (5 hr) 
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16 2,3,7,10,11,12,13,15,19,20,21,23,24,32,34,40 3.1 6.5 11.6 
15 2,3,7,10,11,12,13,15,19,20,21,23,24,32,34 14.0 23.9 23.9 
14 2,3,7,10,11,12,13,15,19,20,21,23,32,34 14.0 23.9 38.0 
13 2,3,10,11,12,13,15,20,21,23,32,34,40 18.2 32.7 42.1 
12 2,3,10,11,12,13,15,19,20,21,23,34 14.0 32.7 55.1 
11 2,3,10,11,12,13,15,20,21,34,40 18.4 34.4 61.1 
10 2,3,10,12,13,15,19,20,21,34 14.0 33.3 64.3 
9 2,3,10,12,13,15,20,21,40 18.4 34.4 69.0 
8 2,3,10,13,15,20,21,40 18.5 41.7 72.7 
7 2,3,10,13,15,20,21 24.3 52.3 86.2 
6 2,10,13,15,20,21 24.3 52.3 118.4 
5 2,10,13,15,20 27.0 63.6 145.9 
4 2,10,13,20 33.6 75.1 164.6 
3 10,13,20 40.0 90.2 196.6 
2 2,20 67.8 197.5 237.2 
 
Table S3.6 mRNA sensor and trigger sequences 
 
mRNA 
Sensor 
Sensor 
Sequence 
mRNA 
Target 
Subsequen
ce 
Full mRNA Target Sequence Switch Plasmid 
Switch 
Plasmid 
Origin/Resist
ance 
KanR 
sensor 
GGGAGGACAA
UUACAAACUU
GUUAUAGUU
AUGAACAGAG
GAGACAUAAC
AUGAACAAAG
GAAUCGAAUG
GAAUAAGAAC
CUGGCGGCAG
CGCAAAAGAU
GCGUAAA 
CAUUCGA
UUCCUGU
UUGUAAU
UGUCCU 
AUGAGCCAUAUUCAACGGGAAA
CGUCUUGCUCUAGGCCGCGAUU
AAAUUCCAACAUGGAUGCUGAU
UUAUAUGGGUAUAAAUGGGCU
CGCGAUAAUGUCGGGCAAUCAG
GUGCGACAAUCUAUCGAUUGUA
UGGGAAGCCCGAUGCGCCAGAG
UUGUUUCUGAAACAUGGCAAAG
GUAGCGUUGCCAAUGAUGUUAC
AGAUGAGAUGGUCAGACUAAAC
UGGCUGACGGAAUUUAUGCCUC
UUCCGACCAUCAAGCAUUUUAU
CCGUACUCCUGAUGAUGCAUGG
UUACUCACCACUGCGAUCCCCGG
GAAAACAGCAUUCCAGGUAUUA
GAAGAAUAUCCUGAUUCAGGUG
AAAAUAUUGUUGAUGCGCUGGC
AGUGUUCCUGCGCCGGUUGCAU
UCGAUUCCUGUUUGUAAUUGU
CCUUUUAACAGCGAUCGCGUAU
UUCGUCUCGCUCAGGCGCAAUC
ACGAAUGAAUAACGGUUUGGU
UGAUGCGAGUGAUUUUGAUGA
CGAGCGUAAUGGCUGGCCUGUU
GAACAAGUCUGGAAAGAAAUGC
AUAAACUUUUGCCAUUCUCACC
pYZ_3WJ
rep_kanR
_sensor 
ColA/kanamy
cin 
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GGAUUCAGUCGUCACUCAUGGU
GAUUUCUCACUUGAUAACCUUA
UUUUUGACGAGGGGAAAUUAA
UAGGUUGUAUUGAUGUUGGAC
GAGUCGGAAUCGCAGACCGAUA
CCAGGAUCUUGCCAUCCUAUGG
AACUGCCUCGGUGAGUUUUCUC
CUUCAUUACAGAAACGGCUUUU
UCAAAAAUAUGGUAUUGAUAAU
CCUGAUAUGAAUAAAUUGCAGU
UUCAUUUGAUGCUCGAUGAGU
UUUUCUAA 
aadA 
sensor 
GGGUUAGCGC
CUCAAAUAUU
GUUAUAGUU
AUGAACAGAG
GAGACAUAAC
AUGAACAAGA
UCCUGUUCAG
CACAUUCAAC
CUGGCGGCAG
CGCAAAAGAU
GCGUAAA 
CUGAACA
GGAUCUA
UUUGAGG
CGCUAA 
AUGAGGGAAGCGGUGAUCGCCG
AAGUAUCGACUCAACUAUCAGA
GGUAGUUGGCGUCAUCGAGCGC
CAUCUCGAACCGACGUUGCUGG
CCGUACAUUUGUACGGCUCCGC
AGUGGAUGGCGGCCUGAAGCCA
CACAGUGAUAUUGAUUUGCUG
GUUACGGUGACCGUAAGGCUUG
AUGAAACAACGCGGCGAGCUUU
GAUCAACGACCUUUUGGAAACU
UCGGCUUCCCCUGGAGAGAGCG
AGAUUCUCCGCGCUGUAGAAGU
CACCAUUGUUGUGCACGACGAC
AUCAUUCCGUGGCGUUAUCCAG
CUAAGCGCGAACUGCAAUUUGG
AGAAUGGCAGCGCAAUGACAUU
CUUGCAGGUAUCUUCGAGCCAG
CCACGAUCGACAUUGAUCUGGC
UAUCUUGCUGACAAAAGCAAGA
GAACAUAGCGUUGCCUUGGUAG
GUCCAGCGGCGGAGGAACUCUU
UGAUCCGGUUCCUGAACAGGAU
CUAUUUGAGGCGCUAAAUGAAA
CCUUAACGCUAUGGAACUCGCC
GCCCGACUGGGCUGGCGAUGAG
CGAAAUGUAGUGCUUACGUUG
UCCCGCAUUUGGUACAGCGCAG
UAACCGGCAAAAUCGCGCCGAA
GGAUGUCGCUGCCGACUGGGCA
AUGGAGCGCCUGCCGGCCCAGU
AUCAGCCCGUCAUACUUGAAGC
UAGACAGGCUUAUCUUGGACAA
GAAGAAGAUCGCUUGGCCUCGC
GCGCAGAUCAGUUGGAAGAAUU
UGUCCACUACGUGAAAGGCGAG
AUCACCAAGGUAGUCGGCAAAU
AA 
pYZ_3WJ
rep_aad
A_sensor 
ColA/kanamy
cin 
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Figure S3.1 Nucleotide-level schematics of three-way junction (3WJ) repressors. 
Three-way junction repressors employ a conserved hairpin structure in the switch RNA 
that places binding domains a* and b* in close proximity and enables effective translation. 
Binding of the trigger RNA through a toehold-mediated interaction forms a 3WJ structure 
that represses translation. Black bases designate sequences that are biologically conserved 
(e.g. terminators, RBS, start codons). White bases indicate sequences determined by 
NUPACK based on the specified secondary structure. Gray bases indicate sequences 
derived from previous riboregulators. 
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Figure S3.2 GFP fluorescence of 3WJ repressor libraries. GFP fluorescence levels were 
measured via flow cytometry for the switch RNA expressed with a non-cognate trigger 
with high secondary structure (colored bars, ON state) and with the cognate trigger (gray 
bars, OFF state) for 3WJ repressors. 
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Figure S3.3 Different E. Coli cell strains, time course and IPTG titration for Synthetic 
repressors performance. a and b, Comparison of GFP fold reduction for 3WJ repressors 
in E. coli BL21 Star DE3, which is RNase deficient, with E. coli BL21 DE3, which has 
wild-type RNase levels. a, GFP fluorescence intensity with cognate trigger (off state) or 
noncognate trigger (on state) in BL21 DE3* or BL21 DE3 cell strain; b, GFP fold change 
in both strains. The devices show comparable fold reductions in both strains. Cells were 
measured via flow cytometry after 5 hours of induction with 0.1 mM IPTG. c, time course 
for representative 3WJ repressors. In general, longer time incubation for the E. Coli cells 
yield higher fold change. This is possibly due to the accumulation of trigger RNA for 
efficient interaction with the switch RNA. d, IPTG concentration was titrated from the 
standard 0.1 mM to 0.2 mM and 0.5 mM. For the two tested repressors, both showed 
moderate increase fold change with increase of IPTG. 
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Figure S3.4 In-cell SHAPE-Seq characterization of trigger variants with varying 
repression efficiencies. a, Design schematic for testing 3WJ repressor variants. A 3WJ 
repressor switch RNA was characterized using in-cell SHAPE-Seq, either expressed alone 
or co-expressed with a trigger RNA. Two triggers were tested, with designed binding 
lengths (ab) of 18 nt or 20 nt. b, Functional characterization of switch RNA expressed 
without trigger (green) and with triggers of increasing interaction length (blue). Weak 
repression (ON/OFF = 3) is observed when ab = 18 nt. Repression efficiency increases 
dramatically (ON/OFF = 17) when ab is increased to 20 nt. c, In-cell SHAPE-Seq reactivity 
profile of the switch RNA expressed alone. A trend of high reactivities is observed across 
the molecule, consistent with the design hypothesis that the switch hairpin can be disrupted 
by ribosome binding and actively translated. d, In-cell SHAPE-Seq reactivity profile of the 
switch RNA co-expressed with a poorly-repressing trigger RNA (ab = 18 nt). Drops in 
reactivity are only observed within the b-b* interaction domain, suggesting that trigger 
binding does not occur across the predicted 3WJ. Improper formation of the 3WJ is the 
likely cause of the weak repression efficiency for this switch-trigger pair. e, In-cell 
SHAPE-Seq reactivity profile of the switch RNA co-expressed with a longer trigger RNA 
(ab = 20 nt) showing improved repression efficiency compared to the shorter trigger (d). 
This length variant shows a reactivity profile more consistent with proper 3WJ formation, 
with reactivity drops observed at the a-a* and b-b* interaction regions, and within the 
switch hairpin. The RBS and start codon (AUG) positions are indicated. 
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Figure S3.5 GFP fluorescence levels for 3WJ repressor orthogonality measurements. 
a-b, Linear-scale (a) and logarithmic-scale (b) GFP fluorescence intensities from 
orthogonality measurements of 16 3WJ repressors after 3 hours of induction. Each switch 
was tested against the same panel of 17 different cognate (gray bars) and non-cognate 
trigger RNAs. The non-cognate trigger “(–)” is an RNA with high secondary structure 
(dark blue bars), while the other non-cognate RNAs are from other 3WJ repressors (light 
blue bars). 
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Figure S3.6 Assessment of 3WJ repressor orthogonality after 4hr and 5hr. a, Three-
way junction repressor crosstalk measured by flow cytometry for 256 trigger-switch 
combinations 4 hours after induction. b, Three-way junction repressor crosstalk measured 
by flow cytometry for 256 trigger-switch combinations 5 hours after induction. 
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Figure S3.7 Synthetic repressor performance with different output protein. Repressor 
switches were put upstream of proteins for regulation of Venus (a and b), mCherry (c and 
d), Cerulean (e and f), and LacZ. a, c, e, fold change of Venus, mCherry and Cerulean 
under regulation of six representative repressors after 3-hour, 4-hour and 5-hour of 
induction. b, fluorescence intensity with cognate trigger (off state) and noncognate trigger 
for Venus, mCherry and Cerulean after 5-hour of induction. g, paper based cell free tests 
for six repressors regulating LacZ β-galactosidase, which catalyzes a yellow substrate 
(chlorophenol red-β-D-galactopyranoside) and converts it to purple color (chlorophenol 
red). All repressors shows LacZ output suppression indicated by the low absorbance at 570 
nm and the yellow color on the paper (right three paper discs in triplicates). Switches were 
encoded in plasmids, and triggers were ligated with T7 promoter as PCR product. Switch: 
1.5ng/µl; trigger: 40 nM. Volume each reaction on paper: 1.8µl. 
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Design of 3WJ Repressor Two-Input NOR Gate RNA 
The two-input NOR gate RNA was designed using two hairpin sensor modules 
upstream of a 3WJ repressor hairpin (Figure S9a). Each sensor module consisted of a 15-
nt toehold domain followed by a hairpin with an 18-bp stem. The loop region of this hairpin 
contained a sequestered internal trigger for the downstream repressor hairpin. The trigger 
sequence length was reduced by 5 nts within the x domain compared to that used for the 
original library characterization to reduce the probability of leakage from the internal 
trigger. The two sensor modules and the repressor hairpin were separated by 18-nt spacer 
sequences having small hairpin secondary structures. These spacers were used to ligate the 
three modules together through Gibson assembly during plasmid construction and their 
hairpin structures were used to reduce the effective distance between the intramolecular 
triggers and the downstream 3WJ repressor hairpin. Input RNAs complementary to the 
toehold and stem domain of the two sensor modules were also designed. These input RNAs 
had 33-nt binding domains to the gate RNA and were flanked by a 5’ hairpin structure and 
the T7 terminator sequence. 
Design of 3WJ Repressor NAND Gate RNAs 
The NAND gate RNAs based on 3WJ repressors were generated by taking the core 
regulatory sequence of the repressors running from the 5’ end of the a* domain through to 
the nucleotide immediately before the 21-nt linker sequence. Since this core regulatory 
sequence had a length of 73 nts, spacers of 3n+2, where n is a non-negative integer, were 
used to connect different 3WJ repressors together. Spacers of this length enabled 
successive repressor modules to remain in-frame through the full length of the gate RNA. 
For testing purposes, we selected 11- and 17-nt spacers to insert between different 3WJ 
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repressor hairpins. The spacers were designed using NUPACK to have single-stranded 
secondary structures when flanked by the two repressor hairpins. Figure S9b shows the 
programmed secondary structure of the four-input NAND gate RNA used in Figure 6 of 
the main text. 
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Table S4.1 2-input NAND gate 3WJ repressor switch sequences 
 
Notes 
Switch RNA sequences are listed up to the 30th base (inclusive) following the end of the 
last trigger binding domain. This 30-nt sequence contains the 21-nt linker sequence and the 
first 9-nts of GFPmut3b. 
2-input NAND Switch Sequence 
NAND_2in_1 
GGGACAAUCAAAUACAAAUUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACAA
UCACAUACAAAGCAAACGACAAAUACAAAUACUAAUCAGAUCUACUUGUUAUAGUUA
UGAACAGAGGAGACAUAACAUGAACAAGCACCUAACAAGACUAAUCAACCUGGCGGCA
GCGCAAAAGAUGCGUAAA 
NAND_2in_2 
GGGACAAUCAAAUACAAAUUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACAA
UCACAUACAAAGCAAACGAACAAUACCCGACUCCUAUCACUUUACUUGUUAUAGUUA
UGAACAGAGGAGACAUAACAUGAACAAGCACACUAACUACAAAUUCAACCUGGCGGC
AGCGCAAAAGAUGCGUAAA 
NAND_2in_3 
GGGAUCAAUCAAUUCUACUUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACA
AUCACAUAAACCUAAGAACUCAAUAUCGCAUACAAUCAAAUACAAAUUGUUAUAGUU
AUGAACAGAGGAGACAUAACAUGAACAAUCACAUACAAAGCAAACGAAACCUGGCGGC
AGCGCAAAAGAUGCGUAAA 
NAND_2in_4 
GGGACAAUCAAAUACAAAUUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACAA
UCACAUACAAAGCAAACGACGCAUCAGAGAUAGUAAGAUUAGAUAUUGUUAUAGUU
AUGAACAGAGGAGACAUAACAUGAACAAGUACAAGAACCGAAACGAGAACCUGGCGG
CAGCGCAAAAGAUGCGUAAA 
NAND_2in_5 
GGGCUCCUAUCACUUUACUUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACA
AGCACACUAACUACAAAUUCGCAAAUACAUCACAAUCAAAUACAAAUUGUUAUAGUU
AUGAACAGAGGAGACAUAACAUGAACAAUCACAUACAAAGCAAACGAAACCUGGCGGC
AGCGCAAAAGAUGCGUAAA 
NAND_2in_6 
GGGACAAUCAAAUACAAAUUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACAA
UCACAUACAAAGCAAACGAAGCAUCACAAUACUACUAUUCACUUAUUGUUAUAGUUA
UGAACAGAGGAGACAUAACAUGAACAAUCCGACACUACAAUUUCGAAACCUGGCGGC
AGCGCAAAAGAUGCGUAAA 
NAND_2in_7 
GGGACUAAUCAGAUCUACUUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACA
AGCACCUAACAAGACUAAUCCAAAUCAAAUCACAAUCAAAUACAAAUUGUUAUAGUU
AUGAACAGAGGAGACAUAACAUGAACAAUCACAUACAAAGCAAACGAAACCUGGCGGC
AGCGCAAAAGAUGCGUAAA 
NAND_2in_8 
GGGCUCCUAUCACUUUACUUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACA
AGCACACUAACUACAAAUUCCAAAGCCACAUACUAAUCAGAUCUACUUGUUAUAGUU
AUGAACAGAGGAGACAUAACAUGAACAAGCACCUAACAAGACUAAUCAACCUGGCGGC
AGCGCAAAAGAUGCGUAAA 
NAND_2in_9 
GGGACAAUCAAAUACAAAUUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACAA
UCACAUACAAAGCAAACGAAACAUAAAGCCAACUAAACUAAUCAGAUCUACUUGUUA
UAGUUAUGAACAGAGGAGACAUAACAUGAACAAGCACCUAACAAGACUAAUCAACCU
GGCGGCAGCGCAAAAGAUGCGUAAA 
NAND_2in_10 
GGGACAAUCAAAUACAAAUUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACAA
UCACAUACAAAGCAAACGACACGAGACCAGAGACAUUAGUAAGAUUAGAUAUUGUUA
UAGUUAUGAACAGAGGAGACAUAACAUGAACAAGUACAAGAACCGAAACGAGAACCU
GGCGGCAGCGCAAAAGAUGCGUAAA 
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NAND_2in_11 
GGGACAAUCAAAUACAAAUUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACAA
UCACAUACAAAGCAAACGAAAUACCGCAAAUACCAUAUCAAUCAAUUCUACUUGUUA
UAGUUAUGAACAGAGGAGACAUAACAUGAACAAUCACAUAAACCUAAGAACUAACCU
GGCGGCAGCGCAAAAGAUGCGUAAA 
NAND_2in_12 
GGGACUAAUCAGAUCUACUUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACA
AGCACCUAACAAGACUAAUCAACUCAAUAUCGCAGAUACAAUCAAAUACAAAUUGUU
AUAGUUAUGAACAGAGGAGACAUAACAUGAACAAUCACAUACAAAGCAAACGAAACC
UGGCGGCAGCGCAAAAGAUGCGUAAA 
NAND_2in_13 
GGGCUCCUAUCACUUUACUUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACA
AGCACACUAACUACAAAUUCACAAUUACCGACGCAAUACAAUCAAAUACAAAUUGUUA
UAGUUAUGAACAGAGGAGACAUAACAUGAACAAUCACAUACAAAGCAAACGAAACCU
GGCGGCAGCGCAAAAGAUGCGUAAA 
NAND_2in_14 
GGGCUCCUAUCACUUUACUUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACA
AGCACACUAACUACAAAUUCACCGCAAAUACAAUAACACUAAUCAGAUCUACUUGUUA
UAGUUAUGAACAGAGGAGACAUAACAUGAACAAGCACCUAACAAGACUAAUCAACCU
GGCGGCAGCGCAAAAGAUGCGUAAA 
NAND_2in_15 
GGGAUCAAUCAAUUCUACUUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACA
AUCACAUAAACCUAAGAACUAAGCCGACAAUACUAACACUAAUCAGAUCUACUUGUU
AUAGUUAUGAACAGAGGAGACAUAACAUGAACAAGCACCUAACAAGACUAAUCAACC
UGGCGGCAGCGCAAAAGAUGCGUAAA 
NAND_2in_16 
GGGACUAAUCAGAUCUACUUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACA
AGCACCUAACAAGACUAAUCAUAUACAAUACCUCCAAAUCAAUCAAUUCUACUUGUU
AUAGUUAUGAACAGAGGAGACAUAACAUGAACAAUCACAUAAACCUAAGAACUAACC
UGGCGGCAGCGCAAAAGAUGCGUAAA 
 
Table S4.2 2-input NAND gate repressor switch and trigger plasmid information 
 
2-input 
NAND 
Switch 
Number 
Switch 
Plasmid 
Origin/Resi
stance 
Trigger 
number 
for 
input 
11 
Trigger 
number 
for 
input 
10 
Trigger 
number 
for 
input 
01 
Trigger 
number 
for 
input 
00 
Trigger Plasmid 
Origin/Resistance 
NAND_2in_
1 13, 19 
ColA/ 
kanamycin 13, 19 13, 12 12, 19 12, 12 
ColE1/ampicillin, 
CDF/Spectinomycin  
NAND_2in_
2 13, 24 
ColA/ 
kanamycin 13, 24 13, 12 12, 24 12, 12 
ColE1/ampicillin, 
CDF/Spectinomycin  
NAND_2in_
3 11, 13 
ColA/ 
kanamycin 11, 13 11, 12 12, 13 12, 12 
ColE1/ampicillin, 
CDF/Spectinomycin  
NAND_2in_
4 13, 10 
ColA/ 
kanamycin 13, 10 13, 12 12, 10 12, 12 
ColE1/ampicillin, 
CDF/Spectinomycin  
NAND_2in_
5 24, 13 
ColA/ 
kanamycin 24, 13 24, 12 12, 13 12, 12 
ColE1/ampicillin, 
CDF/Spectinomycin  
NAND_2in_
6 13, 21 
ColA/ 
kanamycin 13, 21 13, 12 12, 21 12, 12 
ColE1/ampicillin, 
CDF/Spectinomycin  
NAND_2in_
7 19, 13 
ColA/ 
kanamycin 19, 13 19, 12 12, 13 12, 12 
ColE1/ampicillin, 
CDF/Spectinomycin  
NAND_2in_
8 24, 19 
ColA/ 
kanamycin 24, 19 24, 12 12, 19 12, 12 
ColE1/ampicillin, 
CDF/Spectinomycin  
NAND_2in_
9 13, 19 
ColA/ 
kanamycin 13, 19 13, 12 12, 19 12, 12 
ColE1/ampicillin, 
CDF/Spectinomycin  
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NAND_2in_
10 13, 10 
ColA/ 
kanamycin 13, 10 13, 12 12, 10 12, 12 
ColE1/ampicillin, 
CDF/Spectinomycin  
NAND_2in_
11 13, 11 
ColA/ 
kanamycin 13, 11 13, 12 12, 11 12, 12 
ColE1/ampicillin, 
CDF/Spectinomycin  
NAND_2in_
12 19, 13 
ColA/ 
kanamycin 19, 13 19, 12 12, 13 12, 12 
ColE1/ampicillin, 
CDF/Spectinomycin  
NAND_2in_
13 24, 13 
ColA/ 
kanamycin 24, 13 24, 12 12, 13 12, 12 
ColE1/ampicillin, 
CDF/Spectinomycin  
NAND_2in_
14 24, 19 
ColA/ 
kanamycin 24, 19 24, 12 12, 19 12, 12 
ColE1/ampicillin, 
CDF/Spectinomycin  
NAND_2in_
15 11, 19 
ColA/ 
kanamycin 11, 19 11, 12 12, 19 12, 12 
ColE1/ampicillin, 
CDF/Spectinomycin  
NAND_2in_
16 19, 11 
ColA/ 
kanamycin 19, 11 19, 12 12, 11 12, 12 
ColE1/ampicillin, 
CDF/Spectinomycin  
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Table S4.3 2-input NOR gate 3WJ repressor switch sequences 
 
Notes 
1. Switch RNA sequences are listed up to the 30th base (inclusive) following the end of 
the trigger binding domain. This 30-nt sequence contains the 21-nt linker sequence and the 
first 9-nts of GFPmut3b. 
2. Trigger RNA sequences are listed up to the base immediately before the T7 terminator 
used to terminate transcription. 
2-input NOR NOR_2in_1 NOR_2in_2 
Switch Sequence 
GGGAGUAAAGUAUAGAACGCUUGAUG
UUGAUGUUAGCGACACUAAUAGUGUA
GUGUCGGAUAAGUGAAUAUAGUCUAA
CAUCAACAUCAAGCGCCUCAAUUCGAG
GCAAGACUAAGACUAAAUGAUGUAUAG
AUUGAAGAUUGCGACACUAAUAGUGU
AGUGUCGGAUAAGUGAAUAGUAGUCA
AUCUUCAAUCUAUACAGCCUCAAUUCG
AGGCAAGACUACUAUUCACUUAUUGU
UAUAGUUAUGAACAGAGGAGACAUAAC
AUGAACAAUCCGACACUACAAUUUCGA
AACCUGGCGGCAGCGCAAAAACCUGGC
GGCAGCGCAAAAGAUGCGUAAA 
GGGACUAAGACUAAAUGAUGUAUAGA
UUGAAGAUUGCGACACUAAUAGUGUA
GUGUCGGAUAAGUGAAUAGUAGUCAA
UCUUCAAUCUAUACAGCCUCAAUUCGA
GGCAAGAUCAAAGUAUACAAGGGUAGG
GUAGGGUUAUCGCGACACUAAUAGUG
UAGUGUCGGAUAAGUGAAUAGUAGUC
GAUAACCCUACCCUACCGCCUCAAUUCG
AGGCAAGACUACUAUUCACUUAUUGUU
AUAGUUAUGAACAGAGGAGACAUAACA
UGAACAAUCCGACACUACAAUUUCGAA
ACCUGGCGGCAGCGCAAAAACCUGGCG
GCAGCGCAAAAGAUGCGUAAA 
3WJ Repressor 
Switch Number 21 21 
Switch Plasmid 
Origin/Resistance ColA/kanamycin ColA/kanamycin 
Sequence for 
Trigger Plasmid A 
GGGUGACAUAUCCAAGAGCGGAUAUG
UCACUAACAUCAACAUCAAGCGUUCUA
UACUUUACU 
GGGACGUGCGCAGCUCCUACUGCGCAC
GUCAAUCUUCAAUCUAUACAUCAUUUA
GUCUUAGU 
Sequence for 
Trigger Plasmid B 
GGGACGUGCGCAGCUCCUACUGCGCAC
GUCAAUCUUCAAUCUAUACAUCAUUUA
GUCUUAGU 
GGGCUGCAGGUGACAGAUAUCACCUGC
AGCGAUAACCCUACCCUACCCUUGUAU
ACUUUGAU 
Sequence for 
Control Trigger 
Plasmid C 
GGGACGAUAUACGGGUCUACGUAUAU
CGUACAAGAACCAUACAAGACAACGACG
ACACUAGA 
GGGACGAUAUACGGGUCUACGUAUAU
CGUACAAGAACCAUACAAGACAACGACG
ACACUAGA 
Sequence for 
Control Trigger 
Plasmid D 
GGGACAUCAGAGACUAGUAUCUCUGAU
GUAUAAGACAAGACAUAAGAACAGAAA
UACACAGA 
GGGACAUCAGAGACUAGUAUCUCUGAU
GUAUAAGACAAGACAUAAGAACAGAAA
UACACAGA 
Trigger Number 
for input 11 A, B A, B 
Trigger Number 
for input 10 A, C A, C 
Trigger Number 
for input 01 B, C B, C 
Trigger Number 
for input 00 C, D C, D 
Trigger Plasmid 
Origin/Resistance ColE1/ampicillin, CDF/Spectinomycin ColE1/ampicillin, CDF/Spectinomycin 
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Table S4.4 3-input NAND gate 3WJ repressor switch sequences 
 
Notes 
Switch RNA sequences are listed up to the 30th base (inclusive) following the end of the 
last trigger binding domain. This 30-nt sequence contains the 21-nt linker sequence and the 
first 9-nts of GFPmut3b. 
3-input NAND Switch Sequence 
NAND_3in_1 
GGGCUCCUAUCACUUUACUUGUUAUAGUUAUGAACAGAGGAGACAUAACA
UGAACAAGCACACUAACUACAAAUUCCAAAGCCACAUACUAAUCAGAUCUAC
UUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACAAGCACCUAACAAG
ACUAAUCCAAAUCAAAUCACAAUCAAAUACAAAUUGUUAUAGUUAUGAACA
GAGGAGACAUAACAUGAACAAUCACAUACAAAGCAAACGAAACCUGGCGGCA
GCGCAAAAGAUGCGUAAAGGAGAAGAACUUUUCACUGGAACCUGGCGGCAG
CGCAAAAGAUGCGUAAA 
NAND_3in_2 
GGGACUAAUCAGAUCUACUUGUUAUAGUUAUGAACAGAGGAGACAUAACA
UGAACAAGCACCUAACAAGACUAAUCAACUACAUAAACUCCUAUCACUUUAC
UUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACAAGCACACUAACUA
CAAAUUCGCAAAUACAUCACAAUCAAAUACAAAUUGUUAUAGUUAUGAACA
GAGGAGACAUAACAUGAACAAUCACAUACAAAGCAAACGAAACCUGGCGGCA
GCGCAAAAGAUGCGUAAAGGAGAAGAACUUUUCACUGGAACCUGGCGGCAG
CGCAAAAGAUGCGUAAA 
NAND_3in_3 
GGGAUCAAUCAAUUCUACUUGUUAUAGUUAUGAACAGAGGAGACAUAACA
UGAACAAUCACAUAAACCUAAGAACUCAAUAUCGCAUACAAUCAAAUACAAA
UUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACAAUCACAUACAAAG
CAAACGACAAAUACAAAUACUAAUCAGAUCUACUUGUUAUAGUUAUGAACA
GAGGAGACAUAACAUGAACAAGCACCUAACAAGACUAAUCAACCUGGCGGCA
GCGCAAAAGAUGCGUAAAGGAGAAGAACUUUUCACUGGAACCUGGCGGCAG
CGCAAAAGAUGCGUAAA 
NAND_3in_4 
GGGCUCCUAUCACUUUACUUGUUAUAGUUAUGAACAGAGGAGACAUAACA
UGAACAAGCACACUAACUACAAAUUCGCAAAUACAUCACAAUCAAAUACAAA
UUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACAAUCACAUACAAAG
CAAACGACAAAUACAAAUACUAAUCAGAUCUACUUGUUAUAGUUAUGAACA
GAGGAGACAUAACAUGAACAAGCACCUAACAAGACUAAUCAACCUGGCGGCA
GCGCAAAAGAUGCGUAAAGGAGAAGAACUUUUCACUGGAACCUGGCGGCAG
CGCAAAAGAUGCGUAAA 
NAND_3in_5 
GGGACAAUCAAAUACAAAUUGUUAUAGUUAUGAACAGAGGAGACAUAACA
UGAACAAUCACAUACAAAGCAAACGAAAUACCGCAAAUACCAUAUCAAUCAA
UUCUACUUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACAAUCACA
UAAACCUAAGAACUAAGCCGACAAUACUAACACUAAUCAGAUCUACUUGUU
AUAGUUAUGAACAGAGGAGACAUAACAUGAACAAGCACCUAACAAGACUAA
UCAACCUGGCGGCAGCGCAAAAGAUGCGUAAAGGAGAAGAACUUUUCACUG
GAACCUGGCGGCAGCGCAAAAGAUGCGUAAA 
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NAND_3in_6 
GGGACUAAUCAGAUCUACUUGUUAUAGUUAUGAACAGAGGAGACAUAACA
UGAACAAGCACCUAACAAGACUAAUCAACUCAAUAUCGCAGAUACAAUCAAA
UACAAAUUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACAAUCACAU
ACAAAGCAAACGAAAUACCGCAAAUACCAUAUCAAUCAAUUCUACUUGUUA
UAGUUAUGAACAGAGGAGACAUAACAUGAACAAUCACAUAAACCUAAGAAC
UAACCUGGCGGCAGCGCAAAAGAUGCGUAAAGGAGAAGAACUUUUCACUGG
AACCUGGCGGCAGCGCAAAAGAUGCGUAAA 
 
Table S4.5 3-input NAND gate repressor switch and trigger plasmid information 
 
3-
input 
NAND 
Swit
ch 
Num
ber 
Switch 
Plasmid 
Origin/R
esistance 
Trig
ger 
num
ber 
for 
inpu
t 
111 
Trig
ger 
num
ber 
for 
inpu
t 
011 
Trig
ger 
num
ber 
for 
inpu
t 
101 
Trig
ger 
num
ber 
for 
inpu
t 
110 
Trig
ger 
num
ber 
for 
inpu
t 
100 
Trig
ger 
num
ber 
for 
inpu
t 
010 
Trig
ger 
num
ber 
for 
inpu
t 
001 
Trig
ger 
num
ber 
for 
inpu
t 
000 
Trigger 
Plasmid 
Origin/Resista
nce 
NAND
_3in_1 
24, 
19, 
13 
ColA/ 
kanamyci
n 
(19, 
24), 
13 
12, 
(19, 
24) 
13, 
(12, 
24) 
13, 
(24, 
12) 
12, 
(13, 
12) 
(12, 
12), 
19 
(12, 
12), 
24 
(12, 
12), 
12 
ColE1/ 
ampicillin, 
CDF/ 
Spectinomycin  
NAND
_3in_2 
19, 
24, 
13 
ColA/ 
kanamyci
n 
(19, 
24), 
13 
12, 
(19, 
24) 
13, 
(24, 
12) 
13, 
(19, 
12) 
12, 
(13, 
12) 
(12, 
12), 
19 
(12, 
12), 
24 
(12, 
12), 
12 
ColE1/ 
ampicillin, 
CDF/ 
Spectinomycin  
NAND
_3in_3 
11, 
13, 
19 
ColA/ 
kanamyci
n 
(11, 
19), 
13 
13, 
(12, 
19 
11, 
(19, 
12) 
11, 
(13, 
12) 
(11, 
12), 
12 
(12, 
12), 
19 
(12, 
12), 
13 
(12, 
12), 
12 
ColE1/ 
ampicillin, 
CDF/ 
Spectinomycin  
NAND
_3in_4 
24, 
13, 
19 
ColA/ 
kanamyci
n 
(19, 
24), 
13 
12, 
(19, 
24) 
13, 
(24, 
12) 
13, 
(19, 
12) 
12, 
(13, 
12) 
(12, 
12), 
19 
(12, 
12), 
24 
(12, 
12), 
12 
ColE1/ 
ampicillin, 
CDF/ 
Spectinomycin  
NAND
_3in_5 
13, 
11, 
19 
ColA/ 
kanamyci
n 
(11, 
19), 
13 
13, 
(12, 
19) 
11, 
(19, 
12) 
11, 
(13, 
12) 
(11, 
12), 
12 
(13, 
12), 
12 
(12, 
12), 
19 
(12, 
12), 
12 
ColE1/ 
ampicillin, 
CDF/ 
Spectinomycin  
NAND
_3in_6 
19, 
13, 
11 
ColA/ 
kanamyci
n 
(11, 
19), 
13 
13, 
(12, 
19) 
11, 
(19, 
12) 
11, 
(13, 
12) 
(11, 
12), 
12 
(13, 
12), 
12 
(12, 
12), 
19 
(12, 
12), 
12 
ColE1/ 
ampicillin, 
CDF/ 
Spectinomycin  
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Table S4.6 4-input NAND gate 3WJ repressor switch sequences 
 
Notes 
Switch RNA sequences are listed up to the 30th base (inclusive) following the end of the 
last trigger binding domain. This 30-nt sequence contains the 21-nt linker sequence and the 
first 9-nts of GFPmut3b. 
4-input NAND Switch Sequence 
NAND_4in_1 
GGGCUCCUAUCACUUUACUUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACAA
GCACACUAACUACAAAUUCCAAAGCCACAUACUAAUCAGAUCUACUUGUUAUAGUUAU
GAACAGAGGAGACAUAACAUGAACAAGCACCUAACAAGACUAAUCCAAAUCAAAUCACA
AUCAAAUACAAAUUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACAAUCACAU
ACAAAGCAAACGACACAUACCUUCAUCAAUCAAUUCUACUUGUUAUAGUUAUGAACAG
AGGAGACAUAACAUGAACAAUCACAUAAACCUAAGAACUAACCUGGCGGCAGCGCAAA
ACCUGGCGGCAGCGCAAAAGAUGCGUAAA 
NAND_4in_2 
GGGCUCCUAUCACUUUACUUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACAA
GCACACUAACUACAAAUUCCUAACUUUCAAUCCAGCAUCAAUCAAUUCUACUUGUUAU
AGUUAUGAACAGAGGAGACAUAACAUGAACAAUCACAUAAACCUAAGAACUAAGCCGA
CAAUACUAACACUAAUCAGAUCUACUUGUUAUAGUUAUGAACAGAGGAGACAUAACA
UGAACAAGCACCUAACAAGACUAAUCAACUCAAUAUCGCAGAUACAAUCAAAUACAAA
UUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACAAUCACAUACAAAGCAAACGA
AACCUGGCGGCAGCGCAAAACCUGGCGGCAGCGCAAAAGAUGCGUAAA 
NAND_4in_3 
GGGACUAAUCAGAUCUACUUGUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACAA
GCACCUAACAAGACUAAUCAACUACAAAUACAAUAACUCCUAUCACUUUACUUGUUAU
AGUUAUGAACAGAGGAGACAUAACAUGAACAAGCACACUAACUACAAAUUCACAAUUA
CCGACGCAAUACAAUCAAAUACAAAUUGUUAUAGUUAUGAACAGAGGAGACAUAACAU
GAACAAUCACAUACAAAGCAAACGAAAUACCGCAAAUACCAUAUCAAUCAAUUCUACUU
GUUAUAGUUAUGAACAGAGGAGACAUAACAUGAACAAUCACAUAAACCUAAGAACUAA
CCUGGCGGCAGCGCAAAACCUGGCGGCAGCGCAAAAGAUGCGUAAA 
 
Table S4.7 4-input NAND gate repressor switch and trigger plasmid information 
 
4-input NAND NAND_4in_1 NAND_4in_2 NAND_4in_3 
Switch Number 
19, 24, 13, 11 24, 19, 13, 11 24, 11, 19, 13 
Switch Plasmid 
Origin/Resistance ColA/kanamycin ColA/kanamycin ColA/kanamycin 
Trigger number for 
input 1111 
(11, 13), (19, 24) (11, 13), (19, 24) (11, 13), (19, 24) 
Trigger number for 
input 0111 
12, (13, 19, 24) 12, (13, 19, 24) 12, (13, 19, 24) 
Trigger number for 
input  1011 
12, (11, 19, 24) 12, (11, 19, 24) 12, (11, 19, 24) 
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Trigger number for 
input 1101 
12, (11, 13, 24) 12, (11, 13, 24) 12, (11, 13, 24) 
Trigger number for 
input 1110 
12, (11, 13, 19) 12, (11, 13, 19) 12, (11, 13, 19) 
Trigger number for 
input 1100 
(12, 12), (11, 13) (12, 12), (11, 13) (12, 12), (11, 13) 
Trigger number for 
input 1010 
(12, 12), (11, 19) (12, 12), (11, 19) (12, 12), (11, 19) 
Trigger number for 
input 1001 
(12, 12), (11, 24) (12, 12), (11, 24) (12, 12), (11, 24) 
Trigger number for 
input 0110 
(12, 12), (13, 19) (12, 12), (13, 19) (12, 12), (13, 19) 
Trigger number for 
input 0101 
(12, 12), (13, 24) (12, 12), (13, 24) (12, 12), (13, 24) 
Trigger number for 
input 0011 
(12, 12), (19, 24) (12, 12), (19, 24) (12, 12), (19, 24) 
Trigger number for 
input 1000 
(12, 12), (11, 12) (12, 12), (11, 12) (12, 12), (11, 12) 
Trigger number for 
input 0100 
(12, 12), (13, 12) (12, 12), (13, 12) (12, 12), (13, 12) 
Trigger number for 
input 0010 
(12, 12), (19, 12) (12, 12), (19, 12) (12, 12), (19, 12) 
Trigger number for 
input 0001 
(12, 12), (24, 12) (12, 12), (24, 12) (12, 12), (24, 12) 
Trigger number for 
input 0000 
(12, 12), (12, 12) (12, 12), (12, 12) (12, 12), (12, 12) 
Trigger Plasmid 
Origin/Resistance 
ColE1/ampicillin, 
CDF/Spectinomycin 
ColE1/ampicillin, 
CDF/Spectinomycin 
ColE1/ampicillin, 
CDF/Spectinomycin 
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Figure S4.1 Cell population distributions for ribocomputing logic circuits. a, Two-
input 3WJ repressor NAND gate from Figure 4.1b-c. b, Two-input 3WJ repressor NOR 
gate from Figure 4.2b-c. c, Three-input 3WJ repressor NAND gate from Figure 6a-c. e, 
Four-input 3WJ repressor NAND gate from Figure 4.3b-c.  
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Figure S4.2 Nucleotide-level schematics for 3WJ-repressor-based ribocomputing 
devices. a, The two-input 3WJ repressor NOR gate employs two input-sensing hairpins 
with loop-confined triggers for a downstream 3WJ repressor hairpin. b, The programmed 
secondary structure for four-input 3WJ repressor NAND gate RNA. Single-stranded 17-nt 
spacers separate four 3WJ repressor hairpins and do not encode in-frame stop codons. 
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Figure S4.3 Two-input NOT (A AND B) logic operations for 16 repressor based 
devices. Repressors modules were chosen based on low crosstalk and high dynamic 
change. Top 16 devices calculated by NUPACK with lowest defect were tested for logic 
operations. The GFP fold reductions of devices are calculated by dividing the GFP 
fluorescence from gate RNA obtained for the null input case by the GFP fluorescence for 
given input combinations. Relative errors for ON and OFF states are from the SD of three 
biological replicates. Relative errors for the ribocomputing device fold reductions were 
obtained by adding the relative errors of the sensor ON and OFF state fluorescence 
measurements in quadrature. All devices showed largely repressed GFP output for the logic 
TRUE input conditions. Device 16 was shown in the main text. 
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Figure S4.4 Three-input NOT (A AND B AND C) logic operations for repressor based 
devices. 6 devices with lowest defect calculated by NUPACK were tested. GFP fold 
change after 3-hour, 4-hour, 5-hour and 6-hour were shown.  Device 3 was shown in main 
text for data obtained 6-hour post-induction.
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Figure S4.5 Four-input NOT (A AND B AND C AND D) logic operations by repressor 
based device. The GFP fold change after 7-hour induction were plotted for all three devices 
tested. 
 
